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Abstract 
 
Safe and effective delivery of radiosurgery demands a steep dose fall-off outside the 
target, in addition to highly conformal treatment and sub-millimetre overall accuracy. 
This thesis concerns the CyberKnife system - an image-guided radiosurgery system 
capable of treating both intra- and extracranial targets. Plan-specific QA performed 
using an ionisation chamber and radiochromic film confirmed that the dose distributions 
produced by MultiPlan software accurately reflect the treatment delivered, and therefore 
subsequent dosimetric studies using MultiPlan are valid. The relationship between 
prescription isodose value and external dose gradient (measured by the Gradient Index) 
was explored for solitary intracranial spherical targets, and then irregularly-shaped 
lesions. For smaller targets the steepest dose fall-off was achieved by prescribing to as 
close to the 50 % isodose as could be achieved. For larger targets the effect of changing 
the prescription isodose value was less marked but the optimum value was in the range 
60 – 70 %. A planning method to optimise dose fall-off whilst maintaining other aspects 
of plan quality has been proposed. An additional study looked at optimising dose fall-
off on one aspect of a target situated close to the brainstem. It was demonstrated that 
using “VOI” hard limits in treatment planning can reduce the brainstem dose 
substantially without any significant compromise on other important plan parameters. 
Finally, a dosimetric comparison between CyberKnife and the Gamma Knife system 
was performed for solitary intracranial targets. Overall, there was no significant 
difference in conformality and external dose gradient across the lesions studied. 
However the results suggested that Gamma Knife dosimetry may be superior for small 
lesions, and CyberKnife for larger ones. Whilst the experimental findings in this thesis 
relate to intracranial dosimetry, they may also be relevant to extracranial treatment 
planning using the CyberKnife system: this is a suggested area of future research. 
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Chapter 1 - Introduction 
 
Radiosurgery refers to the use of large single fractions of radiation, delivered with high 
accuracy to small, well-localised targets in the head or body. The term is often used 
interchangeably with Stereotactic Radiotherapy (SRT), although radiosurgery usually 
implies a single fraction treatment, whereas SRT may comprise a single or small 
number of high-dose fractions. In fact, “stereotactic” is no longer an all-embracing 
adjective for radiosurgical technologies as some systems now use sophisticated image 
guidance techniques instead of stereotactic coordinates for targeting and tracking during 
treatment. 
 
Radiosurgery is conceptually different to conventionally-fractionated radiotherapy 
(CFR). In CFR, the planning target volume (PTV) comprises the target together with a 
margin of normal tissue. This margin is required to account for any inaccuracies in 
patient setup and treatment delivery. Treatment planning aims to cover as much of the 
PTV as possible with the prescription isodose line, and therefore a reasonable volume of 
normal tissue will inevitably receive the prescribed dose. CFR uses fractionation to 
exploit the different radiobiological behaviour shown by many tumours, relative to the 
normal tissue also encompassed by the prescription isodose line. This results in an 
improved therapeutic ratio (the degree of tumour cell kill for a given degree of normal 
tissue toxicity).  
 
In contrast, radiosurgery uses little or no PTV margin around the target, and harnesses 
the ablative power of a large single dose of radiation. The safe and effective delivery of 
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radiosurgery therefore requires the utmost accuracy in patient immobilisation, target 
localisation (which may involve fusion of different imaging modalities), and treatment 
delivery. Consequently most modern radiosurgery systems have demonstrated “sub-
millimetre” accuracy in phantom studies, as will be discussed later. However, 
radiosurgery also requires the ability to produce treatment plans in which the 
prescription isodose line conforms very closely to the target outline, outside which there 
is a steep dose fall-off (external dose gradient). Both conformality and a steep external 
dose gradient serve to reduce the volume of normal tissue receiving a clinically 
significant dose. These dosimetric parameters – in particular the optimisation of external 
dose gradients – form the basis of the experimental work carried out in this thesis. 
 
History of radiosurgery 
 
Stereotactic mapping of the brain was first described by Victor Horsley and Robert 
Clarke in 1906. They developed a method of accurately locating deep-seated brain 
lesions by assigning coordinates in three planes to neuroanatomical structures, based on 
cranial landmarks. They used their “stereotaxic apparatus” to explore the anatomy and 
function of the cerebellum in cats and monkeys (1). However the variable relationship 
between skull landmarks and cerebral structures in humans prevented the use of this 
technique in patients. In 1946 Spiegel and Wycis (2) developed a technique of relating 
intracranial targets to landmarks within the brain, namely the pineal gland and foramen 
of Monro, which were visualized using a pneumoencephalogram. Central to the design 
was a custom-made plaster head cap known as a stereoencephalatome, and a frame 
based 3-dimensional coordinate system relative to this. This became the first stereotactic 
apparatus used routinely on patients. 
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Meanwhile, following the discovery of x-rays by Roentgen in 1895, the new medical 
discipline of radiology was born. The best documented early report of the therapeutic 
use of x-rays was by Freund (3) in 1897, who treated a large pigmented naevus on the 
back of a five year old girl. The term “radiotherapy” came into use in the 1920s, around 
the time that diagnostic and therapeutic radiology were emerging as distinct specialties. 
Early radiotherapy practitioners used radium, with teleradium units appearing in the 
1930s. Around the same time, the first therapeutic kilovoltage X-ray tubes became 
available, in which photons are produced using thermionic emission. Cobalt beam units 
and then megavoltage linear accelerators were introduced in the 1950s. The higher 
energy of these techniques enabled more effective treatment of deeper targets within the 
body. 
 
Lars Leksell, a Swedish neurosurgeon, was the first person to marry the two developing 
fields of stereotaxy and radiotherapy, and introduced the term “radiosurgery” in 1951. 
He had developed a stereotactic system for performing image-guided surgery on deep 
brain structures. The surgical “tool” was mounted on an arc, which was in turn attached 
to a stereotactic head frame fixed to the skull. Imaging was obtained with the frame in 
place, and the arc positioned so that the target coincided with its centre. Instruments 
inserted from any point along the arc would be incident on the target (Figure 1.1). He 
realised that narrow x-ray beams delivered from multiple points on the arc would result 
in a high dose to the target, and a substantially lower dose to surrounding tissue (4). He 
initially employed multiple orthovoltage tubes (photon energy approximately 250 KV) 
but found they were of both insufficient energy and accuracy for targeting deep brain 
lesions. In 1967 he developed the first Gamma Knife prototype using 179 individual 
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Figure 1.1 Image showing the Leksell stereotactic frame. The frame is afixed to the skull using four 
screws. A needle is attached to an arc which, in turn, is fixed to the frame. Movement of the needle 
relative to the skull is possible in Anterior-Posterior, Left-Right and Superior-Inferior directions, with x,y 
and z coordinates for any needle position. 
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Cobalt-60 sources, each emitting gamma rays of energy 1.17 and 1.33 MeV, and all 
incident on the target. Over the last forty years the system has undergone a number of 
modifications, although the principles remain the same. The latest model, Gamma Knife 
Perfexion (Elekta, Stockholm, Sweden) is described in detail in Chapter 2. 
 
The first radiosurgical treatments were functional ablations in patients with intractable 
pain, with target response assessed clinically, and later at post-mortem. Treatment was 
then expanded to include vascular obliteration of brain arteriovenous malformations 
(AVMs) and growth arrest of acoustic neuromas, since these targets could be accurately 
visualised using angiography and plain tomography respectively. The development of 
computed axial tomography (CAT, or CT) by Hounsfield in the early 1970s (5) allowed 
treatment planning based on axial imaging, thus expanding the range of intracranial 
targets which could be localised for radiosurgery. Also, together with the development 
of computers, CT enabled the use of 3-dimensional dose distributions, which is now 
central to most modern radiotherapy systems. The advent of Magnetic Resonance 
Imaging (MRI) followed a few years after CT, offering enhanced resolution of many 
intracranial targets. This is now the preferred method of target delineation for most solid 
tumours in the brain. 
 
The early 1980’s saw the adaptation of linear accelerators (linacs) for intracranial 
stereotactic delivery, with the earliest published reports from Argentina (Betti et al) (6) 
and Italy (Colombo et al) (7). The required accuracy was again achieved using a pinned 
stereotactic head frame, and radiation was administered via multiple non-coplanar arcs 
around the patient using the linac gantry. This was followed quickly by the development 
of specialist radiosurgical dosimetry software eg X-Knife (Radionics, Boston, MA). 
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Linacs dedicated to delivering radiosurgery started to appear in the 1990’s, and modern 
examples include Novalis TX (BrainLAB, Munich, Germany) and Elekta Axesse 
(Elekta). Recent developments include increased conformality through the use of both 
micro-multi-leaf collimators (micro-MLCs) and modulated arc therapy/tomotherapy. 
 
Whilst a pinned stereotactic frame provides (near) absolute immobilisation, its use is 
limited to the treatment of intracranial targets, which show negligible movement relative 
to the skull. It is also limited to single fraction treatments. Relocatable stereotactic 
frames have been used by some centres to allow fractionation of treatment, usually for 
larger tumours where there may be concerns over using a single fraction. For example 
the Gill-Thomas-Cosman frame uses a mouthbite together with vertical brackets to 
achieve the required immobilization and reproducibility. Its introduction in the UK in 
1989 allowed fractionation of radiosurgery for the first time (8). However, relocatable 
frames are now being replaced by modern image guidance as described below. 
 
Extracranial targets do not share the same fixed relationship with any external body 
contour, and there can be both inter- and intra-fraction target and critical organ 
movement. This has historically limited the use of single fraction radiation treatment to 
targets outside the skull. However, over the last fifteen years, advances in “on-line” 
radiotherapy image guidance technology mean that many extracranial targets can now 
be tracked with the required accuracy to deliver radiosurgical doses safely. Modern 
systems use either volumetric imaging (eg cone-beam CT or in-room CT-on-rails), or 
planar imaging together with implanted fiducial markers or bone-tracking software. As 
a result of this improved technology, “Stereotactic” Body Radiotherapy (SBRT) has 
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emerged as a new treatment, and its use has been increasing steadily over the last 
decade. 
CyberKnife (Accuray Inc, Sunnyvale, CA) is an example of a modern image-guided 
radiosurgery system. It was first conceived in 1990 by John Adler, a neurosurgeon at 
Stanford University, with the first patients being treated a few years later (9). A compact 
X-band linac is mounted on a six-joint robotic arm, allowing delivery of multiple non-
coplanar beams from a wide range of angles around the patient. Image guidance is 
achieved by virtue of two kilovoltage x-ray sources positioned at 90 degrees to each 
other. The use of planar imaging allows intra-fraction image guidance with repeat 
imaging (and adjustment if necessary) after each beam delivered. Thus the system can 
deliver “frameless” radiosurgery to both intracranial and extracranial targets. 
Additionally, since no frame is needed, treatment can be fractionated where appropriate. 
A detailed description of the CyberKnife system components follows in the next 
chapter. 
 
Clinical use of intracranial radiosurgery 
 
There are now over forty years’ published data on the use of intracranial radiosurgery. 
Most of this experience has come from the Gamma Knife system, although there have 
also been important publications from centres using gantry-based linacs and, more 
recently, the CyberKnife system. As stated above, the first radiosurgery treatments were 
for functional disorders such as trigeminal neuralgia, and whilst the technique was 
temporarily abandoned for this indication in the 1970’s-80’s, the availability of high 
quality MR imaging led to a re-emergence of use in the 1990’s, and there have since 
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been some encouraging reports. For example, Régis et al (10) presented prospective 
data from one hundred patients treated with a single maximum dose of 70 – 90 Gy using 
Gamma Knife. At minimum twelve months follow-up, 83/100 were pain-free and 58 
had stopped taking medication. There was a 10 % incidence of mild facial paraesthesia 
or hyperaesthesia. However, the authors acknowledge that microvascular surgical 
decompression (MVD) should be considered as the first-line treatment in most cases.  
 
There is a large body of published experience of the use of radiosurgery for the 
treatment of arterio-venous malformations (AVMs), and it is now regarded as the 
standard of care for many of these patients. High-dose irradiation causes progressive 
stenosis, luminal closure and eventual obliteration of the AVM nidus. The University of 
Pittsburgh Gamma Knife centre has been a regular contributor to the literature. For 
example, Flickinger et al (11) reported a 75 % nidus obliteration rate in 351 patients 
treated with a single marginal dose of 12 – 30 Gy (median 20 Gy). On dose-response 
modelling, there was an estimated 88 % maximum obliteration rate, for doses in the 
region of 22 – 25 Gy. There was no evidence for any benefit of dose escalation beyond 
25 Gy. The same authors had also performed multivariate analysis on the data from 307 
AVM patients, investigating risk factors for developing post-radiosurgical imaging 
(PRI) changes predictive of symptomatic complications. The 12 Gy volume (V12) was 
the only parameter showing a significant correlation with development of PRI changes 
(12). In a further publication (13), these authors have produced V12 graphs for different 
parts of the brain, which predict the risk of complications, and which are used by many 
centres as an aid to radiosurgical treatment planning (Figure 1.2). 
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Figure1.2 Graphs showing the percentage risk of symptomatic radiation necrosis against the volume of 
brain receiving 12 Gy or more, with different plots for the different areas of the brain. Graphs produced 
from Pittsburgh Gamma Knife Center patient data(13). 
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The treatment of small (< 3-4 cm diameter) acoustic neuromas (vestibular 
schwannomas) is another area where many people now regard radiosurgery as the 
standard of care. The radiation dose required to give long-term tumour control is lower 
than orginally predicted, and so prescribed doses have come down (eg 12.5 – 13 Gy in 
one fraction or 18 Gy in three fractions), in turn leading to improved complication rates. 
When compared to most surgical series, modern radiosurgery gives comparable local 
control and improved hearing preservation, together with reduced treatment-related 
morbidity. Lunsford et al (14) presented a retrospective review of fifteen years’ 
experience, treating 829 patients with a median marginal dose of 13 Gy using Gamma 
Knife. In the 252 patients with more than ten years’ follow-up, long-term local control 
was 98 %, although local control was defined as “absence of the need for further 
intervention”. The 5-year actuarial rates of hearing preservation and speech preservation 
were 69 % and 86 % respectively. It has been suggested that fractionating treatments 
may result in less cranial nerve damage (for example, 18 Gy in 3 fractions is favoured 
by Stanford CyberKnife centre (15)) although superiority over single fraction regimens 
remains to be proven. 
 
Surgery remains the best treatment for many intracranial meningiomas, however 
tumours located near the base of skull are very difficult surgical targets, and the risk of 
complications is much higher, even with modern microsurgical techniques. 
Radiosurgery has emerged as a very good treatment option for small meningiomas, 
especially in surgically hazardous locations such as the cavernous sinus and optic nerve 
sheath. The biggest single retrospective analysis of the results of benign meningiomas 
treated with radiosurgery has been performed recently by Santacroce et al (16). 5300 
tumours in 4565 patients were treated across fifteen participating Gamma Knife centres, 
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using a median marginal dose of 14 Gy. Local control was 93 % with median five years 
radiological follow-up. This comprised a decrease in tumour volume in 54 %, and stable 
appearances in the other 39 %. The permanent morbidity rate was 6.6 %. Colombo et al 
(17) have reported on 199 meningioma patients treated with CyberKnife using 2 – 5 
fractions. Local control was 92 % with median 30 months follow-up. Approximately 30 
% of these patients had tumours which would have been considered too large for single 
fraction radiosurgery. 
 
Trans-sphenoidal surgery (TSS) is the preferred primary treatment for most pituitary 
adenomas and, in the case of secreting tumours, patients can feel better in a matter of 
hours. CFR is usually offered as adjuvant treatment, for example, if secreting hormone 
levels do not come down satisfactorily. Radiosurgery is sometimes used in the adjuvant 
setting, but has a more established role in the salvage of patients with small, discrete 
local recurrence. Pituitary tumours are often situated very close to the optic apparatus, 
and the steep external dose gradients produced in radiosurgery are especially important 
here. Mingione et al (18) reported on one hundred consecutive patients with residual or 
recurrent non-secretory pituitary macroadenoma, treated with a single median marginal 
dose of 18.5 Gy (range 5 – 25 Gy). There was 92 % local control with median 45 
months radiological follow-up, with tumour volume decreasing in 66 %. The incidence 
of hormonal deficit in patients with fully-functioning glands was 20 % at median four 
years follow-up. Recent UK data have established the usefulness and safety of 
radiosurgery for treating focal relapse of pituitary adenoma in patients who have already 
received CFR (19). 
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The management of brain metastases is a controversial area. Unlike the above 
conditions, these patients generally have a very poor prognosis. Median overall survival 
is approximately seven months, although this can be stratified using the disease-specific 
graded prognostic assessment (20) in order to identify patients most likely to benefit 
from intervention. Surgery, radiosurgery and whole brain radiotherapy (WBRT) are all 
treatment options, and can be used in combination. The published literature contains 
many different permutations and can appear confusing.  
 
Patchell et al (21, 22) have provided two small randomised trials involving the use of 
surgical resection in patients with single brain metastases. Firstly, the addition of 
surgical resection to WBRT resulted in a significant overall survival advantage (40 
weeks vs 15 weeks) and greater preservation of functional dependence, compared to 
WBRT alone (21). A second trial used surgery +/- post-operative WBRT, again for 
single brain mets. This showed a significant decrease in recurrence, both locally and in 
the rest of the brain, in the arm receiving WBRT. There was no overall survival 
difference, although the trial was underpowered to detect this (22). More recently there 
has been interest in the use of radiosurgery to the post-operative resection cavity (23), 
thus removing, or at least delaying, the need for WBRT. 
 
Andrews et al (24) have provided level 1 evidence of increased local control and overall 
survival from the addition of a radiosurgery boost to patients who have undergone 
WBRT for a single metastasis. However, there was no significant benefit in patients 
with multiple metastases. Chang et al (25) explored the benefit of adding WBRT to 
radiosurgery in 58 patients with up to three metastases. One-year local control rates 
were lower, and distant brain recurrence rates higher, in the radiosurgery-only arm, with 
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a greater number requiring salvage treatment. However, overall survival was actually 
higher in this arm, and cognitive decline (as measured using verbal memory tests) was 
less at four months post treatment. 
The above clinical situations represent the most common indications for radiosurgery, 
although other lesions are also treated, such as craniopharyngiomas and skull base 
chordomas and sarcomas. 
 
Radiobiological considerations in radiosurgery 
 
The Linear Quadratic model is the most commonly used mathematical model of the 
response of different tissues to different doses of radiation (26): 
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where d = dose per fraction, and ! and " indicate the tissue sensitivity to lower and 
higher doses of radiation respectively. Attempts to form a mechanistic justification for 
the mathematical model include the postulation that the linear component is due to 
single radiation track lethal events, and the quadratic component due to two-track 
events. The !/" ratio determines the “bendiness” of the log cell survival curve (Figure 
1.3), and therefore the tissue sensitivity to changes in fraction size. Many malignant 
tumours have a high !/" ratio (eg 10 – 20 Gy for squamous cell carcinoma of the lung) 
and most late normal tissue effects have a low !/". This provides the rationale for 
conventional fractionation (1.5 – 2 Gy per fraction), in order to improve the therapeutic 
ratio, when tumour and normal tissue are both contained within the PTV. In addition to 
fraction size, there are further factors which influence the response of tissues, such as  
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Figure 1.3 Graph of Log10 Surviving Fraction against Dose (Gy) for two different tissues, as predicted by 
the Linear Quadratic Equation. The tissues have different !/" values, giving rise to the different shapes 
seen. The red curve corresponds to !/" = 10, which is often used to model rapidly-proliferating tumours 
eg squamous cell carcinoma of the head and neck. The blue curve corresponds to !/" = 2, which is often 
used to model late normal tissue effects such as spinal cord myelopathy. 
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Withers’ (27) “4 Rs”: Repair, Repopulation, Reoxygenation and cell cycle 
Reassortment (Radiosensitivity is often added as a fifth “R”). Hypofractionation is the 
use of any fraction size larger than 2 Gy. Moderate hypofractionation (for example, 
doses in the range 2.5 – 7 Gy per fraction), as with conventional fractionation, 
corresponds to the curved “shoulder” of the log cell survival curve (Figure 1.3), where 
both linear and quadratic components contribute to the effect. DNA repair and the other 
“Rs” are therefore still important in this dose range. Extreme hypofractionation (for 
examples, doses greater than 8 Gy per fraction) corresponds to the exponential (linear) 
part of the cell survival curve. Radiosurgery uses one large single fraction, and therefore 
represents the most extreme form of hypofractionation. At doses of this magnitude, 
there is a high probability of disrupting both clonogenicity (the ability of cells to form 
colonies by cellular division) and cellular function: this is often referred to as ablation. 
The radiobiological considerations important in conventional fractionation, such as the 
“5 Rs”, become less significant at these doses. Normal tissue is protected by virtue of 
the highly conformal prescription isodose line encompassing a target volume containing 
negligible normal tissue, and the steep external dose gradient outside of this. 
 
In extra-cranial stereotactic radiotherapy (SBRT), slightly larger PTV margins are often 
required in order to account for intra-fraction target movement. Also the targets treated 
may be larger eg prostate gland. This means that a greater volume of normal tissue will 
lie inside (and immediately outside) the PTV. SBRT is often delivered in 3 – 5 
fractions, acknowledging the need for at least some degree of normal tissue recovery. 
Since hypofractionation will usually lower the therapeutic ratio relative to conventional 
fractionation, SBRT only makes logical sense in certain clinical situations. Firstly, when 
the !/" of the tumour is thought to be lower than that of the surrounding tissue late 
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effects, then hypofractionation will actually improve the therapeutic ratio. Secondly, 
when the surrounding normal tissue is a parallel organ then small volume normal tissue 
ablation will not cause any loss in tissue function. This is discussed in more detail 
below. Thirdly, when the PTV and OAR(s) are a sufficient distance apart, then the steep 
external dose gradient results in a safe dose to the OAR. This distance may only need to 
be a few millimetres. 
 
Whilst the linear quadratic equation models tissue response accurately over the range of 
doses used in conventional fractionation and moderate hypofractionation, there have 
been questions raised about its accuracy when very large fraction sizes are used. The 
LQ equation has a continuously bending shape, and may overpredict the effects at large 
doses. There have been a number of proposed modifications in order to increase the 
accuracy at larger doses, such as the Modified Linear Quadratic model by Guerrero and 
Li (28) and the Universal Survival Curve by Park et al (29). However, Fowler (30) has 
suggested that for rapidly-proliferating tumours, increasing the !/" from 10 to 20 
straightens the curve sufficiently over the dose ranges used in radiosurgery and SBRT. 
 
Radiobiology can inform us about normal tissue structural tolerance, however it is 
functional radiation tolerance which is more relevant to the patient. Functional tolerance 
depends on tissue organisation as well as cellular radiosensitivity. A distinction can be 
made between so-called “serial” and “parallel” OARs (31). In a serial organ, damage to 
a small volume may cause loss of function of the whole organ. Spinal cord is often 
considered to be the best example of a serial organ, as function is dependent on the 
integrity of the entire length of the nerve fibres within. From an intracranial perspective, 
the brainstem is the largest serial structure. It is continuous with spinal cord, and is 
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believed to share many radiobiological similarities. Additionally, with regard to 
hypofractionated radiotherapy, spinal cord and brainstem are believed to have a low !/" 
ratio (a value of 2 is often used), and are therefore especially sensitive to large fraction 
sizes.  
 
The radiation tolerance of serial organs is consequently usually defined in terms of 
maximum dose to any part of the organ, for example 50 Gy in 25 fractions, or 15 Gy in 
1 fraction, for brainstem. However, modern planning systems can provide the “point” 
maximum dose to one voxel (often < 1 mm3) of the OAR. It is not entirely clear 
whether it is most useful to apply dose constraints to this tiny volume, or rather the dose 
to some larger, but still very small, volume. Radiosurgical treatment plans often contain 
steep dose gradients, such that the maximum dose to a single voxel can be substantially 
higher than the dose even to a very small volume such as 10 – 20 mm3. A greater 
understanding of the dose-volume effects in serial organs would therefore be of use to 
the radiosurgical community. This is discussed further in Chapter 6, which concerns 
optimising external dose gradient on one side of targets close to (or abutting) the 
brainstem. 
 
Parallel organs (eg lungs, liver) are comprised of multiple subunits which all have the 
same function, and which function independently of each other. Functional damage will 
therefore only occur if a critical volume of tissue is damaged. Dose constraints in 
treatment planning are therefore usually defined in terms of the volume of organ 
receiving a certain threshold dose. For example, V20 (volume receiving at least 20 Gy) 
< 30 % volume is a common lung constraint in 2 Gy/fraction radical radiotherapy. In 
SBRT, when the target lies within the parenchyma of parallel organs, a small volume of 
#*"
"
organ tissue within (and immediately adjacent to) the PTV will be destroyed. However, 
extreme hypofractionation may still be a safe treatment, provided that the target volume 
(and therefore the volume of normal tissue affected) is sufficiently small. 
 
In intracranial radiosurgery, as with the lungs and liver, the target may lie entirely 
within an OAR. It is usually accepted, therefore, that a small rind of normal brain 
surrounding the target is at risk of damage, notwithstanding the steep external dose 
gradient. Brain tolerance limits are often defined in terms of the volume receiving a 
certain dose. For example, as discussed above, the 12 Gy volume (V12) has been shown 
to correlate with post-radiosurgery complications. However, in spite of this no part of 
the brain can be viewed as truly parallel, since even damage to a very small volume of 
cerebral cortex can have profound consequences. The V12 graphs described above 
demonstrate that certain parts of the brain need to be especially respected (Figure 1.2). 
Small targets and a steep external dose gradient will both reduce the V12, and are 
therefore critical to the safe delivery of intracranial radiosurgery. Optimising the dose 
fall-off evenly around the target using the CyberKnife system is covered in Chapters 4 
and 5.  
 
Dose rate has been shown to be a very important variable in radiobiology (32). The dose 
rate effect is likely to be important in radiosurgical practice since fraction times can 
vary significantly across the different modern radiotherapy systems. For example, the 
duration of a single 18 Gy fraction to an intracranial lesion would usually be 30 – 60 
minutes using CyberKnife, but could be as short as 10 minutes using modulated arc 
therapy. It is therefore not clear to what extent 18 Gy delivered using the two different 
techniques actually differs in biological effect. For example, 18 Gy in 1 fraction 
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delivered over “x” minutes may be comparable to 20 Gy in 1 fraction delivered over “y” 
minutes using a different system. However, the effect of dose rate is currently not really 
considered when discussing and comparing radiosurgical treatment plans in everyday 
clinical practice. More research is needed in this area, as will be discussed later. 
 
Dosimetry in radiosurgery 
 
Radiation dosimetry is the calculation of absorbed dose in matter as a result of exposure 
to ionising radiation. This covers radiotherapy system Quality Assurance (QA), and all 
aspects of radiotherapy treatment planning. The general principles of treatment planning 
are the same for radiosurgery as for CFR: the goal is to minimise dose to normal tissue 
(or the volume receiving a particular dose) for a given dose to the target. There are, 
however, some important differences between radiosurgery and CFR in the area of 
dosimetry. 
 
Perhaps the most obvious difference is the much smaller field sizes that are commonly 
used in radiosurgery, which is a direct consequence of the smaller targets treated. This 
has implications with regard to QA, since specialist apparatus (and experience) is 
required to perform small field dosimetry appropriately. The Institute of Physics and 
Engineering in Medicine (IPEM) have recently produced guidelines for small field 
dosimetry (33), but the area remains controversial. Chapter 3 will include an appraisal 
of the different techniques and apparatus that could be potentially used in small field 
QA. 
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Another important difference is the selection of the isodose which covers the target – 
the marginal isodose. In CFR, dose is prescribed to the 100 % value on the treatment 
plan. Most plans conform to ICRU 50 and 62 recommendations (34, 35), such that the 
95 % isodose covers the whole PTV, and the maximum dose on the plan is < 107 %. 
Consequently the dose heterogeneity within the PTV is usually less than 12 %. 
However, in radiosurgical planning 100 % represents the maximum dose delivered, and 
the treatment dose is prescribed to the marginal isodose. Common radiosurgical practice 
is to use lower marginal isodose values, resulting in greater dose heterogeneity inside 
the target (the choice of marginal isodose is central to much of the experimental work in 
this thesis). A consequence of target dose heterogeneity is that it is harder to be sure of 
the true “effective” dose delivered. Additionally, there is considerable variation in 
practice across different radiosurgical systems (and across different centres using the 
same system!). For example, common Gamma Knife practice is to use marginal 
isodoses in the range 40 – 60 %, whereas CyberKnife and gantry-based linac 
publications usually show the use of isodoses in the range 60 – 90 %. This implies that 
the integral dose to the target for two plans with the same prescribed dose can be very 
different, and therefore comparing results between different centres can be problematic.  
 
Radiotherapy clinicians are familiar with using Biologically Effective Dose (BED) or 
Equivalent Dose in 2 Gy fractions (EQD2) (both of which are derived from the linear 
quadratic equation) to compare treatment regimens of different fractions, and can 
perform these calculations by hand. However no attempts are usually made to account 
for the effects of a different marginal isodose in radiosurgery or SBRT. The generalised 
Equivalent Uniform Dose (gEUD) has been proposed by Niemierko (36) as a method of 
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reducing a heterogenous dose distribution across a target to a single dose which, if 
delivered uniformly across the target, would have the same biological effect: 
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where Di is the dose to a voxel i of the volume, N is the total number of voxels and a is 
a tissue-dependent factor. However, even though this formula is a simplification of the 
original EUD equation proposed, it is still too complicated to be calculated by clinicians 
in everyday practice. It would be useful, therefore, if this formula could be incorporated 
into future treatment planning software, so that appropriate plan comparisons can be 
made. 
 
A further difference between CFR and radiosurgery is the very steep external dose 
gradient outside the target which is seen in radiosurgical plans. As stated above, this is 
critical to the safe delivery of ablative doses of radiation. External dose gradient is 
therefore an important radiosurgical parameter, together with target conformality and 
coverage. There have been a number of proposed measures of both external dose 
gradient and conformality, and these are discussed fully in Chapter 4. Optimising 
external dose gradients in CyberKnife radiosurgical planning is the central goal in three 
of the experimental chapters in this thesis. In particular, the relationship between the 
choice of marginal isodose value and external dose gradient is explored in detail. 
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Outline of thesis 
 
This chapter has provided a background of the historical, clinical and radiobiological 
aspects of radiosurgery. It has also introduced the subject of radiosurgical dosimetry, 
which will be the main focus of this thesis. 
 
Chapter 2 will describe the G4 CyberKnife and Gamma Knife Perfexion systems in 
detail. There will be a summary of 3-dimensional radiotherapy planning techniques, 
focusing on the planning software used with the above two systems. 
 
Chapter 3 will seek to verify that treatment plans produced by MultiPlan (the 
CyberKnife planning software) accurately reflect the actual treatment delivered, and 
that subsequent work based on MultiPlan dose distributions is therefore valid. 
 
Chapter 4 will explore the effect of the prescription (marginal) isodose value on the 
external dose gradient, as measured by Gradient Index, for solitary spherical virtual 
targets of different diameters, using two different optimisation algorithms in MultiPlan. 
 
Chapter 5 will continue the work of the previous chapter, but now using irregularly-
shaped lesions from patients treated at this centre. On the basis of these results, a 
method for the planning of solitary intracranial lesions using MultiPlan will be 
proposed. 
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Chapter 6 will consider the situation where an intracranial target lies close to, or 
abutting, the brainstem – where the external dose gradient is therefore especially 
important on one aspect of the target. Once again, spherical virtual targets of different 
sizes will be used. 
 
Chapter 7 will describe a dosimetric comparison of the CyberKnife and Gamma Knife 
systems. Identical target contours will be planned using each system, and various 
important planning parameters compared.  
 
In Chapter 8, all the results of the experimental chapters will be brought together and 
summarised. There will be a general critique of the experimental methods, and areas for 
future research will be proposed.  
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Chapter 2 - Materials and Methods 
 
The vast majority of the work in this thesis has been carried out using the CyberKnife 
system, and therefore this chapter contains a detailed description of the main system 
components. The key components of Gamma Knife hardware and software are also 
summarised, as a planning comparison of the two systems forms part of the 
experimental work which follows. Radiosurgery planning is at the heart of the thesis, 
and so this chapter also covers the various planning techniques and optimisation 
algorithms used in the experimental chapters. 
 
Overview of the radiosurgery systems used 
 
CyberKnife 
 
CyberKnife is a radiosurgery system which uses robotics and image guidance to deliver 
radiotherapy with “stereotactic” accuracy (9). As discussed above, radiosurgical 
systems have traditionally relied upon immobilisation via a rigid stereotactic frame in 
order to treat with the required sub-millimetre accuracy. For frame-based systems 
stereotactic space is within the frame and hence clinically confined to the cranium. The 
ability of CyberKnife to achieve this accuracy without rigid immobilisation allows the 
system to deliver radiosurgery to both intracranial and extracranial targets. Unlike 
gantry-based linear accelerators, there is no fixed isocentre. For each patient, an align 
centre within the patient is chosen during the treatment planning stage, and beam 
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coordinates are relative to this. Figure 2.1 is a picture of a G4 CyberKnife, with the 
different system hardware components labelled. 
 
X-band Linear Accelerator (Linac) 
 
In a linear accelerator, electrons produced by thermionic emission gain megavoltage 
energy by being accelerated through multiple electromagnetic fields within a 
waveguide. The required length of the waveguide is dependent on the frequency of the 
electromagnetic field used to accelerate the electrons. The majority of conventional 
linacs use frequencies within the S-band (2-4 GHz) range. In the last twenty years, 
advances in technology have enabled the production of linacs which use 
electromagnetic fields within the X-band (8-12 GHz) range. This reduces the required 
length of the waveguide by two thirds, leading to a much more compact and lightweight 
design. The G4 CyberKnife system uses a 6 MV X-band linac with a dose rate of 800 
MU/minute, mounted on the robotic arm. 
 
(Secondary) Collimators 
 
In CyberKnife, both fixed and variable aperture (Iris) collimators are available, which 
dictate the field size of the radiation beam. The fixed collimators are tungsten inserts 
with conical holes, creating a circular beam with a penumbra (20 – 80 %) of 
approximately 3.8 mm. There are twelve different fixed collimators with field sizes 
between 5 mm and 60 mm. They are housed on an exchange table, allowing the robot to 
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Figure 2.1: Picture of the G4 CyberKnife system, with the key system components labelled. 
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exchange automatically collimators as required during treatment. Up to three different 
fixed collimators can be used for each treatment. The Iris collimator is a more recent 
development which was introduced with the G4 CyberKnife. It contains two stacked 
hexagonal banks of tungsten segments, offset by 30 degrees to each other. This 
produces a radiation beam in the shape of a dodecagon. The segments move to adjust 
the size the aperture, with all twelve segments being driven by a single motor. In this 
way, the collimator can approximate all 12 fixed collimator circular field sizes, with a 
mechanical reproducibility of less than 0.1 mm. The Iris collimator allows any 
combination of the twelve different field sizes to be used for each treatment. This can 
substantially reduce the overall treatment time and, in some cases, improve the quality 
of the plan. 
 
Robotic manipulator 
 
The manipulator arm is a KUKA KR 240-2 (Series 2000) industrial robot (KUKA 
Robot Group, Augsberg, Germany). It has a payload (carrying capacity) of 240 Kg. The 
maximum reach is 2.7 m, and it has 6 joints, which enables the beam to be pointed in 
any 3-dimensional angle, from every position within the reach of the manipulator. This 
setup produces a large non-coplanar workspace around the treatment couch, from which 
radiation beams can be delivered. The arm has a reproducibility of 0.12 mm, and a rapid 
response time, enabling anticipatory movement of the beam head to track respiratory 
movement, where appropriate. 
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Treatment Couch 
 
The couch consists of a flat carbon fibre top mounted on an additional six joint KUKA 
robotic arm, which enables movement in the 3 translational (left-right, superior-inferior, 
anterior-posterior) and 3 rotational (roll, pitch, yaw) planes. This allows the couch to 
correct for any tumour (or patient) movement which is beyond the pre-specified robot 
limits, without the need to reposition the patient. This can be especially useful when 
treating certain tumour sites (eg prostate) where there may be significant, but variable 
intra-fraction tumour movement. 
 
Kilovoltage X-ray sources and flat panel image detectors 
 
Two kilovoltage x-ray sources are mounted on the ceiling of the treatment room, with x-
ray beams at an angle of 45 degrees to the patient and 90 degrees to each other. The 
beams cross at the imaging centre. Each source has a corresponding in-floor mounted 
flat amorphous silicon image detector. The detectors have a 20 x 20 cm field of view 
and a resolution of 1024 x 1024 pixels. Pairs of images are obtained throughout patient 
setup and treatment. They are compared with the digitally reconstructed radiographs 
(DRRs) generated from the planning CT, and the error for each of the six degrees of 
freedom is calculated. The robotic arm can move the beam head to compensate for 
errors within a certain tolerance; beyond this, the treatment couch must realign the 
patient by moving appropriately, before treatment can resume. 
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Synchrony camera 
 
The Synchrony camera array consists of 3 charged couple device (CCD) detectors 
oriented towards the patient. Together they can track the 3-dimensional position of light 
emitting diodes (LEDs) placed on the patient’s chest. As the chest wall moves with 
breathing, real-time information on chest wall position is fed to the Synchrony software, 
and a breathing model is generated. The Synchrony software is used in conjunction with 
fiducial-based tracking (see below).  Several static KV images are obtained at different 
points in the breathing cycle, and the software correlates fiducial position with 
breathing. A predictive algorithm is generated which enables the radiation beam to track 
the tumour continuously. This obviates the need for respiratory gating. 
 
Tracking  
 
A key aspect of CyberKnife radiosurgery is the ability to track the position of the target 
(or some surrogate for target location) accurately, both during initial treatment setup and 
throughout treatment delivery.  As described above, the KV x-ray sources enable near 
real-time image guidance through comparison with the DRRs. As they are planar 
images, most solid tumours are not visible. The treatment system therefore has a 
number of different tracking methods which are used depending on the treatment site. 
Data on the accuracy of these methods have been published previously (37-42). 
 
 
%!"
"
6D Skull tracking 
This is the method of tracking for all intracranial lesions and some head and neck 
tumours which are felt not to move relative to the skull. The skull is a rich source of 
distinctive bony anatomical features easily seen on planar imaging. The 6D skull 
software compares the images obtained during setup and treatment with the DRRs, and 
can adjust for displacement in the 6 directions of movement using rigid transformation, 
with a demonstrated total system accuracy of 0.44 - 0.48 mm (37, 42). The patient is 
fitted with a thermoplastic shell, to ensure any head movement is limited to a few mm – 
comfortably within the corrective tolerance of the robot.  
Xsight Spine tracking 
The spine is a similarly rich source of bony anatomical features. However, unlike the 
skull, the individual vertebrae move independently of one another during treatment, 
therefore rigid transformation between live images and the DRR is not valid. Instead the 
software performs non-rigid image registration based on a bony region of interest near 
the target. The total system accuracy when using Xsight Spine tracking has been 
measured at 0.52 - 0.61 mm (38, 39). It can be used to treat most spinal tumours, and 
selected soft tissue tumours which are within a few cm of the spinal column, and which 
are not likely to move relative to the spine. 
Fiducial-based tracking 
This method is used in most cases where neither 6D skull nor Xsight Spine tracking is 
appropriate. Small gold cylindrical fiducial markers are inserted into (or close to) the 
tumour, and act as a surrogate for tumour position. Fiducial insertion occurs under 
radiological guidance, via a percutaneous, trans-rectal (prostate tumours) or endoscopic 
(selected thoracic and abdominal tumours) approach. This software relies on rigid 
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transformation, therefore if a fiducial has migrated more than 1.5 mm between planning 
CT and treatment, it cannot be used, and there must be a minimum of 20 mm between 
each marker. Additionally, fiducials which overlap in either 45 degree imaging plane 
cannot be used. A minimum of 3 fiducials are required to apply both translational and 
rotational corrections; a single fiducial is sufficient for translational corrections alone. 
Phantom studies have shown the accuracy of fiducial tracking to be 0.68 +/- 0.29 mm 
when used alone for stationary targets (40), or 1.5 mm as part of the Synchrony system 
for targets moving with breathing (41). 
Xsight Lung is a recent development which can track selected lung tumours without the 
need for implanted fiducials, thus avoiding a procedure which carries the risk of 
pneumothorax. The tumour must be visible on both 45 degree KV images and larger 
than 15 mm in maximum diameter. 
 
MultiPlan Treatment Planning System 
 
MultiPlan (Accuray Inc) is the system software which manages all aspects of 
CyberKnife treatment plan generation. The tasks are arranged into six sections which 
are displayed as tabs across the top of the page (Figure 2.2). The workflow passes 
logically through each section in turn, the final result being a deliverable treatment plan 
which can be exported to the treatment delivery system. 
 
 1. Load. New plans are created here by importing the planning CT dicom files, together 
with any additional imaging datasets as appropriate. Pre-existing plans can be loaded for 
further work.
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Figure 2.2: Screenshot showing the layout of MultiPlan version 3.5.1 software, with the tabs at the top of 
the screen subdiving the various planning taks. In the screenshot the “Contour” window is shown, which 
allows axial, sagittal and coronal views to be reviewed simultaneously. A “virtual” spherical target has 
been drawn, toghether with 3 optimisation shells at 3, 6 and 15 mm distance from the edge of the target. 
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2. Fuse. This tab displays tools for registering the primary (planning CT) image series 
with any secondary series imported to aid target delineation, such as contrast-enhanced 
CT, MRI or PET. Common anatomical “seed points” (eg spinous process) are selected 
on both image sets, and an initial transformation is carried out. The system can perform 
an intensity-based registration process to improve the accuracy of fusion. The results 
can also be adjusted manually with reference to axial, sagittal and coronal planes. The 
accuracy of image fusion is critical to the total system accuracy, and therefore the 
importance of this step should be stressed.  
 
3. Contour. Targets and Organs at Risk are created here using a variety of contouring 
tools. Each “volume of interest” (VOI) is contoured in axial, sagittal or coronal plane, 
with options to expand or erode VOIs as required. The “ball-cube” function allows the 
creation of a spherical target, the location and diameter of which can then be adjusted as 
appropriate. This function will be used in Chapters 4 and 6. 
 
4. Align. As previously mentioned, there is no fixed isocentre in the CyberKnife system. 
Before treatment planning can begin, an align centre must be chosen, which will also be 
the imaging centre for the plan. This point is selected such that all the anatomical 
information required to track the target is included in the DRRs (and subsequent in-
room KV images). For example, with 6D skull tracking, the align centre will be a point 
within the brain selected so that as much skull anatomy as possible is visible in the 20 x 
20 cm DRRs. For fiducial tracking, the align centre is usually the mid-point between all 
fiducials present. All beam coordinates are now relative to this fixed point. The number 
of fractions, tracking method, and choice between using Iris or fixed collimators are all 
decided at this stage. 
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5. Plan. In this section treatment plans are generated, evaluated and modified, and can 
be saved at any point during this process. MultiPlan has the option of both isocentric 
and non-isocentric planning techniques.  
 
In isocentric planning, a point within the target is chosen as the isocentre, and beams 
from each location in the treatment path are selected, all of which converge on that 
point. Whilst this is a quick and relatively simple method of planning, it lacks the 
flexibility inherent in the non-isocentric planning techniques, and is therefore only used 
rarely. 
 
In non-isocentric planning, whilst all the beams are convergent on the target, they do 
not meet at a single point. There are a huge number of potential beams which could be 
selected for each plan, and multiple other variables to consider, and therefore inverse 
planning optimisation algorithms are used here (see below). MultiPlan has a choice of 
three different optimisation algorithms: Simplex and Iterative (conformal planning 
algorithms), and Sequential optimisation. Radiotherapy treatment planning techniques 
and, in particular, the Simplex and Sequential algorithms are discussed in more detail 
below. 
 
MultiPlan uses a Ray-Tracing algorithm as the standard method of dose calculation. The 
algorithm traces a straight line from each beam to each point in the patient. The 
“equivalent path length” is calculated based on the distance to that point and the density 
of the tissue traversed in reaching it (based on the CT number of each pixel in the 
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beam’s path). Using the equivalent path length, the dose delivered to that point is 
calculated based on the known depth-dose data for the beam. 
 
Ray-Tracing produces accurate results when tissue density is more or less uniform, but 
will tend to overestimate the dose delivered when the beam passes through an area of 
relatively lower density within the body, such as nasal cavity/sinuses or the lungs. This 
is because the algorithm fails to take into account the reduced secondary electron 
production in the lower density region, relative to the higher density region upstream. 
Consequently, inaccurate results may be obtained near boundaries of significant density 
change.  
 
Monte Carlo is regarded as the gold standard radiotherapy dose calculation algorithm. It 
simulates the probable particle interactions of each photon delivered (and every 
secondary electron produced) during treatment. Until recently, use of Monte Carlo in 
radiotherapy planning systems was limited due to the processing power needed to 
perform the calculation. However, the current MultiPlan versions are now capable of 
performing Monte Carlo dose calculation. Whilst it is still time-consuming, it would be 
recommended to recalculate plans using Monte Carlo where there is significant tissue 
heterogeneity as described above. 
 
Experimental work in this thesis concerns targets within the brain parenchyma, where 
tissue density is largely homogenous. In this situation, Ray-Tracing has been shown to 
produce accurate dose calculations. Ray-Tracing will therefore be the dose calculation 
algorithm used in this thesis. 
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6. Visualise. Within this tab are further ways to visualise the plan before approving it, 
such as viewing multiple slices of the isodose arrangement simultaneously, and a 3-
dimensional viewing option. Exporting DICOM files and 3-dimensional dose 
information is also possible here, as will be used in Chapter 7. 
 
Gamma Knife 
 
Gamma Knife is a dedicated radiosurgery system which delivers a single high dose of 
radiation to targets inside (or very close to) the skull. Central to the accuracy of 
radiation delivery is the use of a rigid frame which is fixed to the patient’s skull using 
metal screws. Thus, any target which does not move relative to the skull is effectively 
immobilised with this technique. Additionally, the frame defines the stereotactic space 
which is used for patient setup and treatment delivery. The system comprises the least 
possible number of movable components in order to preserve the accuracy achieved 
through immobilisation. Studies of overall system accuracy, including every step from 
frame immobilisation through to delivered treatment plan, have shown an accuracy of 
0.48 – 0.70 mm (43, 44).  A consequence of the frame is that unlike CyberKnife, the 
whole procedure, from image acquisition right through to treatment, needs to be 
performed in a single session. Another difference is that the system uses live radiation 
sources (Cobalt-60) which must be shielded adequately when not in use. The most 
recent system version is the Leksell Gamma Knife Perfexion, and this is the model 
which has been used in this thesis. The main components are summarised below. 
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Sources 
 
An array of 192 Cobalt-60 sources is arranged in a cone section configuration. All 
sources emit radiation which, via collimators, converge at a single point (isocentre), 
with a source to focus distance (FSD) varying from 374 to 433 mm. The resultant 
aggregate beam is referred to as a “shot”. The sources are subdivided into eight 
independently-movable sectors, each with 24 sources, mounted on the collimator body. 
Cobalt-60 emits gamma rays with energies of 1.17 and 1.33 MeV (and low energy beta 
particles which are easily shielded). The decay half life is 5.27 years, and cobalt sources 
should be replaced at least every three years to maintain adequate dose rate. The whole 
radiation unit sits in a cast iron body, and steel shielding doors are closed when 
treatment is not ongoing. Additionally, in the “Beam off” position, the sources are 
withdrawn from the collimators and not aligned with the collimator holes, thereby 
providing further shielding. 
 
Collimators 
 
Unlike previous Gamma Knife models, there is a single, 120 mm thick, tungsten 
collimator array with 576 collimator channels. This allows automatic change of 
collimator size during treatment. There are three different collimator sizes: 4 mm, 8 mm 
and 16 mm. The tray housing the sources moves to align them with the appropriate 
collimator size during treatment (Figure 2.3). The eight independently movable groups 
of sources can be aligned with different size collimator channels, and there is also the 
%*"
"
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Cross-sectional diagram through the Gamma Knife Perfexion collimator assembly.  Three 
Cobalt-60 sources (blue) are housed on a source tray (red) which can move along horizontally so that the 
sources align with the appropriate collimators. The 4, 8 and 16 mm collimators are shown here in yellow, 
green and red respectively. In the diagram the sources are aligned to the 4 mm collimator.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Screenshot from GammaPlan showing the treatment plan for an acoustic neuroma, consisting 
of six shots. Five of the shots are spherical, but shot 3 (shown in red) is non-spherical due to the blocking 
of segments 1,2,4,5 and 8. This allows the shot to conform more closely to the shape of the lesion, as 
shown in the axial, sagittal and coronal views. 
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option of blocking each individual sector of sources. These refinements allow the 
generation of a non-spherical shot, where desirable (Figure 2.4). 
 
Patient positioning system 
 
The patient lies on a flat couch and the frame is attached to a docking device which 
immobilises the frame (and skull) relative to the couch. The couch then moves the 
patient into the beam delivery unit, and sets the position according to the x, y and z 
spatial coordinates defined in the treatment plan. 
 
Leksell Coordinate G Frame 
 
This is a rectangular aluminium frame with engraved, scaled rulers which provide x, y 
and z coordinates.  It is fixed to the skull by means of four screws, each of which pass 
through one of the four rigid corner posts. The zero point of the coordinate system is 
superior, lateral and posterior to the frame on the patient’s right side. The radiation 
beam coordinates are relative to this point in stereotactic space. Indicator boxes specific 
to the imaging modality (CT, MRI or Angiography) are attached to the frame prior to 
scanning, and they impose reference fiducials which facilitate image registration. 
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Leksell GammaPlan Treatment Planning System 
 
GammaPlan deals with all aspects of image import, target delineation and treatment 
planning for the Gamma Knife system. It can handle CT, MR and PET images, in 
addition to projectional images from angiograms. Since all imaging is usually acquired 
with the frame in-situ, and the appropriate imaging box attached, accurate image 
registration can be performed easily. As with MultiPlan, the target and organs at risk 
can be contoured using a variety of different tools, and with access to axial, sagittal and 
coronal planes during this process. Unlike CyberKnife, a CT is not a requirement for 
treatment planning (although it may be desirable in some cases), since the CT number 
(density) of different tissues inside the skull is not taken into account. The patient’s 
skull contour is measured manually and uniform density is assumed for all tissue inside 
this contour. 
 
Gamma Knife treatment planning is a forward-planning process which involves the 
manual positioning of one or more shots in such a way as to maximise tumour coverage 
with the prescription isodose and minimise dose to normal tissue. This is discussed in 
more detail below. 
 
3-dimensional radiotherapy planning 
 
Before the implementation of axial scanning for radiotherapy, treatment planning was 
performed either by hand or with simple 2-dimensional computer dose calculation. 
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There was no compensation for inhomogeneity of tissue density, and much less 
flexibility to adjust established beam arrangements.  In the 1990s, CT planning arrived 
in the UK together with more sophisticated computer dose calculation software capable 
of processing the increased information obtained. Since then, computer planning 
systems have continued to evolve with ever greater complexity. Within 3-dimensional 
radiotherapy planning, the different planning techniques can be broadly divided into 
two categories: forward and inverse planning. 
 
Forward Planning 
 
In the case of forward planning for traditional 3-dimensional conformal radiotherapy, 
the planner has control over the number, direction, size, shape and weighting of 
individual beams (and in some cases the intensity across each beam). The planner 
attempts to produce a solution which best meets the clinical requirements by 
manipulating these variables. Often the number of beams and basic beam arrangement 
will be largely consistent for a particular treatment site (eg anterior and two opposed 
lateral beams for prostate radiotherapy), but patient-specific optimisation relies on fine-
tuning the remaining variables, and recognising when the “standard” beam arrangement 
needs to be modified. 
 
Gamma Knife planning is another example of forward planning in that the size, 
position, number and shape of the shots used is manually adjusted on a trial and error 
basis, in order to come up with a plan in which tumour coverage, conformality and dose 
fall-off outside the target have been optimised. Whilst occasionally a single shot is 
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sufficient to cover a lesion adequately, usually the planning process involves the 
positioning of multiple shots within the PTV and then fine-tuning the positions and 
weightings to optimise plan parameters.  
 
Similarities have been drawn between the Gamma Knife planning process and 
mathematical “sphere packing” problems, where the goal is to fill as much of a defined 
space as possible with a number of identical spheres. However, there are a few key 
differences, which have limited the ability to find “best solutions” through mathematical 
modelling. The standard sphere packing problems deal with identical, non-overlapping 
spheres inside a regularly-shaped space. In Gamma Knife planning, the spheres can be 
of different sizes, they can overlap inside the PTV, and the PTV itself is irregularly-
shaped. Additionally, with the advent of Gamma Knife Perfexion, non-spherical shots 
can now be used. The “composite shot” feature enables the generation of a single shot 
composed of different beam diameters. This, together with the ability to block specific 
sectors of sources, means that a wide variety of different shapes can be generated 
(Figure 2.4). Whilst such new features have made it easier to produce isodose 
arrangements which conform well to the targets, the quality of the plan produced 
remains largely dependent on the experience of the planner. Indeed, planning 
experience is a major potential confounding factor in any comparative study of different 
radiosurgical techniques, as will be discussed in Chapter 7. 
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Inverse Planning 
 
In the last twenty years, 3-dimensional planning has become more sophisticated with 
the emergence of Intensity-Modulated Radiotherapy (IMRT) and radiosurgery systems 
with huge flexibility, such as CyberKnife. With increased sophistication usually comes 
an increase in the number of variables which impact on the plan parameters. For 
example, with IMRT, in addition to the number, direction and weighting of beams, the 
fluence across the beam can be varied to improve dosimetry. Consequently in many 
situations it may not be possible to manipulate all these variables effectively with a 
forward planning technique. Inverse planning algorithms have therefore been developed 
with the processing power required to deal with this increased complexity. 
 
In inverse planning, the planner sets a series of goals and constraints relevant to the 
clinical situation, usually with some way of prioritising these, such as a weighting 
measure. The planning system then comes up with a solution which best meets the 
original goals. Unlike forward planning, therefore, the planner has no control over the 
precise number, position or weighting of the beams, or indeed any of the other variables 
such as beam fluence. 
 
An inverse planning optimisation algorithm will only attempt to achieve what it is 
specifically asked to, and if a particular set of goals are not possible to achieve, it may 
appear to “give up” rather than produce the nearest possible solution. Special care must 
therefore be paid when setting goals and constraints, and in addition, certain techniques 
are required to get the best out of the system.  
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Tuning structures are an important component of the inverse planning process as they 
give the planner increased control over the distribution of dose within a plan. The 
inverse planning goals which are set by the planner mainly apply to contoured structure 
sets. For example, a minimum dose to the PTV can be specified, together with a 
maximum dose to an OAR. Consequently, one may achieve a solution which meets the 
goals of PTV prescription isodose coverage and OAR constraints, but which still has 
undesirable features such as high dose in other areas, or shallow dose fall-off outside the 
PTV. Tuning structures are contour sets which do not relate to anatomical structures, 
but which the planning system recognises as structures with constraints attached. They 
can therefore help to guide the system to produce a plan with the best overall isodose 
arrangement.   
 
An optimisation shell (also sometimes referred to as a ring structure) is one such tuning 
structure which is central to the planning technique for many inverse-planned 
radiosurgical systems, and is used extensively throughout this thesis. A shell consists of 
a narrow 3-dimensional ring of tissue around the PTV, at a distance from the edge of the 
PTV (Figure 2.2). The shell contour is usually generated by an isotropic expansion of 
the PTV boundary, and is therefore the same shape as the PTV. A series of 2 or 3 shells 
at different distances from the PTV boundary are often used together. Goals and dose 
constraints can be applied to the shells in the same way as any other volume of interest. 
For example, by setting a maximum dose goal to a shell, this will encourage the 
planning system to ensure the dose has fallen off to this value over the distance between 
the PTV boundary and the shell. “Pushing” the system by setting more challenging shell 
goals may result in a steeper dose fall-off, but may also negatively impact on other 
parameters such as conformality. This is discussed in more detail later in the thesis. In 
&'"
"
general, for a given tumour coverage and conformality, the use of shells encourages 
steeper dose fall-off and helps to prevent high-dose fingers at a distance from the target 
(Figure 2.5). 
 
CyberKnife treatment planning deals with a huge number of possible beams from a 
large 3-dimensional space, and each selected beam only comprises a small proportion of 
the overall dose to the target. Inverse planning is therefore usually necessary to generate 
the best beam arrangement for each clinical situation.  As described above, there are 
three different inverse planning optimisation algorithms available in MultiPlan. Simplex 
and Sequential optimisation feature heavily in this thesis and are now discussed in more 
detail. 
 
Simplex optimisation 
 
Simplex is one of the two conformal planning algorithms. It requires the user to choose 
a desired minimum and maximum dose to the PTV, a maximum dose to other VOIs 
(organs at risk and optimisation shells), and a weighting applied to each of these values, 
based on their relative importance. The weighting can vary between 0 and 100, where 0 
means that the constraint is ignored, and 100 means that it must be met. All constraints 
with weighting > 0 but < 100 are referred to as “inexact constraints”. The planning 
system then aims a random selection of beams at different points on the PTV surface. 
The optimisation algorithm adjusts the delivery MUs of all the beams in order to 
minimise the total deviation away from the inexact constraints that have been set, and 
minimise the total MU delivered. In mathematical terms, the algorithm minimises
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Figure 2.5: Two screenshots from MultiPlan version 3.5.1 each showing a different treatment plan. An 
identical virtual spherical target of 15 mm diameter has been planned in both cases. The Sequential 
optimisation plan settings were identical, except that in plan A two optimisation shells were used), and in 
plan B no shells were used. In plan A the shells are shown in green, positioned at 3 and 6 mm distance 
from the edge of the PTV. The isodosimetry is shown in each case, with the lines corresponding to the 
following doses: green = 18 Gy (prescription isodose line), white = 15 Gy, pink = 12 Gy, purple = 9 Gy, 
light blue = 6 Gy, dark blue = 3 Gy. The plans illustrate that optimisation shells can help to produce a 
steeper, more even dose fall-off outside the target, and reduce the amount of moderate dose distant to the 
target. 
Plan A 
Plan B 
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Where #i is the deviation factor for each constraint, $i is the weighting for each 
constraint, and xj is the MU for each beam. There is no feedback during the 
optimisation process; the algorithm simply produces the best solution at the end. It is 
usually necessary to modify the constraints and weightings a few times to get the best 
solution, but each time the algorithm must start from the beginning. Thus, simplex 
optimises multiple, potentially conflicting objectives in a single step. 
 
Sequential optimisation 
 
Sequential differs from the more conventional optimisation algorithms (such as 
Simplex) where multiple objectives are grouped together in a single cost function and 
optimised simultaneously. Instead the algorithm is executed sequentially as a series of 
individual optimisation steps, where each step corresponds to a clinical objective (Table 
2.1). The steps are ordered in terms of clinical priority (rather than having weightings 
applied to them). It is argued that these features make the planning process more 
intuitive to the treating physician, thus encouraging more clinician input into the 
process.  
 
The user initially sets “hard” maximum dose limits for all the VOIs (PTV, OARs and 
shells), and certain other limits such as the maximum total MU to be used and 
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Table 2.1: showing the seven clinical objectives which can be used as individual steps during Sequential 
optimisation. Each step applies to a single specified structure eg PTV1, Shell1, or spinal cord (OAR). 
Each optimisation requires a minimum of one step; optimisation time will tend to increase as the number 
of steps increases. 
  
Objective 
 
 
Description 
 
Target   
 OMI “Optimise Minimum Dose”. Attempts to maximise the 
minimum dose to the whole target, bringing this up to 
as close to the desired prescription dose as possible. 
 OCO “Optimise Coverage”. Attempts to maximises the % of 
the target receiving at least the desired prescription 
dose, bringing this up to as close to 100 % as possible. 
 OHI “Optimise Homogeneity”. Attempts to cover the 
whole target with the prescription dose, whilst also 
minimising the dose variation inside the target. 
Optimisation Shell   
 OCI “Optimise Conformality”. Attempts to minimise 
overall maximum dose to any point in the shell, as 
close to the goal value as possible. 
Organ At Risk   
 OMA “Optimise Maximum Dose”. Attempts to give the 
smallest maximum dose to any point in the target, as 
close to the goal value as possible. 
 OME “Optimise Mean Dose”. Attempts to give the smallest 
total dose to the selected OAR, as close to the goal 
value as possible 
Overall Plan   
 OMU “Optimise Monitor Units”. Attempts to reduce as far 
as possible the total MU required to deliver the 
treatment, within the constraints applied by previous 
optimisation steps. 
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maximum MU per beam. These limits will be respected during the optimisation 
sequence. The steps are then selected in order of importance. A goal value is specified 
for each step (for example, optimise coverage of the PTV by the 18.5 Gy dose line), 
together with a relaxation value. The relaxation value informs the system how much the 
result of the current step can be compromised in order to achieve any step further down 
the list. 
 
For each step in turn, the result represents the optimal achievable value for that 
objective, given the existing constraints and relaxation values. Each result is applied as 
an additional constraint for each subsequent step. The plan is therefore built up one 
objective at a time, with gradual improvement seen after each step. Unlike Simplex, the 
planning process can be paused at any time to allow the adjustment of relaxation factors 
before being restarted at the same point. Reordering of the steps does however require 
restarting from the beginning. 
 
There are a number of additional planning variables within MultiPlan which are not 
covered here, but which can have a big impact on the final result, such as Target 
Boundary Distance (in Simplex and Sequential) and the Sequential Beam Reduction 
step. These, and their effects on plan parameters, are discussed in Chapters 4 and 5.  
 
This Chapter has provided a summary of the main features of both the radiosurgical 
systems which will be used in the experimental chapters, together with an introduction 
to the radiosurgical planning techniques which lie at the heart of this thesis. The 
following five chapters will describe and discuss the experimental work performed.  
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Chapter 3 – Assessing the concordance of planned and delivered dose 
distributions on the CyberKnife system, using plan-specific QA 
!
Introduction 
 
In later chapters, this thesis will explore ways to optimise the quality of radiosurgical 
plans produced with CyberKnife, and compare plans produced using CyberKnife and 
Gamma Knife systems. It is therefore important to verify that plans produced by the 
MultiPlan treatment planning software accurately reflect the actual treatment delivered, 
both in terms of the dose delivered and the spatial dose distribution. The purpose of this 
chapter is to establish the best method for doing this, and then to perform “plan-
specific” Quality Assurance (QA) on treatment plans produced in MultiPlan and 
delivered on a solid water phantom. 
 
QA refers to a program for the systematic monitoring and evaluation of the various 
aspects of a project, service, or facility to ensure that standards of quality are being met. 
QA is central to the safe and effective delivery of radiotherapy. It includes both the 
measurements performed during commissioning of a new radiotherapy system, and, for 
a working system, the regular checks to ensure that it continues to function with the 
required accuracy and reliability. Radiotherapy departments are responsible for 
designing and implementing appropriate QA protocols, which will specify both how 
often each test should be performed and the permitted tolerances in each case. These 
protocols are influenced by national QA radiotherapy guidelines, for example IPEM 
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Report No. 81 (45). Additionally, radiotherapy system manufacturers also often 
recommend a minimum set of procedures as being essential for safe use of their system.  
 
Since the widespread introduction of CT planning in the 1990s, conventional 
radiotherapy planning has become increasingly sophisticated with movement from 
parallel opposed fields to multi-field conformal radiotherapy, and then to IMRT. In 
IMRT, the total treatment field is made up of multiple small beamlets, making it much 
harder to carry out the traditional “calculations by hand” which would be done to verify 
conventional plans. Also, IMRT often entails the use of moving multi-leaf collimator 
(MLC) leaves during radiation delivery. This adds an important potential source of error 
in terms of both dose delivered and spatial dose distribution. Consequently, IMRT 
treatment requires a more rigorous QA protocol. Many centres perform “patient-
specific” QA of each IMRT plan before the course of treatment, which involves 
transferring the plan on to a phantom, delivering a fraction, measuring the dose 
delivered and comparing this with the planned dose. Patient-specific QA is not part of 
the Accuray recommended minimum QA for CyberKnife. However, some centres 
would consider this to be advisable, especially when using the Iris collimator, where the 
moving segments introduce the possibility of additional error in a similar way to the 
moving leaves of IMRT treatment. 
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Reference Dose Measurement 
 
As mentioned above, two important aspects of radiotherapy quality assurance are the 
verification of dose, and the spatial accuracy achieved. Ionisation chambers represent 
the most accurate method of reference dose verification for radiotherapy centres. They 
measure the electrical charge generated by radiation-induced ionisation inside the 
chamber. This is converted to dose (units of gray or J/Kg) using a series of conversion 
factors specific to the beam quality and ionisation chamber. Individual field chambers 
must be regularly calibrated, showing “traceability” back to the “primary standard”, 
which in the UK is held at the National Physical Laboratory. This is usually via a 
“secondary standard” ionisation chamber held at each centre. 
 
Ionisation chamber readings are most reliable when a single radiation beam covers the 
chamber completely, as in this situation partial volume effects can be ruled out. This is 
the common setup when calibrating linac output during commissioning or routine QA. 
One potential problem with the use of ionisation chambers in radiosurgical plan QA is 
that multiple small beams are used, some of which may only partially irradiate the 
chamber. One cannot assume charged particle equilibrium at the beam edge, and the 
behaviour of the ion chamber is therefore less well characterised in this situation. 
Nevertheless, ionisation chambers are still likely to be the most accurate way for 
departments to measure the dose delivered in a radiosurgical plan. The Farmer chamber 
(PTW, Freiburg, Germany), with a measuring volume of 0.6 cm3, is a commonly-used 
thimble chamber for reference dosimetry. The use of a smaller chamber such as a 
PinPoint chamber (PTW), which has a volume of 0.015 cm3, would appear to be an 
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attractive option as there will be fewer beams which only partially irradiate the 
chamber. Indeed, the PinPoint chamber is specifically designed for stereotactic field 
measurements. However, smaller chambers produce a smaller signal, and therefore will 
be more affected by any “noise” in the system. This makes them potentially less 
accurate, and for this reason PinPoint chambers are generally not recommended for 
reference dosimetry. The Semiflex chamber (PTW), with a measuring volume of 0.125 
cm3, is a useful compromise providing both reasonable spatial resolution and reasonable 
dosimetric accuracy. 
 
Semiconductor diodes (SCDs) provide an alternative means of measuring dose output. 
They are small and relatively easy to use, produce an instant reading, and provide a 
good measure of relative dose. However, they are less stable than ionisation chambers 
for measuring true dose delivered: whilst they can also be calibrated to a secondary 
standard, dose readings are much more prone to drift than with a field ionisation 
chamber. 
 
Spatial Dose Distribution Analysis 
 
Most radiotherapy centres assess spatial dose distribution by analysis of a 2-dimensional 
(2D) plane of dose within the 3-dimensional treatment plan. The delivered dose is 
measured over a series of points in the 2D plane and compared with the intended 2D 
distribution on the corresponding “slice” of the plan. The result is then assumed to be 
representative of the whole plan. Multiple ion chambers or SCDs can be arranged in a 
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2D array to enable measurement of the spatial dose distribution. However, in both cases 
the spatial resolution is limited by the gaps between the individual chambers or diodes, 
for example 10 mm with a PTW Seven29 ion chamber array (PTW). This array is 
commonly used for IMRT patient-specific QA, but the resolution is insufficient for use 
with small fields, and may not be the best way to measure dose in areas of steep dose 
gradient. Radiographic film has been widely used in the past, providing sub-millimetre 
spatial resolution. However, there are problems with using this technique. It requires 
post-exposure chemical processing to develop and fix the pattern on the film. This 
process introduces many potential sources of error and uncertainty into the analysis, and 
in the era of linac electronic portal imaging, many centres no longer have the necessary 
equipment and materials. Another problem is the sensitivity of radiographic film to any 
light, meaning that extra precautions must be taken with the film prior to processing.  
 
Radiochromic film has become an increasingly popular tool for spatial dosimetry 
measurement. Once again it provides sub-millimetre spatial resolution, but unlike 
radiographic film it requires no chemical processing. It is also much less sensitive to 
room light.  It can measure relative signal across a 2D plane, but only has limited 
accuracy in measuring true dose delivered. Gafchromic EBT2 (International Specialty 
Products Inc, Wayne, NJ) is the main commercially available radiochromic film suitable 
for plan QA, replacing EBT film in 2009. Using the original EBT film, Saur et al 
reported  a dose uncertainty (with 95 % confidence) within 4 % for doses between 1 and 
3 Gy (46). A recent study using EBT2 film estimated that dose could be measured with 
an overall accuracy of 4 - 5 % (47). On the basis of these results, any analysis of a 
spatial dose distribution using EBT2 film as a true measure of dose will not be able to 
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compare dose difference with a tolerance of greater than about 5 %. A more detailed 
discussion about EBT2 film will be provided later in this chapter. 
 
In modern radiotherapy plan QA it is usually desirable to test the spatial accuracy of the 
radiotherapy dose distribution to a tighter tolerance than 5 % dose difference, and 
therefore film is often used as a measure of the relative dose across the 2D plane, rather 
than true dose. A single point on the film is normalised either to a previously measured 
reference dose at that point, or to the dose at that point on the planned dose distribution 
(48). The former method is usually favoured where possible, as this uses an independent 
measure of dose. On a gantry-based linear accelerator, the treatment plan is usually 
delivered twice on a solid water phantom, firstly with an ionisation chamber within the 
“PTV”, and then with a portion of film positioned at the same point within the PTV 
relative to the isocentre. The signal on the relevant part of the film is then normalised to 
the ionisation chamber dose.  
 
Unfortunately this technique would not be possible on the CyberKnife system using the 
solid water phantom available at this centre (Figure 3.1, and see below). The align 
centre for treatment is the mid-point of three metal fiducial markers embedded in the 
layer of solid water which contains the space for the ionisation chamber. Film is placed 
between layers of solid water, and it is therefore not possible to position it in the same 
location as the chamber, relative to the align centre. Whilst both the chamber and part of 
the film will be contained within the PTV, the dose within the PTV will vary by up to 
50 % of the prescribed dose in the treatment plans used in this study. Consequently it is 
not possible to normalise a point on the film to the ionisation chamber. For relative dose 
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Figure 3.1: Photograph of the WT1 solid water phantom positioned on the CyberKnife treatment couch 
such that the centre of the phantom aligns with the centre of the beam. A measuring post is being used to 
verify that the source to surface distance (SSD) is 75 cm. The phantom consists of five individual layers 
stacked on top of each other. There is a purpose-built hole in the second layer down, into which a Farmer 
chamber has been inserted (blue cable attached). The chamber is at 5 cm depth within the phantom. 
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analysis, the only option with the equipment used here is to normalise to a point on the 
planned dose distribution. This technique unfortunately does not use an independent 
measure of dose delivered during treatment, and the results of spatial dose comparison 
will depend to some extent on the dose point chosen for normalisation. 
 
Choosing a Dose Evaluation Metric and Appropriate Tolerances 
 
Historically, various dose evaluation metrics have been proposed for comparison 
between planned and delivered spatial dose distribution. One simple approach is to 
calculate the dose difference between planned and delivered dose for each point. 
However in areas of steep dose gradient, a small spatial shift between intended and 
delivered plans may produce very large dose differences. Another approach is to 
overlay the planned and delivered dose distributions and calculate the shortest distance 
from a point on one distribution to the nearest point on the other with the same dose 
value. This “distance to agreement” method is useful in areas of the plan with a steep 
dose gradient, but in areas of shallow dose gradient, a small change in dose may 
correspond to a large distance to agreement. The Gamma Index (49) combines dose 
difference (DD) and distance to agreement (DTA) methods in a single index, thus 
largely avoiding the potential problems in areas of steep and shallow dose gradient. For 
each point on the delivered dose distribution, this evaluation method automatically finds 
the closest agreement with the planned distribution, on the basis of a vector combination 
of DD and DTA measures. If this agreement lies within the pre-specified tolerances 
then that point has “passed”. The pass/fail status of each point can then be shown on the 
spatial dose distribution. The Gamma Index is not without its limitations (although a 
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detailed discussion is beyond the scope of this chapter). Nevertheless, it is now widely 
used in radiotherapy departments around the world. 
 
Patient-specific QA in radiotherapy has become much more widely used since the 
implementation of IMRT, as mentioned above. Commonly quoted Gamma Index 
tolerances for IMRT QA using an ionisation chamber array are 3-4 % DD and 3-4 mm 
DTA. For example, IPEM Report 96 (48) provides examples of clinical tolerances in 
use in the UK. For head and neck IMRT, which often involves particularly complicated 
treatment plans, a tolerance of 4 % (DD)/4 mm (DTA) is cited, with the suggestion that 
at least 95 % of pixels inside the 10 % isodose region of interest should pass these 
criteria. Many centres would aim for tighter tolerances than this with modern 
radiotherapy systems. 
 
As discussed above, radiosurgery, with its small fields and areas of steep dose gradient, 
requires sub-millimetre spatial accuracy, and therefore it can be argued that 
radiochromic film needs to be used to evaluate radiosurgical spatial dose distribution. It 
also seems appropriate that the distance to agreement tolerance for a radiosurgery plan 
should be 1 mm. With respect to dose difference, it would be desirable to follow the 
established IMRT practice and use a 3-4 % tolerance. Unfortunately, due to the current 
uncertainties of measuring true dose with Gafchromic film, it would not be possible to 
use a DD tolerance of less than 5 % in this situation. Indeed, a recent publication of 
radiosurgical QA on the Tomotherapy system used EBT film for reference dosimetry, 
and chose 5 % DD and 1 mm DTA as tolerance values (50). However, if using film to 
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measure relative signal by normalising to the planned dose distribution, then a 3 % DD 
should be achievable. 
 
In summary, the purpose of this study is to verify that the treatment plans created using 
the MultiPlan treatment planning system are an accurate reflection of the radiotherapy 
treatment which would be delivered, by performing plan-specific QA. The following 
method is proposed. Treatment plans will be generated in MultiPlan and delivered on a 
solid water phantom. A Semiflex ionisation chamber placed inside the phantom will be 
used to measure the reference dose. With respect to reference dose, a plan will be 
deemed to have “passed” the QA test if the delivered dose is within 3 % of the dose 
calculated by MultiPlan. At the same time EBT2 film placed inside the phantom will be 
used for 2D spatial dose evaluation. The Gamma Index will be the chosen spatial dose 
evaluation metric. Analysis will be performed firstly by measuring reference dose 
across the film, with tolerances of 5 %/1 mm, and then measuring relative dose after 
normalising to the planned dose distribution, with tolerances of 3 %/ 1 mm.  For the 
purposes of this verification study, any plan in which >/= 95 % points within the region 
of interest meet these tolerances will have passed the spatial dose distribution QA. 
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Methods 
 
Treatment plans were generated using MultiPlan treatment planning system, version 
3.5.1. A WT1 solid water phantom (St. Bartholomew’s Hospital, London) was scanned 
using a GE LightSpeed 16 slice CT scanner (GE Healthcare, Buckinghamshire, UK). 
Prior to scanning, a 0.125 cm3 Semiflex (ionisation) Chamber (PTW, Germany) was 
positioned inside the phantom, through the purpose-built hole in one of the layers. An 8 
x 10 inch sheet of EBT2 film (with one triangular corner cut out to ensure correct 
orientation) was carefully placed between the first and second solid water layers and 
secured with tape. The axial slice thickness of the CT scan was 1.25 mm, as is standard 
for all CyberKnife planning CT scans at this centre. The scan was then imported into 
MultiPlan. A 3 cm diameter spherical “virtual” planning target volume (PTV) was 
created using the ball-cube function, and positioned in the phantom such that it 
contained the ionisation chamber thimble and a portion of the sheet of EBT2 film. The 
size of the target (3 cm diameter) was chosen as it could comfortably contain both the 
whole measuring volume of the chamber and a reasonable area of film. Within the PTV, 
the measuring volume of the chamber was contoured as a separate structure (Figure 
3.2). 
 
Ten treatment plans were produced, five using the simplex optimisation algorithm with 
3 fixed collimators, and five using the sequential algorithm with the Iris variable 
aperture collimator. Ray-Tracing was used as the dose calculation algorithm. For each 
plan, a prescription dose of 3 Gy was used, and the variables were configured to 
produce a prescription isodose between 65 and 70 %. This meant that the maximum
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Figure 3.2: Screenshot from MultiPlan version 3.5.1 showing a treatment plan for the 30 mm spherical 
target (red overlay) produced using Sequential optimisation. Axial, sagittal and coronal views are shown, 
together with a “hedgehog” view of the beam arrangement (top left – beams are shown in light blue). The 
ionisation chamber can be seen in the sagittal view (bottom left), and the measuring volume of the 
chamber is shown in blue overlay inside the target. The outline of a piece of gafchromic film (with one 
corner chopped off) is seen in the coronal view (bottom right), positioned between two layers of the 
phantom for the planning CT.  
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dose to any point would be no more than 4.6 Gy, which is safely below the saturation 
level of the EBT2 film (approximately 8 Gy). Steps were taken during the planning 
process to minimise the heterogeneity of dose within the chamber measurement volume. 
For each plan, the mean, minimum and maximum dose to the measurement volume was 
recorded. Each plan was saved as “deliverable” and transferred to the treatment delivery 
console. 
 
The solid water phantom was then moved to the CyberKnife bunker and positioned on 
the treatment couch. At the start and end of each treatment session, the CyberKnife linac 
output was measured using a 0.6 cm3 Farmer chamber (PTW) positioned at 5 cm depth 
in the solid water phantom, with 75 cm source to surface distance (SSD) (Figure 3.1). 
200 MU was delivered using the 60 mm fixed collimator, and the electrical charge in 
the chamber recorded on a Unidos Webline electrometer (PTW), with the polarity set at 
-400 V. If the output was different at the end of the session compared to the beginning, 
the average of the two readings was taken as the output during the treatment session.  
 
For the treatments, the Farmer chamber was replaced with the Semiflex chamber and a 
new piece of EBT2 film positioned exactly as for the planning CT scan (Figure 3.3). 
Each batch of film had been previously calibrated against the Farmer chamber across a 
range of MU levels from 0-800. The calibration curve generated was subsequently used 
by the dose verification software (see below). A new piece of film was used for each 
treatment plan. Each of the ten plans generated was delivered once. For each plan the 
dose recorded with the ionisation chamber was compared to the mean chamber dose 
seen in the corresponding treatment plan: the percentage difference was recorded.
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Figure 3.3: Photograph showing the bottom four layers of solid water positioned on the CyberKnife 
treatment couch. An 8 x 10 inch piece of Gafchromic EBT2 film with one corner cut off has been placed 
on top of the upper solid water layer, and fixed in place with tape. A Semiflex chamber has been inserted 
into the custom-built hole in the upper layer. A fifth and final solid water layer is placed on top of the four 
layers shown to complete the phantom setup.
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The irradiated film was collected and stored for 48 hours to allow completion of the 
development process. It was then uploaded for analysis using an Epson Expression 
10000XL A3 scanner (Seiko Epson Corporation, Japan). Care was taken to position 
each film in the same position on the scanner bed, as there is usually a non-uniform 
response across the scanner bed (Figure 3.4) (see discussion). Each film was also 
scanned in the same orientation, as there have been reports that EBT film shows a 
different response when scanned in different orientations (51, 52). The scan resolution 
was set at 72 dots per inch (dpi), giving the film a spatial resolution of 0.35 mm. The 
scanned images were imported into Verisoft (PTW) verification software, together with 
the corresponding plan dose distributions which were imported directly from MultiPlan. 
For each case, the planned and delivered dose distributions were overlaid using a 
translational movement such that the centre of the delivered dose distribution was on the 
centre of the planned dose distribution. The region of interest for comparison was the 
central 21 x 16 cm rectangle of the film, which allowed exclusion of approximately 2 
cm on all sides around the edge of the film. This excluded areas where the film had 
been written on (labelled), handled, or cut, any of which would affect the reading. 
 
Comparison between the planned and delivered dose distributions was then performed 
using the Gamma Index evaluation metric. The comparison was carried out twice for 
each plan. Firstly, the film was used as a measure of reference dose, with a factor 
applied to account for the machine output on the day the film was exposed. A Gamma 
Index analysis was then applied with tolerances of 5 %/1 mm. Secondly, the film was 
used for relative dose measurement, after normalisation to the planned dose distribution. 
An arbitrary dose point was selected in an area of relative dose homogeneity within the 
PTV and close to the prescription isodose line. The planned dose at this point and the
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Figure 3.4: Photograph showing a piece of exposed EBT2 film placed on the flatbed scanner. A ruler has 
been placed up against two sides of the scan bed. The film is positioned according to the ruler 
measurements, to ensure that each successive film is scanned in exactly the same position. 
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coordinates of the point were recorded. The corresponding dose measured on the film 
was calculated by taking the mean dose of the nine dose points nearest to the 
coordinates (the film spatial resolution is 0.35 mm, compared to the 0.97 x 0.97 mm 
pixel size on the planning CT). An appropriate normalisation factor was then applied 
across the whole film, based on the planned dose and film dose at this point. Gamma 
Index analysis was then applied with tolerances of 3 %/1 mm. 
 
Dose points on the planned distribution which were less than 5 % of the prescribed dose 
were excluded from analysis. Since dose difference tolerances (eg 3 %) are relative to 
the maximum dose on the plan, low dose points are much less likely to “fail” on this 
criterion. Restricting analysis to points over 5 % of the prescribed dose prevented the 
results from being “unrealistically” good, whilst still ensuring that there was a 
sufficiently large area of dose points for spatial analysis of the plan. Films on which < 
95 % points passed the Gamma Index criteria were investigated qualitatively.
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Results 
 
Ionisation chamber reference dosimetry 
 
The ionisation chamber dose measurements for the ten treated plans are shown in Table 
3.1, together with the mean planned dose across the ionisation chamber and the 
percentage error of the plan, where: 
!!!""#" ! ! !"#$%&"'!!"#$ !!"#$!!"#$$%&!!"#$!!"!!!!"#$% !!"#$!!"#$$%&!!"#$!!"!!!!"#$%  
Table 3.1 also shows the minimum and maximum planned doses to the chamber in each 
plan, together with the percentage variation across the chamber, where: 
!!!"#$"%$&'! ! !"#$$%&!!!!"#$%! "#!!"#$ ! !"#$$%&!!!!"#$%! "#!!"#$!"#$!!"#$$%&!!"#$!!"!!!!"#$%  
The percentage error ranged from 0.4 % - 2.01 %, with mean 1.07 % and standard 
deviation 0.53 %. All measured doses were comfortably within 3 % of the planned dose, 
and were therefore acceptable in this regard. The mean error for the fixed collimator 
plans was 0.78 %, compared to 1.36 % for the iris plans. The distribution of error scores 
is not likely to be normally distributed, therefore the assumptions for performing a 
parametric test to compare the two groups of errors were not met. Using the Mann-
Whitney U test to compare the two groups of data, there was no statistically significant 
difference in error between the two groups at the 5 % level (p = 0.095).
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Table 3.1: Comparison of the planned dose to the ionisation chamber with the dose measured on 
delivering the treatment, for each of the ten treatment plans produced. 
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Radiochromic film analysis of spatial dose distribution 
 
Table 3.2 shows the percentage of points in each treated plan which passed the Gamma 
Index analysis, firstly at 5 %/1 mm tolerance using dose measured by the film, and then 
at 3 %/1 mm after normalising to a point on the planned dose distribution. In all ten 
plans, >/= 95 % of points within the region of interest “passed” at 5 %/1 mm. Figure 3.5 
shows a summary of one of these results. At 3 %/1 mm, nine of the ten plans exceeded 
the required 95 % pass rate. In the remaining plan, “Fixed 2”, only 92.9 % points passed 
the analysis. The ionisation chamber dose error result for this plan (0.94 %) was well 
within the pre-specified tolerance, as was the Gamma Index result using measured dose 
at 5 %/1 mm tolerances (99.8 %). Nevertheless a more qualitative analysis of the 
Gamma Index results for this plan was carried out. 
 
Figure 3.6 shows the isodose lines of the “Fixed 2” planned dose distribution, with the 
delivered dose distribution overlaid. The spatial arrangement of the 7.9 % failed points 
is also shown. There is no clear pattern to the arrangement of the failed points. 
However, a large proportion of them lie in one small area of the region of interest. 
Visual inspection of the film did not show any obvious damage in this area. These failed 
points are hot (the measured dose was higher than the planned dose), and therefore 
could represent a treatment overdose in this area. Whilst this portion of film 
corresponds to a low dose area of the plan, where doses are less than 20 % of the 
prescription dose, the clinical acceptability would depend on the nature of the tissue 
being overtreated. The area of steep dose gradient outside the PTV is relatively free of 
failed points, which is important as this is often the area where organ-at-risk tissue most 
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Reference dosimetry 
 
 
Relative dosimetry 
 
Plan Name % points passed at 5 %/1 mm % points passed at 3 %/1 mm 
      
Fixed 1 99.6 98.4 
      
Fixed 2 99.8 92.9 
      
Fixed 3 99.8 95.1 
      
Fixed 4 99.6 97.9 
      
Fixed 5 99.7 97.9 
      
Iris 1 99.1 97.6 
      
Iris 2 95.8 97.7 
      
Iris 3 95.5 96.6 
      
Iris 4 100.0 99.5 
      
Iris 5 99.8 98.8 
"
Table 3.2: Percentage of dose points passing the Gamma Index analysis for each of the ten plans 
produced. Results are shown for two different tolerance levels: 5 %/1 mm with no normalisation, and 3 
%/1 mm after normalising the film to a point on the planned dose distribution. The value shown in red 
failed the pre-specified 95 % pass rate
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Figure 3.5: Screenshot from Verisoft software, showing the results of a Gamma Index analysis 
performed on the “Fixed 5” treatment plan using 5 %/1 mm tolerance levels. The planned and delivered 
dose distributions are shown in the top left and bottom left windows (landscape view) respectively. The 
top right window shows the plan statistics including the overall pass rate (highlighted in green). The 
bottom right window shows the planned and delivered dose distributions superimposed. 
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Figure 3.6: Image taken from Verisoft software showing the planned and delivered dose distributions of 
the “Fixed 2” plan overlaid. A colourwash has been applied showing more broadly the dose distribution 
across the film. Additionally, the dose points on the film which failed the Gamma Index analysis at 3 %/1 
mm tolerance are shown in red and blue for “hot” and “cold” points respectively. The majority of hot 
points are in one area at the bottom right of the film. The majority of cold points are inside the PTV. 
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Figure 3.7: Image taken from Verisoft software showing the planned (orange curve) and measured (blue 
curve) doses for points on a one-dimensional line through the PTV, as shown in yellow in Figure 3.6. The 
y axis numbers show the dose as a % of the maximum dose on the plan. 
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at risk of damage is located. Within the PTV there are a number of failed points which 
are cold (measured dose lower than planned dose). Figure 3.7 shows a comparison of 
the planned (orange curve) and measured (blue curve) doses for points on a one-
dimensional line through the middle of the PTV, as shown in yellow on Figure 3.6. The 
y axis scale runs from 0 - 100 % dose; the prescription isodose for this plan is 68 %. 
The graph shows that in the area where the measured dose is “cold”, the dose points are 
still receiving substantially more than the prescription dose, and therefore these failed 
points within the PTV are unlikely to be clinically significant if this was a real treatment 
plan. 
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Discussion 
 
CyberKnife treatment plans are usually complex, consisting of multiple small, non-
coplanar beams incident on a small target. The ionisation chamber reference dosimetry 
results here show that the system is able to deliver such plans with dose accuracy 
comfortably within the pre-specified 3 % error value. Although there was a trend 
towards smaller errors with the fixed collimator plans, there was no statistically 
significant difference between the two groups. Whilst a bigger sample size may have 
shown a significant difference, the error values seen with the iris collimator plans were 
still easily within 3 %. 
 
With respect to spatial dose distribution analysis, all of the ten plans “passed” the 
Gamma Index analysis with tolerances of 5 %/1 mm without normalising the film, and 
nine out of the ten passed at 3 %/1 mm, after normalising the film dose to the planned 
dose distribution. In the one plan which did not pass at 3 %/1 mm (“Fixed 2”), a 
qualitative analysis revealed that this plan would probably be a borderline case in terms 
of acceptability. The significance of the failed points in the low dose area would depend 
on the tissue being irradiated here. As will be discussed later, it is not clear to what 
extent the failed points in this analysis were due to inaccuracy at some step in the 
treatment process, or to problems with intra-film variability in response to radiation. 
 
Radiotherapy QA can be performed using a variety of different techniques and tools. In 
the introduction section of this chapter, many of these different techniques were 
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discussed, and a method for performing CyberKnife plan-specific QA was proposed. 
Whilst care was taken to ensure that this method was reasonable given the nature of the 
task and the techniques available, there are still a number of limitations and possible 
sources of error which will now be discussed. 
 
The biggest source of error in the results obtained is likely to be the use of EBT2 film. 
There is no doubt that a meticulous, consistent technique is critical to film dosimetry (as 
it is for all radiotherapy QA), but even with this in place there is still a large potential 
for error using this film. Original EBT film was introduced in 2004, consisting of two 
identical active transparent layers which darken on exposure to radiation, and which are 
sandwiched between two protective surface layers. As discussed previously, it is easier 
to handle than radiographic film and is self-processing. Unfortunately it has been shown 
that even with the use of a high quality scanner and appropriate scanner technique 
(discussed below), including a flattening correction, there was still uncertainty of 
absolute dose measurement in the region of 4 % (46). The manufacturer attributes this, 
in the main part, to intrinsic variation of the thickness of the active layer. Whilst it may 
be expected that different batches of film will differ in the active layer thickness, 
unfortunately this variation can be seen across different films in the same batch, and 
even across an individual sheet of film.  
 
EBT2 film was introduced in 2009 with the aim of improving the accuracy of dose 
measurement. A radiation-insensitive yellow dye was added to the active layer which 
causes attenuation of the signal in the scanner’s blue channel, and thus provides a 
measure of the thickness of the active layer. In theory, therefore, the variation in 
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thickness across the film can be corrected for by measuring the signal from the standard 
red channel, together with the signal from the blue channel. Unfortunately, the 
correction protocol is extremely complicated, and at the time of writing only one brand 
of commercial dose verification software (“Film QA” (International Specialty 
Products)) is capable of processing this information. Also it involves measuring signal 
through the blue channel, which is not usually recommended for dosimetry. Without 
this correction in place, EBT2 is no more accurate than EBT at measuring dose, and 
unfortunately shows greater intra-sheet inhomogeneity. For example, Hartmann et al 
(53) reported intra-sheet inhomogeneities increasing from +/- 1 % with EBT to +/- 3.7 
% with EBT2. This is fairly consistent with results obtained at this centre, using the 
equipment described. A single piece of film was cut into four pieces and each placed in 
turn at 5 cm depth within the solid water phantom. 400 MU were delivered from above, 
through a single 60 mm beam. The measured dose was found to differ from the 
ionisation chamber reference dose by -1.6 %, -3.0 %, -3.7 % and -4.2 % for the four 
pieces of film. 
 
For Gamma Index analysis of radiosurgical spatial dose distribution, tolerances of 3 %/1 
mm would seem appropriate. When using EBT2 film, due to the above problems, it is 
not possible to use a DTA tolerance of 3 % without normalisation either to a ionisation 
chamber point dose or to a point on the MultiPlan dose distribution. Even with 
normalisation, the intra-film inhomogeneity means that results must still be interpreted 
with caution. Whilst normalising to the planned dose distribution could be criticised as 
being less robust than using an independent dose measurement, the problems of intra-
film inhomogeneity remain with either technique. More work needs to be done to 
improve both the accuracy and reliability of dose measurement with EBT2. It is hoped 
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that either the EBT2 correction protocol becomes more widely-usable (and more 
manageable) or an alternative product is developed without the above problems. 
 
The scanner provides an additional source of error related to film analysis. In this study, 
a high quality professional flatbed charge-coupled device (CCD) scanner was used. A 
relative flattening correction was applied within Verisoft to account for non-uniformity 
across the scanner, as documented by Devic et al (54), amongst others. Also, care was 
taken to ensure consistency across different films with respect to the position and 
orientation on the scanner bed, as this too has been reported as a source of error (51, 
52). Films were scanned in “landscape” mode, as this is recommended by the EBT 
manufacturers, and has been shown to have less pronounced non-uniformity in the 
direction of the CCD array, when compared to scanning in portrait mode (46). In spite 
of these measures there may be further possible error. For example, Lynch et al showed 
that with repeated scans, the temperature of the scan bed will increase, and this 
increased temperature can affect the optical density of the film on the scan bed (51). 
However, any residual error related to the scanner is likely to be small in comparison 
with the film-related uncertainty discussed above. 
 
The size of ion chamber (0.125 cm3) was chosen as it provided a reasonable 
compromise between spatial resolution and dosimetric accuracy. It could be argued that 
the measuring volume was too large to provide a meaningful value for comparison with 
the planned dose. In this study, the chamber reading was compared against the mean 
dose delivered to the measuring volume on the treatment plan. However, the planned 
dose within the measuring volume varied by as much as 7.6 % of the mean dose, across 
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the ten plans generated (Table 3.1). It would be good to have a smaller volume chamber 
which produces sufficient signal to maintain dosimetric accuracy. Liquid ionisation 
chambers produce greater signal than air chambers for a given measuring volume. 
MicroLion (PTW), with a measuring volume of 0.0017 cm3 is an example of one such 
chamber designed for stereotactic QA. However, one possible disadvantage is that the 
irradiation direction is axial, compared to the radial direction of the air chambers used in 
this study. In other words it is designed to measure radiation which enters directly 
through the end of the chamber, as opposed to the whole cylindrical circumference as 
with the air chambers. One can predict that with a CyberKnife treatment plan, involving 
multiple non-coplanar beams originating from a wide space around the patient, it will 
not be possible to ensure that all beams are incident on the chamber in the appropriate 
way. In any case, a liquid ion chamber was not available for use in this study. 
 
Only one size (and shape) of target (30 mm sphere) was used. This size was chosen as it 
allowed the Semiflex chamber and a section of the film both to be contained within the 
virtual PTV, and also ensured that most of the area inside the 10 % isodose was 
included in the film region of interest. Using targets significantly bigger or smaller than 
this would have caused a problem in these respects. Keeping to a single size and shape 
of target also allowed a fair comparison between the performance of fixed and iris 
collimators. However, the size of the target did mean that fixed collimators larger than 
30 mm were not used, and the iris aperture size similarly did not go above this size. The 
accuracy of the larger collimator sizes has therefore not been verified here. However, it 
was felt that any small errors in field size would have more effect on the smaller 
collimator sizes/iris settings, as they would represent a greater proportion of the overall 
field size. Nevertheless, a continuation of this project, performing ionisation chamber 
*+"
"
and film analysis on treatment plans of real lesions of varying shapes and sizes would 
be useful, perhaps once EBT2 film analysis can be easily performed with greater 
dosimetric accuracy. 
 
Summary 
 
Based on this study, the CyberKnife system is able to deliver treatment plans using 
either fixed or Iris collimators with an ionisation chamber reference dose accuracy well 
within 3 %. With regard to spatial dose distribution, it is more difficult to make firm 
conclusions based on the results here, because of the problems obtaining reliable results 
using EBT2 film. It is acknowledged that there is a need for improved film dosimetry in 
CyberKnife QA, and possible ways to improve the method have been discussed. 
However, the analyses performed here did not reveal any results which would be a 
major cause for concern. 
 
For the purpose of this thesis, on the basis of the work carried out, it is reasonable to 
conclude that the calculated dose and spatial dose distribution produced by MultiPlan 
accurately reflect that which is administered during treatment. Dosimetric planning 
studies which rely heavily on MultiPlan dose calculation algorithms can now be carried 
out with reasonable confidence that the plans produced are realistic in terms of patient 
treatment. 
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Chapter 4 – Establishing the relationship between prescription isodose 
value and external dose gradient for spherical intracranial targets 
 
Introduction 
 
Radiosurgery uses the ablative power of very high doses of radiation with the intention 
of destroying all tissue within the PTV.  In order to achieve this safely, the volume of 
normal tissue receiving a high dose of radiation must be minimised. There are three 
main ways in which this is achieved. 
 
Firstly, the volume of normal tissue contained within the PTV should be minimised. 
Within the PTV the gross tumour volume (GTV) represents the macroscopic extent of 
the tumour as visualised on the appropriate axial imaging. The clinical target volume 
(CTV) consists of the GTV together with a margin added on all sides to account for any 
subclinical tumour spread. This margin depends on the tumour type and location, and 
can vary from 0 mm in certain benign brain tumours up to as much as 25 mm in 
conventional radiotherapy for glioblastoma multiforme. A margin is then added to the 
CTV on all sides to account for inter- and intra-fraction tumour and organ motion, and 
inaccuracies of patient setup and treatment delivery: the resultant volume is the PTV(34, 
35). Reducing the CTV - PTV margin will therefore reduce the volume of normal tissue 
within the PTV. One of the main differences between conventionally-fractionated 
radiotherapy (CFR) and radiosurgery is the size of the CTV - PTV margin required.  For 
example, even though intracranial tumours show negligible movement, a margin of 3 - 5 
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mm is still usually recommended in CFR to the brain in order to account for setup and 
delivery inaccuracy, and any patient head movement within the (relatively) firm-fitting 
thermoplastic shell. However, radiosurgery systems can treat intracranial tumours with 
sub-millimetre accuracy, either through rigid immobilisation with a pinned stereotactic 
frame or, as in the case of CyberKnife, accurate alignment using near real-time image 
guidance (37, 42). As a result, a CTV - PTV margin of 0 - 2 mm is standard practice in 
intacranial radiosurgery, depending on whether any image fusion needs to be accounted 
for. This substantially reduces the volume of normal tissue within the PTV, compared to 
conventional radiotherapy treatment (Figure 4.1). It should be reiterated here that 
simply choosing smaller targets will also reduce the normal tissue volume within the 
PTV, which is why target size is such an important consideration in radiosurgery. 
 
The second way to minimise the volume of normal tissue receiving a high dose of 
radiotherapy involves the creation of a treatment plan where the dose distribution 
follows the contour of the PTV as closely as possible. The term “conformality” refers to 
the degree to which the prescription isodose line “conforms” to the PTV contour, and is 
an important radiosurgical parameter. Whilst it is clearly important that the prescription 
isodose line should cover as much of the PTV as possible (this is known as PTV 
coverage), it is also important to minimise the coverage of normal tissue lying 
immediately outside the PTV. Indeed, the safe delivery of obliteratively high doses of 
radiation requires a very conformal treatment plan. The perfect treatment plan, in terms 
of conformality, would be one where 100 % of the PTV is covered by the prescription 
isodose line, and 0 % of normal tissue outside the PTV is covered.
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Figure 4.1: Diagram showing the different volumes used in radiotherapy planning, as per ICRU 50 and 
62 guidelines. The different margins required in radiosurgery and conventionally fractionated 
radiotherapy are illustrated. 
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It is useful to have a universal measure of conformality, for example when comparing 
potential treatment plans on an individual patient, or comparing plans produced by 
different radiosurgery systems. A number of different measures have been proposed. 
Shaw et al (55) proposed the PITV ratio as a conformity index (CI): 
!" ! !"#!"  
where PIV is the volume contained within the prescription isodose line (prescription 
isodose volume) and TV is the target volume. Whilst this is easy to calculate, it is only a 
valid measure if it is assumed that the centre of the PIV is positioned at the centre of the 
(P)TV, and that the PIV and PTV are the same shape. If not, then this index can give 
inappropriate values, as illustrated by Figure 4.2. Knoos et al (56) in their work on 
conventional radiotherapy, proposed an index which is broadly equivalent to:  
!" ! !"!"#!"  
where TVPIV is the volume of the target which is contained within the prescription 
isodose volume. Unfortunately, whilst this corrects the flaws present in the Shaw index, 
there is another problem. Any plan where the PIV covers the TV completely will give a 
perfect score of 1, regardless of how much normal tissue is contained within the PIV 
(Figure 4.3). 
 
Paddick (57) proposed an alternative index which appears robust to the above problems: 
!" ! !"!"# !!"!!"#
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Figure 4.2: Four diagrams, each showing the same radiosurgical target, but with different prescription 
isodose lines containing the prescription isodose volume (PIV). The PIV has the same volume as the 
target in each case, and therefore the conformality index (CI) would be a perfect score of 1, using the 
measure proposed by Shaw et al (55). This score would be appropriate for diagram A, but not for 
diagrams B (wrong position), C (wrong orientation) or D (wrong shape). Reproduced from Paddick (57) 
with permission. 
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Figure 4.3: Diagram showing a radiosurgical target fully covered by the prescription isodose line, 
containing the PIV. The conformality index (CI) would be a perfect score of 1, using the measure 
proposed by Knoos et al (56), which is inappropriate since a large volume of tissue outside the target is 
also contained within the prescription isodose line. Reproduced from Paddick (57) with permission. 
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Using this index, a conformity index of 1 represents the perfect radiosurgical plan, with 
lower values corresponding to progressively worse conformality. The reciprocal of this 
measure has been incorporated into the MultiPlan system as an automatically generated 
value for every plan produced.  It is referred to as the new Conformity Index (nCI), and 
is the conformality measure chosen for use in this study. An nCI of 1 still represents 
perfect conformality, but now the value increases as conformality worsens. 
 
The third strategy used in radiosurgery to reduce the volume of normal tissue receiving 
a high dose of radiation is the generation of a steep dose fall-off outside the PTV. This 
strategy is very important in intracranial cases where the target is often surrounded by 
normal brain tissue. In this situation a steep dose fall-off on all sides is required. 
Sometimes an especially radiosensitive organ lies close to the target on one side. Here, 
whilst a steep dose gradient on all sides is desirable, it is especially important to achieve 
steep fall-off on the side which is closest to the critical organ. This situation will be 
examined in Chapter 6.  Radiosurgical treatment plans use multiple small beams (or 
multiple arcs), all incident on the target, which results in a steeper dose gradient away 
from the PTV than can be achieved with CFR. Furthermore, the CyberKnife system can 
select from a very large number of non-coplanar beams which reduces beam overlap 
outside the PTV, thus further increasing the external dose gradient. 
 
As with conformality, it is useful to have a measure of external dose gradient to allow 
comparison of different treatment plans and technologies. Once again a number of 
measures have been proposed. The volume of tissue within the 12 Gy isodose line 
(V12) is a widely used parameter as it has been shown to correlate with normal tissue 
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complications in radiosurgery for AVMs (12) and intracranial tumours (58). However, 
whilst it is very useful clinically, it is not a pure measure of dose gradient per se, as it 
will also depend on both the prescribed dose and the size of the PTV. Liscak et al (59) 
used the following measure of gradient: 
!"#$%&'( ! !"#$%&! "#!!"!!!!! ! ! !" ! !!"#$#"%!!"#$!"#$%&! "#!!"!!!!!!! !!"#$!"#!!"#$  
where x = the chosen prescription isodose of the plan. The authors found a positive 
correlation between this value and risk of cranial nerve complications in a group of 
patients with acoustic neuromas. Whilst this demonstrates the importance of a steep 
external dose gradient, once again it is not an ideal measure, as it is influenced by the 
choice of prescription isodose in each plan. For example, if x = 40 % in one 18 Gy 
treatment plan, then (x-20) corresponds to the 9 Gy isodose line. However if x = 60 % 
in another plan of the same dose, then (x-20) corresponds to the 12 Gy isodose line. A 
comparison of the two plans using this measure of external dose gradient would not be 
fair. 
 
Paddick and Lippitz (60) have proposed a gradient index which is independent of the 
chosen prescription isodose: 
!"#$%&'(!!"#$% ! !"#$%&! "#!!"! !! !!!"#$#"%!!"#$!"#$%&! "#!!"!!! !!"#$#"%!!"#$  
where x = prescripton isodose of the plan (Figure 4.4). This index is therefore a measure 
of the speed of dose fall-off from prescription dose to half this dose, and can be used to 
compare plans with different chosen prescription isodoses. When comparing two plans, 
the plan with the lower gradient index (GI) value has a steeper dose fall-off.
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Figure 4.4: Screenshot (zoomed in) of the isodose arrangement in a treatment plan for a spherical target 
(red overlay) prescribed to the 80 % isodose. In this example the gradient index (GI) (60) is calculated by 
dividing the volume within the 40 % (purple) line by the volume within the prescription isodose line 
(green). 
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Paddick and Lippitz used their GI in a retrospective analysis of 50 multi-isocentre 
acoustic neuroma treatment plans created on the Gamma Knife system. The chosen 
prescription isodose % was varied in each of the 50 plans in order to observe the effect 
of this on the GI. The prescription isodose which optimised the GI was noted for each 
lesion. The mean optimal prescription isodose was found to be 39.8 % (median 38 %, 
range 30-61 %). This was considerably lower than expected. Indeed, the mean 
prescription isodose originally chosen for these treated plans was 49.4 %, and 48 of the 
50 plans would have benefited from choosing a lower prescription isodose. However, it 
should be noted that in the above analysis the plans were not adjusted to maintain the 
same conformality, and in some cases an optimised GI came at the expense of worse 
conformality (60). Table 4.1 shows the details of five Gamma Knife publications 
selected from the period 2008 - 2009 (61-65). The prescription isodose is most 
commonly in the 40-60 % range, and some centres aim to prescribe to the 50 % isodose 
for most/all lesions, although the work by Paddick and Lippitz raises some questions as 
to whether this is necessarily the best approach. 
 
Table 4.2 shows the details of five CyberKnife publications selected from the same 
period (2008 - 2009) (17, 61, 66-68). In these series, the prescription isodose is largely 
in the 60-90 % range. It is not entirely clear why a higher prescription isodose value 
tends to be used for CyberKnife treatment plans when compared to Gamma Knife plans. 
Prescribing to a lower prescription isodose will inevitably result in greater 
inhomogeneity of dose within the PTV. In the past, there has been concern raised about 
the possible effects of PTV dose inhomogeneity on treatment-related toxicity (69). 
However several larger, more recent analyses have not shown this to be a risk factor for 
complications following radiosurgery (12, 70, 71). Indeed, most radiosurgery long-term 
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Author 
 
Centre 
 
Lesions 
Median Target 
Volume and 
Range (cm3) 
 
Prescription 
Isodose 
(%) 
Wowra Munich single metastasis Mean 5.2 +/- 5.5 (1 sd) 
Mean 53 +/- 7 
(1 sd) 
Kased San Francisco one or more mets 
0.22 
(0.01 – 13.2) 
Median 55 
(38 – 96) 
Haselsberger Graz meningioma 19.0 (5.4 – 42.9) 
Median 45 
(30 – 60) 
Kano Pittsburgh haemangioblastoma 0.72 (0.08 – 16.6) 
50 % for most 
lesions 
Lasak Wichita acoustic neuroma 1.5 (0.09 – 6.1) 
50 % for all 
lesions 
 
Table 4.1: Selected Gamma Knife radiosurgery publications over the period 2008 – 9, showing the 
choice of prescription isodose. Abbreviations: mets = metastases; sd = standard deviation. 
 
 
 
 
 
Author 
 
Centre 
 
Lesions 
Mean Target 
Volume and 
Range (cm3) 
 
Prescription 
Isodose 
(%) 
Wowra Munich single metastasis 5.1 +/- 7.6 (1 sd) 
Mean 67 +/- 5 
(1 sd) 
Colombo Vicenza meningioma 7.5 (0.1 – 64.0) 70 - 90 
Hara Stanford one or more mets 1.5 (0.02 – 35.7) 
Median 80 
(65 – 98) 
Gwak Seoul one or more mets 12.4 (0.2 – 58.3) 
Mean 80 
(65 – 84) 
Ju Taipei acoustic neuroma 5.4 (0.1 – 25.0) 
Mean 83 
(80 – 89) 
 
Table 4.2: Selected CyberKnife radiosurgery publications over the period 2008 – 9, showing the choice 
of prescription isodose. Abbreviations: mets = metastases; sd = standard deviation. 
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toxicity data have come from Gamma Knife experience, where the well-established 
practice of using low prescription isodoses shows no signs of changing. An alternative 
explanation for the use of higher prescription isodoses in CyberKnife is that the 
practitioners are predominantly clinical oncologists with extensive experience of CFR. 
For these professionals, a prescription isodose of 60 - 90 % represents an ideological 
mid-ground between the 95 %-plus conventions set out in ICRU 50/62 (34, 35) for 
conventional radiotherapy, and the low prescription isodoses used in Gamma Knife 
practice. 
 
To the author’s knowledge there has not been a study looking at how the choice of 
prescription isodose affects the external dose gradient for radiosurgical plans using 
CyberKnife. The objective of this study is to explore this for spherical targets of 
different sizes, across the range of prescription isodoses comfortably achievable with 
the planning software. Whilst CyberKnife has the capability of treating both intracranial 
and extracranial targets, the study will be carried out on intracranial targets as this is the 
traditional radiosurgical treatment site.
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Methods 
 
The study used MultiPlan versions 3.1.0 and 3.5.1 (a software upgrade being carried out 
partway through the project).  The unenhanced brain CT scan images of a previously-
treated patient were used as the baseline CT dataset, with axial slice thickness of 1.25 
mm. All previously contoured structure sets were deleted from the plan. An intracranial 
spherical “virtual” target was created using the ball-cube function. Four different plan 
baselines were created, each with a sphere of different diameter centrally located within 
the brain. Previous planning studies have found that plan parameters are largely 
independent of the (intracranial) location of the target (72, 73). It was therefore decided 
that a single central intracranial location would be sufficient for this study, using the 
same location for each target used.  Spheres of 8 mm, 15 mm, 30 mm and 50 mm 
diameter were chosen as being reflective of the range of lesions commonly treated 
(although it is acknowledged that a 50 mm intracranial target would not be treated in a 
single fraction). As this was a dosimetric exercise aiming to optimise the dose fall-off 
on all sides of the target, the target was positioned such that it was comfortably away (> 
3 cm) from particularly radiosensitive structures such as brainstem or optic apparatus, 
and therefore no specific organs at risk needed to be considered in the optimisation 
steps. For each target, two optimisation shells were produced: an inner shell 
approximately 2.5 - 3 mm away from the edge of the PTV, and an outer shell 
approximately 5 – 8 mm away. 
 
The main study objective was to observe the variation (if any) in gradient index (GI) 
when comparing plans produced with different prescription isodose values. Four 
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different prescription isodoses were selected: 50, 60, 70, and 80 %. These cover much 
of the range of prescription isodoses which can be achieved by the MultiPlan system, 
based on preliminary investigation, and on experience of clinical cases treated at this 
centre. Whilst a prescription isodose of < 50 % or > 80 % can be achieved in certain 
situations, this may not be possible depending on tumour size and shape. At initial 
setup, the planning variables were adjusted in order to try to produce a plan which 
would have a marginal isodose of one of these four percentages. For every plan 
produced, the prescription isodose was selected as the one which resulted in the best 
conformality (nCI) whilst also achieving > 95 % PTV coverage. If this turned out to be, 
for example, 49 % or 51 %, then the plan was not accepted for further analysis. This 
was to prevent prescribing up or down to reach eg 50 %, at the expense of conformality 
or coverage. 
 
Each spherical target was planned using two different optimisation algorithms: Simplex 
and Sequential. These algorithms were discussed in detail in Chapter 2. The Simplex 
algorithm is used solely with fixed collimators, and allows a maximum of three 
collimator sizes to be used. For the larger sphere sizes (30 mm and 50 mm), where there 
are a number of possible collimator sizes to select from, a minimum of two 
combinations of three collimator sizes was tried for each target. The Sequential 
algorithm can be used either with the fixed collimators or the Iris collimator. For this 
study, the Iris collimator was used as this provides a greater range and flexibility of 
collimator sizes for each plan. In either case the basic planning setup was performed as 
described above. The optimisation variables were then manipulated over multiple 
inverse-planning iterations, in order to find the solution with the steepest dose fall-off, 
as measured by GI. For each solution, the following plan characteristics were recorded: 
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prescription isodose, number of beams, number of monitor units (MU), conformality 
(nCI), PTV coverage (%) and GI.  Each of these values is automatically produced by the 
MultiPlan system except for GI, which was calculated from the dose volume histogram 
(DVH) produced.  
 
One of the main goals of the study was to provide information which may influence the 
CyberKnife planning technique for future patients at this centre. It was therefore 
important to make this a clinically accurate and relevant dosimetric project. To this end, 
care was taken to make this as clinically realistic as possible. All beams which would 
pass through the orbits to reach the target were disallowed, so that the system could not 
select them as part of the treatment plan. The plan was setup to deliver a single fraction 
of 18 Gy to the PTV, a common prescription dose for intracranial lesions. High 
resolution optimisation and calculation was used in order to produce a high quality, 
accurate and deliverable plan. As high resolution optimisation takes substantially longer 
than the low resolution option, the calculation grids were made just large enough to 
cover the PTV and shells, and PTV skip factors were used for the larger targets. This is 
done routinely in normal clinical practice in order to produce a plan within a reasonable 
amount of time, but may have a minor effect on the conformality achieved, as will be 
discussed later. Candidate plans then underwent high dose calculation with a much 
larger calculation grid to allow a more qualitative analysis, such as the detection of high 
(iso)dose “fingers” away from the target which may render a plan clinically 
unacceptable. 
 
!+&"
"
Overall treatment time is a very important aspect of radiosurgery, in terms of both 
patient and departmental resource factors. It was therefore felt that there should be a 
limit on the number of beams and monitor units allowed for an accepted treatment plan 
in this project. For the G4 CyberKnife (linac output of 800 MU/minute) with 6D skull 
tracking, the following equation can be used to estimate the treatment time: 
!"#$%&#'%!!"#$! !"#$%&' ! !"#$%&!!"!!"#$%!! ! !!"#$%&!!"! "!""  
For example, a plan using 180 beams and 16000 MU would take 50 minutes to deliver.  
It was decided that the maximum treatment time for acceptable plans should be 60 
minutes. Finally, whilst the external dose gradient is an important feature of 
radiosurgical plans which should be optimised, this should not be at the expense of 
other important parameters such as PTV coverage and conformality, as was observed by 
Paddick and Lippitz (60). As explained above, all clinically acceptable plans had > 95 
% PTV coverage by the prescription isodose line. In addition, it was felt that 
conformality should be maintained for plans generated throughout this study. Plans for 
each spherical target were therefore only accepted if the conformality (nCI) was within 
0.03 of the best (lowest) nCI value achieved for that target using the same optimisation 
algorithm. Preliminary analysis showed that with spherical targets, > 90 % of plans 
generated had a nCI within 0.03 of the best value that can be achieved consistently. 
Applying more challenging constraints to certain planning variables will lead to nCI 
values outside this range. Whilst the GI may sometimes (but by no means always) 
improve as a result, these plans were not considered valid solutions. Thus there were 
rigid criteria to ensure that the GI achieved was not at the expense of coverage or 
conformality. 
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Statistical analysis 
 
For each spherical target, multiple plans were produced for each of the four prescription 
isodose values. The ten “clinically acceptable” plans with the best (lowest) GI values 
were selected for each isodose and compared. This was done using Simplex and 
Sequential algorithms in turn. Whilst the selection of the ten best plans in each group 
(as opposed to selecting ten plans at random) may introduce the possibility of selection 
bias, this method was chosen as it makes the comparative process more relevant to real 
clinical practice, where a treatment plan is often chosen after a comparison between two 
or more of the best candidate plans generated. This will be discussed further below. 
 
The ten best plans for each of the four isodose values (50, 60, 70 and 80 %) were 
compared, with the null hypothesis being that there is no difference in GI between the 
four groups. If the null hypothesis was rejected, further pre-specified analysis would 
compare 50 % vs 60 %, 60 vs 70 % and 70 % vs 80 %. The Bonferroni correction (74) 
would be used to address the potential problem of multiple comparisons.  
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Results 
 
Multiple treatment plans were generated as described above, and the results analysed. 
Table 4.3 shows the mean and range of the ten best GI values for plans prescribed to 
each isodose, for each sphere/optimisation algorithm combination. The range of nCI 
values of the plans produced is also shown. nCI values for the 30 mm and 50 mm 
sphere were slightly higher than for the two smaller targets. One would normally expect 
the values to be at least as good for the larger targets, but the results were due to the fact 
that skip factors were applied to the larger targets for optimisation. This allows 
treatment plans to be generated within an acceptable amount of time, but may result in 
worse conformality since not every point within the target is used for optimisation. 
 
For the 8 mm target it was not possible to obtain a prescription isodose of 50 %, 
regardless of how the planning variables were adjusted. This is probably due to the fact 
that the system is unable to generate sufficient internal dose gradient for such a small 
target, in order to achieve a marginal isodose as low as 50 %. For this target, therefore, 
only results at 60, 70 and 80 % are shown. 
 
Figure 4.5 shows graphs of mean GI score (for the ten best plans) against prescription 
isodose for each target. For the 8 mm and 15 mm targets, a positive trend is observed 
between prescription isodose and GI, with both optimisation algorithms, over the range 
of prescription isodoses 50 – 80 % (60 – 80 % with the 8 mm sphere). In other words 
the GI score increases (dose fall-off becomes less steep) as the prescription isodose 
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Table 4.3: Mean and range of ten best Gradient Index scores for clinically acceptable plans produced for 
each target/prescription isodose/optimisation algorithm combination. Abbreviations: Vol. = volume; nCI 
= new Conformity Index; GI = Gradient Index 
Target Vol. (cm3) Algorithm nCI range 
Mean GI (and range) from 10 best plans 
 produced at each isodose: 
 
50 % 60 % 70 % 80 % 
8 mm 
sphere 0.3 
Simplex 1.01 – 1.04 - 3.18 (3.11 – 3.27) 
3.75 
(3.63 – 3.87) 
4.40 
(4.26 – 4.51) 
Sequential 1.01 – 1.04 - 3.35 (3.32 – 3.39) 
3.98 
(3.92 – 4.05) 
4.66 
(4.57 – 4.76) 
15 mm 
sphere 1.8 
Simplex 1.02 – 1.05 2.54 (2.53 – 2.55) 
2.72 
(2.69 – 2.75) 
2.91 
(2.86 – 2.94) 
3.25 
(3.23 – 3.30) 
Sequential 1.01 – 1.04 2.57 (2.55 – 2.58) 
2.64 
(2.63 – 2.66) 
2.75 
(2.73 – 2.76) 
3.05 
(3.02 – 3.09) 
30 mm 
sphere 14.1 
Simplex 1.03 – 1.06 2.37 (2.36 – 2.39) 
2.38 
(2.36 – 2.40) 
2.44 
(2.41 – 2.48) 
2.71 
(2.60 – 2.77) 
Sequential 1.03 – 1.06 2.46 (2.41 – 2.50) 
2.44 
2.40 – 2.47) 
2.43 
(2.40 – 2.48) 
2.50 
(2.45 – 2.52) 
50 mm 
sphere 65.4 
Simplex 1.06 – 1.09 2.38 (2.30 – 2.53) 
2.27 
(2.25 – 2.31) 
2.32 
(2.27 – 2.35) 
2.63 
(2.56 – 2.70) 
Sequential 1.04 – 1.07 2.37 (2.33 – 2.39) 
2.36 
(2.33 – 2.39) 
2.31 
(2.25 – 2.35) 
2.40 
(2.33 – 2.46) 
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Figure 4.5: Graphs showing the mean Gradient Index of the ten best clinically acceptable plans, plotted 
against prescription isodose, for each sphere and using both Simplex and Sequential optimisation. 
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increases, over the range plotted. For the 30 mm and 50 mm targets, the effect of 
prescription isodose on GI is less marked, and the relationship a bit more complicated, 
but once again, the worst GI score in each case was obtained with the 80 % isodose 
value. 
 
The distribution of GI values across the clinically acceptable plans was found to be 
right-skewed for each of the target/isodose value/optimisation algorithm combinations. 
As an example, Figure 4.6a shows a frequency plot of the GI values obtained in plans 
for the 15 mm sphere, prescribed to the 80 % prescription isodose, using Sequential 
optimisation. This is not surprising when one considers the underlying planning process. 
There is a limit to how low a GI value can be obtained, due to the limitations of the 
treatment system. On the other hand, there is a larger range of potential GI values that 
are worse than the mean value, leading to a long right-sided tail of data. A logarithmic 
transformation was applied to the data to see if a normal distribution could be obtained, 
but the resulting data were not normally distributed (Figure 4.6b). Parametric statistical 
comparison of the groups using Analysis of Variance (ANOVA) was therefore not 
appropriate, and non-parametric testing was used instead. 
 
The results of the statistical analysis are summarised in Table 4.4. For each target and 
each optimisation algorithm a statistically significant difference between the isodose 
groups was detected using the Kruskal-Wallis Test with ! = 0.05, and the null 
hypothesis was therefore rejected in each case. The pre-specified individual 
comparisons (50 vs 60 %, 60 vs 70 % and 70 vs 80 %) were performed using the Mann-
Whitney U Test. The Bonferroni correction was applied, resulting in ! = 0.0167 for 
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Figure 4.6a: Frequency plot showing the range of GI values from clinically acceptable plans of the 15 
mm spherical target, prescribing to the 80 % isodose, and using Sequential optimisation. 
 
 
 
 
Figure 4.6b: Frequency plot of the GI values plotted in Figure 4.6a, but following logarithmic 
transformation using the natural logarithm (ln(e)). 
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Table 4.4: Results of statistical comparison between the ten best GI scores for each prescription isodose 
value, for each target/optimisation algorithm combination. Overall comparisons were performed using the 
Kruskal-Wallis test, with ! = 0.05. Comparisons between 2 isodoses were performed using the Mann-
Whitney U test, with ! = 0.0167 (Bonferroni correction applied). Values in colour are statistically 
significant. The red values indicate a significant result where the lower GI score was obtained with the 
lower isodose value. The blue values indicate a significant result where the lower GI score was obtained 
with the higher isodose value. 
Target Algorithm Overall p value 
p value of comparisons between 2 isodoses 
50 vs 60 % 60 vs 70 % 70 vs 80 % 
8 mm  
sphere 
Simplex < 0.0001  0.0002 0.0002 
Sequential < 0.0001  0.0002 0.0002 
15 mm 
sphere 
Simplex < 0.0001 0.0001 0.0001 0.0001 
Sequential < 0.0001 0.0001 0.0001 0.0001 
30 mm 
sphere 
Simplex < 0.0001 0.1313 0.0001 0.0001 
Sequential < 0.0001 0.0616 0.6701 0.0002 
50 mm 
sphere 
Simplex < 0.0001 0.0002 0.0008 0.0002 
Sequential < 0.0001 0.4181 0.0006 0.0003 
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each of the three comparisons (such that overall ! = 0.05 for all three comparisons 
together). 
 
For the 8 mm and 15 mm targets there was a statistically significant difference in each 
of the pre-specified comparisons. There is therefore a significant positive relationship 
between prescription isodose and GI across the explored range of isodose values, using 
both optimisation algorithms. For the 30 mm and 50 mm targets, the GI values for the 
80 % isodose were significantly higher than at 70 %, again using both algorithms. In 
these two larger targets, the optimum prescription isodose appeared to be somewhere in 
the 60-70 % range. 
 
Figure 4.5 also shows the relative results of simplex and sequential algorithms for the 
four targets. Generally, the differences between the two algorithms are relatively small, 
in comparison to the main effect being studied (choice of prescription isodose). Neither 
algorithm consistently out-performed the other in terms of GI values across the four 
targets. For example, whilst the GI values for the 8 mm target were generally slightly 
lower using Simplex, the opposite was the case with the 15 mm target. When comparing 
the nCI values achieved by both algorithms (Table 4.3), again there is little difference, 
with the same range for 8 and 30 mm targets, although Sequential optimisation (with the 
Iris collimator) did perform slightly better with the 15 and 50 mm targets.
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Discussion 
 
Radiotherapy planning studies are often complicated by the fact that when it comes to 
assessing candidate treatment plans there is no single correct answer. It is not 
immediately clear for any given solution whether the plan parameters could be 
improved yet further by making small adjustments to the planning variables. This is 
especially the case with inverse planning algorithms where multiple variables influence 
the resultant plan parameters. Indeed, as planning algorithms have become more 
complicated, it is increasingly hard to be confident that a “best possible plan” has been 
reached. In clinical practice there are guidelines which help to identify plans as being 
clinically acceptable (eg ICRU 50 and 62 for conformal radiotherapy (34, 35)). 
Additional time spent on a clinically acceptable plan is likely to improve it further 
(especially with inverse planning), but it may take significantly longer to produce a plan 
only marginally better. In busy clinical departments, whilst a plan is rarely accepted if it 
does not meet the criteria for being “clinically acceptable”, the time available to 
improve clinically acceptable plans even further is usually limited by departmental 
resources and patient workload.  
 
The purpose of this study was to optimise the external dose gradient of CyberKnife 
treatment plans, without compromising on other plan parameters, and to explore how 
dose gradient is affected by the choice of prescription isodose. The data obtained have 
come from a very thorough and systematic approach to the manipulation of the 
optimisation variables. The study was designed to keep the planning process as simple 
as possible: a single spherical target with no organs at risk to consider. In spite of this, 
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for the above reasons, one cannot be certain that these results are the best solutions 
achievable with CyberKnife for the targets used. However, by gaining an understanding 
of the effect of the different variables on the gradient index and other parameters, we 
can be confident that the results are likely to be very close to the best obtainable. It is 
intended that this experience can now be carried over for use in future studies, and in 
the routine departmental planning of clinical cases. 
 
The appropriate use of optimisation shells is of critical importance when attempting to 
optimise the dose fall-off in CyberKnife treatment plans. When using the Simplex 
algorithm, decreasing the maximum dose constraint to the optimisation shells will 
produce a plan with a steeper dose fall-off. It will also tend to lower the prescription 
isodose, but this can usually be compensated for (to keep at the desired prescription 
isodose %) by reducing the value of the maximum PTV dose constraint. The harder the 
shell dose constraints are “pushed”, the lower is the GI of the resultant plan. However, 
beyond a certain point, this is usually achieved at the cost of gradually worsening 
conformality, and therefore a compromise must be reached.  
 
The same can be observed with Sequential optimisation when hard limits are applied to 
the shells. Decreasing the shell hard limit doses will lower the GI, but ultimately at the 
expense of plan coverage and conformality. Alternatively, instead of pushing the shells 
with hard limits, Sequential has the option of setting shell optimisation goals. Whilst 
this more flexible approach may be a better method in more complex situations where 
there are multiple organ-at-risk optimisation steps, it does not usually create as steep a 
!!'"
"
dose fall-off as when using shell hard limits in the clinical situation relevant to this 
study ie solitary intracranial lesion > 3 cm away from brainstem and optic apparatus. 
 
The experience of this study has shown Target Boundary Distance (TBD) to be another 
important variable when attempting to optimise the GI, using either of the two planning 
algorithms. TBD allows the planner to specify a virtual boundary either outside 
(positive) or inside (negative) the PTV, which all beams must pass through. For these 
four spherical targets, using a negative TBD always improved the GI, compared to a 
TBD of 0, and usually resulted in a smaller number of beams and MU. However, the 
optimum negative TBD varied depending on the size of the target and optimisation 
algorithm used, and was established by trial and error for each target in this study. An 
additional effect of a negative TBD is that it in some situations it can push down the 
prescription isodose. It may therefore not be possible to use the optimum negative TBD 
and still produce a plan with the desired prescription isodose. For example, when using 
the Simplex algorithm for a 15 mm spherical target, and aiming for a 80 % prescription 
isodose, the optimum TBD in terms of GI would be -6 mm, but it is not possible to use a 
TBD of less than -1 mm and still prescribe to the 80 % isodose. 
 
Both algorithms may generate plans with a large number of beams and MU, especially 
when planning larger targets. The resultant plans may be high quality in terms of 
conformality and external dose gradient, but not feasible in terms of overall treatment 
time. In order to stay within the 60 minute treatment time restriction, planning variables 
which lead to a reduction in the number of beams and MU sometimes had to be 
exploited. Four ways of reducing the beams and/or MU have been identified. Firstly, as 
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discussed above, using a negative TBD appropriately can help to reduce beams and 
MU, especially with the 8 and 15 mm targets. Secondly, in Sequential planning, an 
“Optimise Monitor Unit” (OMU) step can be selected, usually as the final optimisation 
step. This will lower MU and to a lesser extent the beam number. Whilst this is usually 
achieved with no worsening of conformality, it almost always has a negative effect on 
the external dose gradient. It should therefore be avoided unless necessary. As discussed 
previously, MU optimisation is already built into the Simplex algorithm, and so there is 
no equivalent additional variable here. Thirdly, using larger collimators will lower the 
number of MU, and will also tend to reduce beam number. When using the Iris 
collimator with Sequential planning, a similar effect is produced by disabling the 
smallest collimator size(s) from selection. In either case, this may lead to plans with 
worse nCI and GI values, but sometimes they can be relatively unaffected. 
 
A fourth method is to remove beams from a plan which has already been produced. 
When using Simplex, this is a manual process whereby all beams delivering MU below 
a specified level are removed from the plan, and the dose distribution is simply 
recalculated. In other words, there is no re-optimisation of the remaining beams 
according to the original plan goals. If only a few beams (with small MU) are removed, 
there may be no real effect on the plan parameters. However, if a larger number are 
taken out it can have quite a dramatic negative effect on the coverage, conformality and 
dose fall-off. This obviously restricts the number which can be safely removed by this 
process. In Sequential planning, the “Beam Reduction” step allows re-optimisation after 
beams have been removed. Consequently it is a much more useful tool, and the number 
of beams in a plan can sometimes be reduced dramatically without any significant effect 
on coverage, conformality and dose fall-off. In Sequential planning it is therefore 
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always advisable to use beam reduction; OMU should be used only if the treatment time 
and/or MU of the plan is still unacceptable. 
 
The results demonstrate a statistically significant positive relationship between 
prescription isodose and GI for the 8 mm and 15 mm diameter spheres. For the 8 mm 
target, this relationship was observed over the isodose range 60 – 80 %, since it was not 
possible to produce a plan with a 50 % prescription isodose. As stated above, this was 
probably because with a target as small as this, the planning system cannot generate 
sufficient internal dose gradient to produce a 50 % marginal isodose. Nevertheless, the 
results suggest that for very small targets, the best dose fall-off will be achieved by 
prescribing to the lowest isodose which can be reached. 
 
For the 15 mm target, prescription isodose values throughout the range 50-80 % could 
be comfortably achieved, and it was possible to prescribe even lower than 50 %. In view 
of this, the study was extended to explore whether the observed relationship between 
prescription isodose and GI continued down to the 40 % isodose. Figure 4.7 shows an 
extension of the previously-presented data for the 15 mm sphere, with the data for plans 
prescribed to the 40 % isodose. For both algorithms, the results for the 40 % isodose 
were very similar to those obtained for the 50 % isodose, therefore there does not appear 
to be an additional benefit in prescribing down below 50 %. Preliminary analysis using 
a 90 % prescription isodose showed that GI values were substantially worse than even 
those achieved when prescribing to the 80 % line, so this was not studied further.
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Figure 4.7: Extension of the graph previously shown in Figure 4.5 for the 15 mm spherical target, with 
additional data points added for plans prescribed to the 40 % isodose. 
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In the case of the larger two targets, the GI values were significantly lower when 
prescribing to the 70 % as compared to the 80 % isodose. In general, though, the effect 
of prescription isodose on GI was less marked in these targets. The relationship was also 
less consistent over the range 50 – 70 %, with the optimum prescription isodose likely 
to be somewhere around 60 % for the 30 mm sphere and 65 % for the 50 mm sphere. 
 
The results suggest that when planning solitary intracranial targets, in terms of external 
dose gradient, it is not advisable to choose a prescription isodose above 70 %. Also, 
since most intracranial radiosurgery targets are likely to be less than 3 cm diameter, the 
optimum prescription isodose will usually be substantially lower than 70 %. 
 
Table 4.3 and Figure 4.5 show that, compared to the effect of prescription isodose, the 
effect of optimisation algorithm on GI is quite small, with neither one consistently out-
performing the other. Slightly improved conformality was seen with the Sequential 
algorithm/Iris collimator for two of the four targets. This is perhaps unsurprising since 
the Iris collimator allows more flexibility in choice of beam sizes for a given plan, 
compared to using Simplex, where a maximum of three fixed collimator sizes can be 
chosen per plan. Subsequent planning studies in this thesis will focus solely on 
Sequential planning using the Iris collimator. 
 
Choosing a lower prescription isodose value will inevitably result in greater 
inhomogeneity of dose within the PTV. In the past, there have been concerns raised 
about the possible risk of complications associated with PTV inhomogeneity. For 
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example, Nedzi et al (69) reported that of sixty patients treated with radiosurgery, 
fourteen experienced complications, with median follow-up of 8 months. On univariate 
analysis, tumour dose inhomogeneity was found to be a risk factor for developing 
complications, as was tumour volume, and maximum dose to normal tissue. 
Consequently, PTV homogeneity has been viewed by some as an important 
radiosurgical parameter. However, more recent, larger analyses have specifically not 
shown any relationship between target dose inhomogeneity and post-radiosurgery 
complications (12, 70, 71). Instead, the following risk factors have been identified: 
tumour volume, prescription isodose volume, and volume of normal tissue inside 
prescription isodose (71); conformality (70), and V12 (12). Finally, most of the 
radiosurgical long-term follow-up data come from Gamma Knife practice, and these 
centres continue to use prescription isodoses of around 40 - 60 %, accepting target dose 
inhomogeneity with little concern. 
 
Occasionally an organ-at-risk may lie inside the PTV, for example in some cases of 
acoustic neuroma and optic sheath meningioma. The use of a lower prescription isodose 
in this situation may increase the risk of delivering a dose higher than the prescribed 
dose to normal tissue contained within the PTV (and to normal tissue lying outside the 
PTV, but covered by the prescription isodose line). Choosing a higher prescription 
isodose would therefore appear attractive in this situation, although, as demonstrated in 
this project, this may result in a shallower dose gradient outside the PTV. However, the 
flexibility of CyberKnife planning allows the use of a low prescription isodose whilst at 
the same time optimising dose away from the critical structure in the middle of the 
target. This is illustrated by the “virtual HDR” prostate cancer planning technique 
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described by Fuller et al (75) (Figure 4.8), and now the subject of a multi-centre phase 
II trial in the USA. 
 
The selection of the ten clinically acceptable plans with the lowest GI score at each 
prescription isodose leads to the possibility of selection bias – more specifically 
sampling bias. A more statistically sound method of sampling would have been to 
choose ten plans at random from all of those generated at each prescription isodose for 
subsequent comparisons. However this method was rejected as being less relevant to 
everyday clinical practice. The process of producing a clinical treatment plan usually 
involves the generation of multiple candidate plans. Each plan is reviewed, and 
variables are usually modified for the next iteration in an attempt to improve each 
subsequent plan produced. The selection of a final treatment plan then usually involves 
a comparison of the strengths and weaknesses of the two or three best plans generated. 
Some plans produced early on in this process may be “clinically acceptable” but clearly 
worse than others produced for the same target, and would therefore never be selected 
as the final treatment plan. In this study, the planning process was consistent across the 
different prescription isodoses so that, as far as possible, the only variable under 
investigation was the prescription isodose value itself.  Nevertheless selection bias is 
still a possibility, and results need to be interpreted with this in mind. 
 
In this study, statistical analysis involved the use of non-parametric tests (Kruskal-
Wallis and Mann-Whitney U tests), as the criteria for performing parametric testing 
were not met. In general, these tests are less powerful than their parametric equivalents 
(ANOVA and unpaired t-test) since, instead of using all the information from the data,
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Figure 4.8: Axial slice of a prostate radiotherapy plan, showing the prostate (dark blue line), urethra 
(magenta line), and treatment isodose lines. The isodose values (%) are shown in the key at the top right 
of the image. The plan is prescribed to the 57 % isodose (yellow line), which covers the entire prostate 
conformally. “Hot” areas of 86 % dose (red line) are shown within the prostate, but the urethra is spared 
from doses above the prescription dose. 
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only the ranks of each data point are used in comparisons between the groups. This 
means that they are less likely to identify a statistically significant difference if there is 
one present. However, the analysis still yielded a number of significant results. The 
Bonferroni correction was used in the pre-specified comparisons between pairs of 
isodose values. This ensured that the probability of false positive results did not increase 
as a result of the multiple comparisons, but this came at the cost of a further reduction in 
the statistical power of the analysis. The significant results seen in the study have 
therefore been obtained in spite of these factors. 
 
The study had a number of further limitations. Firstly, only four prescription isodose 
points were studied, with 10 % between each value. It can be hard to establish the 
precise relationship between prescription isodose and GI with only four data points for 
each target. Secondly, whilst the results give us an idea about the relationship between 
prescription isodose and GI, and how this relationship changes with the size of the 
target, only spherical targets were studied. It is not clear to what extent these results 
would also apply to non-spherical or irregularly-shaped targets.  
 
Thirdly, the study only looked at one measure of external dose gradient: the Gradient 
Index. This was chosen as it is a pure measure of dose fall-off, being independent of the 
target volume or prescribed dose. However, it has not yet been shown to correlate with 
complications in the way that the V12 has, as discussed above. Also it only provides 
information on the dose fall-off to half the prescription dose. Whilst this covers the high 
dose area around the target, where normal tissue complications are most likely to occur, 
it provides no information on dose fall-off beyond half the prescribed dose. The volume 
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of normal tissue receiving a lower dose also has important implications, such as 
possible impact on the risk of radiation-induced malignancy. Finally, the results can 
only be applied directly to the planning of solitary intracranial lesions, and situations 
where an even dose fall-off on all sides of the target is desirable. Some of these 
limitations will be addressed by future work in this thesis. 
 
Summary 
 
This study has shown that in CyberKnife radiosurgery planning of solitary intracranial 
lesions, it is possible to produce plans with steep external dose gradients (as measured 
by the gradient index), without compromising on overall treatment time, conformality 
or PTV coverage. For smaller targets, inhomogeneity of dose within the PTV is the 
consequence of achieving the steepest dose fall-off possible. For larger targets it is not 
necessary to use such a low prescription isodose to maximise the GI, although an 
isodose as high as 80 % should be avoided unless dose homogeneity is a major 
requirement. 
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Chapter 5 – External dose gradient with irregularly-shaped targets: 
how do the results compare? 
 
Introduction 
 
The main purpose of this study is to explore further the relationship between 
prescription isodose value and external dose gradient in CyberKnife planning of solitary 
intracranial lesions, when an even external dose gradient on all sides is required. The 
aim is to build on the results of the previous chapter by addressing some of the 
limitations highlighted. Specifically, three of these limitations will be addressed in the 
design of this study. 
 
Firstly, the previous study used spherical “virtual” targets centrally located in the brain, 
as the main aim was to observe the effect of prescription isodose value on dose fall-off, 
and effect of target size on this relationship. It was believed that any variation in target 
shape (and possibly location) might make the results harder to interpret, and it may have 
been more difficult to understand the effects of the individual planning variables on the 
resultant plan parameters. Having obtained the results described in Chapter 4, and 
gained some understanding of the above relationship, a logical step would be to see if 
this relationship is the same when real intracranial lesions (with irregular shape and 
variable intracranial location) are used. This study will therefore use a random selection 
of intracranial lesions previously treated at this centre. 
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Secondly, only four prescription isodose values were studied previously: 50, 60, 70 and 
80 %. This was due to the time required to produce at least ten clinically acceptable 
plans for each isodose value, for each of the two different optimisation algorithms 
(Simplex and Sequential). Since the choice of algorithm had little effect on Gradient 
Index (GI) compared to the effect of prescription isodose value on the same parameter, 
it was decided that further studies would focus solely on the Sequential algorithm - the 
only one which supports the use of the Iris collimator. In this study, plans will be 
produced at each of six different prescription isodose values in the range 50 – 80 %, for 
each of the five intracranial lesions selected. 
 
Thirdly, GI was chosen as the measure of external dose gradient, since it is independent 
of both target size and prescribed dose. However, there have not yet been any published 
data looking at the relationship between GI and post-radiosurgical complications. Also, 
GI only concerns fall-off from the prescribed dose to half this value. For the present 
study, therefore, two additional measures of external dose gradient will be calculated for 
each clinically acceptable plan produced. The volume contained within the 12 Gy 
isodose line (V12) was selected it has previously been shown to correlate with post-
radiosurgical complications (12, 58). For the second additional measure, a new 
parameter is proposed: the Quarter Dose Index (QDI): 
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where x = prescription isodose value for the plan. So, for a prescribed dose of 18 Gy, 
this parameter provides a measure of dose fall-off down to 4.5 Gy. 
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For the present study, the GI will once again be used as the basis for selecting the best 
plans at each prescription isodose value. However, by also calculating the V12 and QDI 
for each plan, it will be possible to assess the degree to which these parameters correlate 
with the GI. This will provide more information as to whether or not GI should be used 
alone as the measure of dose fall-off when analysing CyberKnife radiosurgical plans. 
 
A further aim of this chapter is to use the experience gained from both this study and the 
previous one to produce a stepwise method for the planning of solitary intracranial 
lesions using MultiPlan. This will apply specifically to situations where an even dose 
fall-off on all sides of the target is desired. By following the guidelines it should be 
possible to optimise external dose gradient without compromising on the other 
important plan parameters. The method will hopefully be a useful aid to the future 
planning of intracranial lesions at this and other CyberKnife centres.
!#*"
"
Methods 
 
The methods for this study were very similar to the previous chapter, but with some 
important differences which are now described. MultiPlan version 3.5.1 was used 
throughout the study. The intracranial solid tumours treated at this centre between 
February 2009 and May 2010 were examined. Twenty lesions were treated, of which 
eleven were > 2 cm away from brainstem or optic apparatus, and therefore fit with the 
study objective of producing an even dose fall-off around the target. From these eleven 
lesions, five were selected at random and used in this study. The unenhanced brain CT 
images, with axial slice thickness of 1.25 mm, together with the PTV and organ-at-risk 
contours, were used for each of the five lesions. As with the previous study, two 
optimisation shells were created around each lesion: one 2.5 - 3 mm away, and the 
second 5 – 8 mm away, depending on the size of the lesion. Sequential optimisation was 
used throughout, with the Iris collimator. For each lesion, the planning variables were 
adjusted to produce treatment plans with a prescription isodose of one of the following 
six values: 50, 56, 62, 68, 74 and 80 %. As previously, the planning variables were 
manipulated in order to optimise dose fall-off (as measured by Gradient Index (GI)) for 
the plans at each of the six prescription isodose values. In addition to GI, the V12 and 
QDI were also calculated from the DVH graph of each plan produced. 
 
Multiple plans were produced for each lesion, but once again only “clinically 
acceptable” plans were accepted for further analysis. The criteria for clinical 
acceptability were the generally the same as in the previous study, including > 95 % 
PTV coverage by the prescription isodose line, and a treatment time of < 60 minutes, 
assuming the delivery of a single fraction of 18 Gy. There was, however, one difference 
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in the acceptability criteria. When using spherical targets, the New Conformity Index 
(nCI) for each plan had to be within 0.03 of the best achievable value for that particular 
target/prescription isodose value/optimisation algorithm combination. Preliminary 
analysis had shown that > 90 % of plans produced would lie within this range. Early 
work studying the real (irregularly-shaped) lesions found that there was a greater 
variation in nCI values across the plans produced, compared to the results with the 
spherical targets. > 90 % of plans produced had nCI values within 0.05 of the best 
achievable value for that target/prescription isodose value combination, and so the nCI 
criterion for clinical acceptability was increased from 0.03 – 0.05. 
 
The ten clinically acceptable plans with the lowest GI scores for each target/isodose 
combination were selected for comparison. As before, the null hypothesis stated that 
there was no difference in GI across the isodose groups for each lesion. If the null 
hypothesis was rejected then pre-specified comparison of the following isodose values 
was performed: 50 vs 56 %, 56 vs 62 %, 62 vs 68 %, 68 vs 74 % and 74 vs 80 %. As 
before, the Bonferroni correction (74) would be applied to the ! value to maintain an 
acceptable false-positive rate.
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Results 
 
The volume and maximum axial dimensions of the five lesions are shown in Table 5.1. 
The lesions were located within the brain as follows: left parietal lobe (lesions 1 and 4), 
left occipital lobe (lesion 2), left temporal lobe (lesion 3) and right frontal lobe (lesion 
5). Table 5.1 also shows the mean and range of the ten best GI scores in clinically 
acceptable plans produced for each lesion/prescription isodose value combination, 
together with the range of nCI values achieved in each case. The nCI values ranged 
from 1.04 to 1.15 across the five lesions. This is slightly higher than that seen for the 
spherical targets in the previous chapter. This is unsurprising as one would expect the 
conformality to be slightly worse for irregularly-shaped targets. The table shows that for 
two of the five lesions (lesions 1 and 4) it was not possible to produce clinically 
acceptable plans prescribed to the 50 % isodose. Whilst these were not the smallest two 
lesions by volume, inspection of the contours showed that of the five lesions, these two 
had the smallest axial dimensions through at least part of the volume. Results were, 
however, obtained across the isodose range 56 – 80 % for all five lesions. 
 
Figure 5.1 is a graph of the mean GI scores shown in Table 5.1, with the results for all 
five lesions displayed on the same graph. For the 3 smaller lesions (lesions 1 – 3) a 
positive relationship between prescription isodose value and GI was observed across the 
achievable range of isodose values. This resembles the results seen with the two smaller 
spherical targets in the previous chapter. For the two larger lesions (lesions 4 and 5), the 
effect of prescription isodose value on GI was not as great, as shown by the shallower 
gradient of these two curves. However, the worst GI scores for all five lesions were seen 
when prescribing to the 80 % isodose.
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Table 5.1: showing the new Conformity Index (nCI) and Gradient Index (GI) scores for clinically 
acceptable plans produced for each target lesion used in this study.
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Figure 5.1: Graph showing the mean Gradient Index of the ten best clincally acceptable plans, plotted 
against prescription isodose for each of the five lesions. 
 
Target Overall p value 
p value of comparisons  between 2 isodoses 
50 vs 56 % 56 vs 62 % 62 vs 68 % 68 vs 74 % 74 vs 80 % 
Lesion 1 < 0.0001  0.0019 0.0002 0.0002 0.0002 
Lesion 2 < 0.0001 0.0019 0.0015 0.0003 0.0002 0.0002 
Lesion 3 < 0.0001 0.3643 0.0009 0.0963 0.0002 0.0002 
Lesion 4 < 0.0001  0.4497 0.0963 0.0007 0.0004 
Lesion 5 < 0.0001 0.0009 0.0963 0.5967 0.0019 0.0002 
 
Table 5.2: Results of statistical comparison between the ten best GI scores for each prescription isodose 
value, for each lesion. Overall comparisons were performed using the Kruskal-Wallis test, with ! = 0.05. 
Comparisons between 2 isodoses were performed using the Mann-Whitney U test, with ! = 0.01 
(Bonferroni correction applied). Values in colour are statistically significant. The red values indicate a 
significant result where the lower GI scores were obtained with the lower isodose value. The blue values 
indicate a significant result where the lower GI scores were obtained with the higher isodose value. 
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Table 5.2 summarises the results of the statistical analysis performed. Comparison 
across all the prescription isodose values together using the Kruskal-Wallis test showed 
a statistically significant difference in mean GI scores, for each of the five lesions (p < 
0.0001). The null hypothesis was therefore rejected in each case, and the pre-specified 
comparisons between different pairs of isodose values were performed using the Mann-
Whitney U test. For lesions 1 and 2 the positive relationship shown in Figure 1 was 
statistically significant across the whole range of values (! = 0.01). For lesion 3, three of 
the five comparisons were significant (56 vs 62 %, 68 vs 74 %, and 74 vs 80 %). For 
lesions 4 and 5 there was no significant difference in GI across the range 56 – 68 %. 
However, as with the other three lesions, the rising GI values over the 68 – 80 % 
prescription isodose range were statistically significant. 
 
Figure 5.2 contains a series of graphs illustrating the relationship between mean GI and 
the other two measures of external dose gradient, V12 and QDI, across the range of 
isodose values studied for each lesion. For lesions 1 – 3, the positive relationship 
between GI and prescription isodose described above is also seen for both V12 and QDI 
across the isodose range studied. In fact, V12 values also show a positive relationship 
across all values for lesion 4 and most of the range in lesion 5, with the lowest mean 
values being seen at the lowest prescription isodose values. However, for these latter 
two lesions, the lowest GI and QDI scores are observed somewhere in the range 56 – 68 
%. 
 
A more formal assessment of the association between GI and both the V12 and QDI 
values was also carried out. Spearman’s Rank correlation coefficient values (rs) were 
calculated for GI vs V12 and GI vs QDI relationships, using the ten best clinically 
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Figure 5.2: Graphs showing the effect of prescription isodose value on the Gradient Index (GI), 12 Gy 
volume (V12) and Quarter Dose Index (QDI) for each of the five lesions. 
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Figure 5.2 (continued): Graphs showing the effect of prescription isodose value on the Gradient Index 
(GI), 12 Gy volume (V12) and Quarter Dose Index (QDI) for each of the five lesions. 
 
Parameters 
for 
correlation 
Lesion 1 Lesion 2 Lesion 3 Lesion 4 Lesion 5 
GI and V12 0.964 0.924 0.881 0.835 0.693 
GI and QDI 0.973 0.705 0.750 0.455 0.197 
 
Table 5.3: Spearman’s Rank Correlation Coefficient (rs) values for the association between Gradient 
Index (GI) and 12 Gy volume (V12), and between GI and Quarter Dose Index (QDI), using the ten plans 
with the lowest GI scores at each prescription isodose value. The table shows the results for each of the 
five lesions. Values in red are statistically significant (two-tailed p value < 0.05). 
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acceptable plans at each prescription isodose value. There were therefore 60 data points 
for lesions 2, 3 and 5, and 50 points for lesions 1 and 4 (no data at the 50 % isodose 
value). The results are summarised in Table 5.3. For lesions 1 – 3, there was a 
statistically significant strong positive association between GI and both V12 and QDI  
(rs 0.705 – 0.964), as might be expected from studying Figure 5.2. In the case of lesions 
4 and 5, the association between GI and V12 is also relatively strong, and significant (rs 
0.693 – 0.835). However, the association between GI and QDI is less strong (rs 0.197 – 
0.455), and, for lesion 5, not statistically significant.
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Discussion 
 
This study can be viewed as an extension of the experimental method described and 
carried out in Chapter 4. Central to both studies was the development of an 
understanding of the effect of the individual planning variables on important 
radiosurgical parameters, such as PTV coverage, conformality, external dose gradient 
and treatment time. The planning variables exert their effects in a number of different 
ways, including, in some cases, by direct influence on the prescription isodose of the 
resultant plan. The key planning variables in both Simplex and Sequential optimisation 
algorithms, and their effects on these parameters, have already been discussed in depth 
in the previous chapter. The current study has focused on Sequential optimisation and, 
with regard to the effects of the planning variables, there do not appear to be any major 
differences when planning irregular lesions as opposed to spherical targets. 
 
The main experimental aim for both studies was to establish the effect, if any, of 
prescription isodose value on external dose gradient, as measured by Gradient Index 
(GI). The results for the intracranial lesions studied here are generally consistent with 
those seen with the spherical targets, implying that the shape (and location) of the target 
does not influence the above relationship (and the effect of target size on this 
relationship) in any significant way. 
 
It was not possible to produce clinically acceptable plans prescribed to the 50 % isodose 
for lesions 1 and 4, as was observed with the 8 mm spherical target in the previous 
chapter. It was suggested in the previous chapter that this may be due to the system 
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being unable to generate sufficient internal dose gradient to give a marginal isodose as 
low as 50 %. Lesion 4 had a volume of 9.6 cm3 and lesion 1, whilst considerably 
smaller at 2.25 cm3, still had a larger volume than that of the 15 mm sphere (1.8 cm3), 
for which prescribing to the 50 %  isodose (or even the 40 % isodose) was not 
problematic. This would suggest that it is the minimum diameter of the lesion, rather 
than the volume per se, which dictates the lowest marginal isodose value which can be 
reached. 
 
This study demonstrated a statistically significant positive relationship between 
prescription isodose and GI over the range of achievable isodose values for the smallest 
two lesions (1 and 2). These results are the same as for the two smaller spherical targets 
studied previously. In the case of lesion 3, a similar positive relationship was observed, 
although the differences were not statistically significant throughout the whole range of 
values. Additionally, for these three lesions, a strong, statistically significant, positive 
association was demonstrated between GI and both the V12 and QDI measures of dose 
fall-off. This would justify the use of GI as a sole measure of external dose gradient 
when assessing any CyberKnife plan of a small solitary intracranial target. 
 
The largest two lesions (4 and 5) show a statistically significant positive relationship 
between isodose value and GI over the range 68 – 80 %, but the differences in the range 
56 – 68 % are non-significant, and generally smaller. Whilst the correlation between GI 
and V12 is moderately strong (and statistically significant) for these lesions, the V12 
continues to get smaller as the prescription isodose is lowered right down to the lowest 
achievable value. On the other hand, QDI correlates less well with GI, and the optimum 
prescription isodose for QDI was 68 % in both cases. 
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Whilst acknowledging that caution should be shown before drawing firm conclusions 
from what is still a relatively small number of targets studied (four spheres and five 
irregular lesions), two groups of targets appear to have emerged:  
 
1. Smaller targets, where the optimum dose fall-off is achieved by prescribing down to 
as close to 50 % as can be comfortably reached. In these targets, GI correlates well with 
both the V12 and QDI measures, and can therefore be used alone. 
 
2. Larger targets, where the optimum GI is usually achieved by choosing a prescription 
isodose in the range 55 – 65 %. As volume increases, the optimum isodose value moves 
closer to 65 % (or even towards 70 % for very large targets). Additionally, choosing a 
value of less than 55 – 60 % may actually produce significantly worse results. The 
association between GI and both V12 and QDI is less strong in this group, although 
choosing an isodose in the 60 – 65 % range may often be the best compromise for all 
these different measures of dose fall-off. 
 
It is important to know where the line between smaller and larger targets should be 
drawn. The best answer based on the results here is that lesions of volume < 5cm3 or 
maximum diameter < 20 mm will almost certainly fit in the group for smaller lesions. 
Targets of volume > 8 cm3 or maximum diameter > 25 mm will probably fit in the 
larger lesion group. Targets in between these values could show mixed features of both 
groups. Reference is made to these two groups in the proposed method for planning 
solitary intracranial lesions described below. 
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The basic plan setup, as described in the methods section, involved the use of two 
optimisation shells. All plans produced were inspected qualitatively before being judged 
clinically acceptable. This involved expanding the calculation grid to cover the whole 
head, and observing the full isodose arrangement including low and medium dose areas. 
The addition of a third optimisation shell at a greater distance from the PTV (eg 15 – 25 
mm) would probably have improved the overall plan dosimetry for larger targets. It is 
less important for smaller targets, as the overall dosimetry was usually excellent even 
without a third shell. The additional shell becomes especially important when a specific 
organ at risk on one side of the target is to be avoided, and will therefore be used in 
Chapter 6, where this clinical situation is explored. 
 
The selection of the ten best “clinically acceptable” plans at each prescription isodose 
value followed the same method as the previous study. The rationale for this approach 
over choosing ten plans at random has previously been discussed: as stated in the 
previous chapter, the possibility of selection bias cannot be excluded, and results must 
be interpreted with this in mind. 
 
Similarly, as in the previous study, statistical analysis here has involved non-parametric 
tests (Kruskal-Wallis, Mann-Whitney U, and Spearman’s Rank correlation coefficients) 
since the GI scores (and other dose fall-off measures) for plans prescribed to a particular 
prescription isodose value are unlikely to be normally distributed. Whilst the tests are 
likely to be less powerful than their parametric equivalents, any statistically significant 
results obtained are just as valid.
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Proposed planning method for solitary intracranial lesions using MultiPlan 
 
The following is a proposed step-wise method for the planning of solitary intracranial 
lesions in situations where even dose fall-off on all sides of the target is desired. It 
enables optimising dose fall-off outside the target, whilst not compromising on other 
plan parameters. In situations where the target is very close to brainstem or optic 
apparatus, the best method is likely to be different, and this will be the subject of the 
following chapter. 
 
Initial setup: 
 
Set relatively strict maximum MU values per beam and node (eg 200 and 500 
respectively). This will help to prevent the appearance of areas of moderately high dose 
distant to the target.  
 
Use at least two optimisation shells in association with VOI limit values. The closest 
shell should be approximately 3 mm outside the PTV, and the second between 6 and 8 
mm outside the PTV, depending on the PTV diameter (bigger margin for bigger target). 
This should result in the isodose line which is half of the prescription isodose lying 
somewhere between these two shells, for an optimised plan. A third shell positioned at 
approximately 15 – 25 mm outside the PTV will further help to reduce the areas of 
moderately high dose distant to the target. Select VOI limits for the two inner shells, 
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using values which straddle the half-prescription dose eg 13.5 Gy and 7.5 Gy for inner 
and second shells respectively if prescribing to 18 Gy. 
 
Set the calculation grid to as small a size as can cover the target and shells. This will 
allow several iterations to be performed relatively quickly, whilst the optimum variable 
settings are established. The use of low resolution optimisation for the early iterations 
will also increase the speed, although results can be quite different when you change to 
high resolution optimisation. 
 
Planning process: 
 
1. Set the variables to achieve a prescription isodose of around 55 %, with a target 
boundary distance (TBD) of 0. MultiPlan should be able to achieve a 55 % prescription 
isodose for most lesions, and it will often be quite close to the optimum value. 
 
2. Vary the TBD, starting at -1 mm and setting to increasingly negative values. Measure 
the gradient index (GI) for each result and find the value which gives the lowest GI 
score. This is likely to be between -1 and -4 mm for most lesions. 
 
3. Start constraining the optimisation shells with increasingly tight VOI hard limits, 
through a series of further iterations. This will give steeper dose fall-off and may push 
the prescription isodose down. Eventually, as the shells are pushed further, conformality 
will start to worsen, and PTV coverage may also be affected. Establish the lowest 
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values which maintain conformality and coverage within your pre-specified desired 
range. > 95 % PTV coverage is a commonly used criterion, although it is often possible 
to achieve > 97 % coverage without any compromise. An nCI range of 0.05 will cover 
the large majority of plans produced for a given target. 
 
4. For smaller targets (volume up to approximately 5 cm3, or maximum diameter up to 
20 - 25 mm), try changing settings to lower the prescription isodose down towards 50 % 
(if this has not already happened as a result of the above steps). This may further lower 
the GI. For larger targets, explore the prescription isodose range 55 - 65 %. In either 
case, find the value which gives the best solution with respect to dose fall-off, 
conformality and coverage. 
 
5. Estimate the treatment time using the equation: 
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Treatment time can be reduced if unacceptably long. In Simplex, manual beam removal 
will safely remove a small number of low-MU beams, but if further time reduction is 
required, it may be necessary to re-plan with larger collimators. This potential problem 
will usually be picked up earlier in the planning process. In Sequential, the Beam 
Reduction tool will usually be sufficient to reduce treatment time to an acceptable level. 
For best results run the process two or even three times, as low-MU beams may be 
added in the re-optimisation process. Beam Reduction can sometimes actually improve 
plan parameters (including GI) so when using Sequential it is worth trying it even if the 
treatment time is already acceptable. 
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6. Expand the calculation grid for the final plan produced in step 5, so that the whole 
brain and skull is included. Re-do the high dose calculation and perform a qualitative 
analysis, checking for any features which would make the plan clinically unacceptable, 
such as “fingers” of moderate/high dose away from the target. If this analysis finds no 
problems, save the plan as deliverable. 
 
Summary 
 
The choice of prescription isodose value does affect the external dose gradient in 
CyberKnife planning of solitary intracranial lesions, and this has been demonstrated 
both for spherical virtual targets (previously) and real intracranial solid tumours. The 
nature of this relationship is different in the case of smaller targets, as opposed to larger 
ones, as described above. 
 
Gradient Index correlates very well with both the 12 Gy volume and Quarter Dose 
Index for smaller lesions, but less well for larger ones, therefore it may be advisable to 
use more than one measure of external dose gradient when assessing treatment plans for 
larger lesions. 
 
On the basis of the results, a stepwise method for the planning of solitary intracranial 
lesions using MultiPlan has been proposed, to aid future treatment planning. The 
method seeks to optimise external dose gradient on all sides of the target, whilst not 
compromising on other important plan parameters. 
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Chapter 6 - Exploring ways to optimise dose fall-off on one aspect of a 
target, and the effects on overall plan quality 
 
Introduction 
 
The last two chapters have been concerned with creating clinically acceptable treatment 
plans with as steep a dose fall-off on all sides as possible. This is very important for 
many intracranial lesions, as cerebral cortex often surrounds the target. Whilst the dose 
to the cortex should always be as low as possible, within the skull there are some 
structures considered to be either especially radiosensitive or especially important in 
terms of function (or both). Brainstem, optic nerves and optic chiasm are the best 
examples here. For targets situated close to (or abutting) one of these structures, 
achieving an especially steep dose fall-off in that direction is often essential for the safe 
delivery of an ablative dose of radiation.  
 
In radiotherapy planning, particularly favourable dosimetry on one side of a target is 
sometimes achieved at the expense of a significantly less favourable dose profile on the 
other aspects. This may be acceptable if the tissue on other sides is not considered to be 
particularly radiosensitive or functionally important. However, it is not really an 
acceptable solution for many intracranial lesions which are surrounded by cerebral 
cortex.  Whilst the main priority may be to reduce the dose on one aspect, the radiation 
tolerance of the surrounding cerebral cortex must still be respected. The ideal solution 
will therefore be to optimise dose fall-off in one direction, but not at the expense of any 
substantial increase in dose to the cortex. A compromise will inevitably have to be 
made, due to the dosimetric limitations of the radiosurgery system being used. A 
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thorough understanding of the planning system (and optimisation algorithm) being used 
will enable the best compromise to be reached in any such situation.  
 
The brainstem provides a connection between the cerebral cortex and spinal cord, with 
densely-packed nerve fibres comprising much of its volume. The nuclei for cranial 
nerves III – XII are also located here, as are centres controlling respiratory drive and 
cardiovascular homeostasis. Consequently brainstem damage is often life-threatening, 
and therefore when considering radiosurgery to any lesion close to the brainstem, the 
highest priority is usually given to obeying brainstem dose tolerances. This can be the 
dose-limiting factor in the planning of many skull base targets. 
 
 As discussed previously, the brainstem is an example of a serial organ in 
radiobiological terms. A high dose to a very small volume of brainstem could have 
major consequences. For this reason, the maximum dose to the brainstem is one 
important measure when assessing a radiosurgical plan. However, the point maximum 
brainstem dose on a plan corresponds to the highest dose to a single voxel, which in turn 
usually represents less than one cubic millimetre of brainstem volume (< 0.001 cm3).  In 
an area of steep dose fall-off, the dose to what may still be a very small volume of 
brainstem may be substantially lower than the point maximum dose. For example, in the 
treatment of trigeminal neuralgia, a dose of up to 90 Gy is delivered to a target only a 
couple of millimetres away from the brainstem. The point maximum brainstem dose 
may be as high as 40 Gy whilst the 12 Gy volume is usually well below 0.1 cm3. This 
practice has been shown to be safe with regards to brainstem toxicity with long-term 
follow-up (76). On the other hand, Sahgal et al (77)  performed retrospective analysis of 
five patients with myelopathy following spinal SBRT, comparing the treatment plans 
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with those from  nineteen patients with no myelopathy.  They found that the only spinal 
cord dose-volume endpoint with significant difference between both groups of patients 
was the point maximum dose.  
 
This raises the question as to what is the most clinically useful serial organ dose-volume 
measurement when assessing a radiosurgical plan. Dose-volume studies on the spinal 
cord in animals have suggested that the spatial dose distribution may actually be more 
relevant to cord tolerance than simply the irradiated volume (78). If this were true for 
human spinal cord, neither DVH analysis nor absolute volume constraints will reliably 
predict complications. Nevertheless, until the relationship between dose distribution and 
tolerance is understood more clearly, dose-volume values should still be used. The 
recent QUANTEC (Quantitative Analyses of Normal Tissue Effects in the Clinic) 
recommendations for brainstem tolerance state that radiotherapy studies should at the 
very least report on point maximum dose, dose to 1 cm3, and mean dose (together with 
dose per fraction, although this is not relevant for single fraction treatment) (79).  
 
This study is a further dosimetric exploration of the CyberKnife system and concerns 
the radiosurgical planning of a solitary intracranial target which is largely surrounded 
by cerebral cortex, but is also situated very close to the brainstem on one side. As with 
the previous study, MultiPlan’s Sequential optimisation algorithm will be used. This is 
the most widely used algorithm, and the only one which allows use of the Iris 
collimator. Sequential optimisation is discussed in more detail in Chapter 2. The most 
powerful way to limit dose to an organ-at-risk (OAR) in Sequential planning is to use a 
“VOI limit” (Volume of Interest limit). This can be applied to any contoured structure 
(or shell) and acts to limit the maximum dose to that structure according to the value 
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specified. It is selected during the setup of the initial plan variables, and is separate to 
the goal values specified in the optimisation steps. During optimisation, the algorithm 
works through the planning steps in order, trying to produce the best solution for each 
step in turn whilst attempting not to compromise on the solution to the previous step(s). 
However, it is also constrained even more strongly at each step by any VOI limits that 
have been specified.  
 
When using a VOI limit, the only limit that can be applied is to the maximum dose to 
that structure. Limiting the maximum dose is clearly important for serial organs such as 
the brainstem, but as discussed above, it may not be the only consideration. It is not 
clear whether a VOI limit is also effective at limiting dose to, for example, 1 cm3 
volume, or even the mean dose to the structure. It also not clear to what extent the 
algorithm will be able to continue to lower the maximum dose to the OAR as the VOI 
maximum dose constraint is “pushed” progressively lower, and in what way other 
important plan parameters may be compromised in so doing. 
 
The previous two studies have demonstrated that the choice of prescription isodose 
value affects the steepness of the external dose gradient when aiming for even dose fall-
off on all sides of a solitary intracranial target. This effect is much greater for smaller 
targets than larger ones. It is not known whether the choice of prescription isodose will 
also influence dose fall-off when the priority is to spare dose to an OAR on one side of 
the target. This will also be explored in the current study. 
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In summary, the purpose of this study is to improve understanding with regard to the 
planning of solitary intracranial lesions located close to (or abutting) the brainstem, 
using Sequential optimisation  in MultiPlan. More specifically, it is hoped that the 
experimental work will provide answers to the following questions: 
1. When using a brainstem VOI limit, how much is it possible to reduce the 
brainstem dose whilst still producing a clinically acceptable plan? 
2. Does the brainstem point maximum dose correlate with other dose-volume 
endpoints, such as the dose to 1 cm3 or the mean dose, when a VOI limit is 
applied? 
3. What is the relationship between brainstem dose and overall external dose 
gradient, as measured by gradient index (GI) and quarter dose index (QDI)? 
4. Are the answers to the above questions affected by the choice of prescription 
isodose, the size of the target, or the distance from the target to the brainstem?  
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Methods 
 
Certain parts of the experimental method are once again similar to that described in 
Chapter 4. The unenhanced CT scan (1.25 mm axial slice thickness) of a previously-
treated patient was used as the baseline CT dataset, together with the contours of the 
main intracranial OARs. A spherical “virtual” target was created using MultiPlan’s ball-
cube function and positioned close to the brainstem. Two different spheres were created, 
with diameters of 15 mm and 30 mm. Results from chapters 4 and 5 suggest that the 
effect of prescription isodose on external dose gradient is different for “smaller” and 
“larger” targets, with the line between the two groups being drawn somewhere between 
20 and 25 mm diameter. One smaller (15 mm) and one larger (30 mm) target were 
therefore selected here. Virtual targets were chosen rather than real lesions, as this 
allowed the distance between target and brainstem to be varied. Three optimisation 
shells were used around each target. They were positioned at 2.5, 6 and 15 mm outside 
the 15 mm sphere, and 3, 7 and 20 mm outside the 30 mm sphere. 
 
 Each sphere was placed at four different positions, with varying distance from the 
brainstem. The 2-dimensional distance between target and brainstem is measured by the 
planning system in terms of the number of CT pixels between the two structures. The 
CT images used in this study had an axial resolution of 512 x 512 pixels, and a 45 cm 
field of view. The axial distance across 1 pixel was therefore 0.88 mm. At the four 
different positions, the shortest 2-dimensional distances between target and brainstem 
were 12 pixels (10.5 mm), 6 pixels (5.3 mm), 3 pixels (2.6 mm) and 0 pixels (here the 
contours actually overlapped at the closest point). Thus eight plan baselines were 
created: four for each of the two spherical targets. 
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For each plan baseline, the method for planning solitary intracranial lesions proposed in 
the previous chapter was followed in order to produce a clinically acceptable plan with 
the steepest possible dose fall-off on all sides (as measured by the GI). The point 
maximum dose delivered to the brainstem was recorded in each case. This represented 
the maximum dose to the brainstem when no specific brainstem dose limit had been 
applied. Following this, a VOI limit was then applied to the brainstem. In the case of the 
30 mm sphere, the initial maximum dose limit was set at the nearest 1Gy to the 
maximum brainstem dose just recorded. For example, if the point maximum brainstem 
dose had been 12.65 Gy, then the VOI maximum dose limit was set at 13 Gy for the 
next optimisation. The first clinically acceptable plan produced using this VOI limit was 
saved for further analysis. The brainstem VOI maximum dose limit was then lowered in 
steps of 1 Gy, with new optimisations at each new value, until a clinically acceptable 
plan could no longer be produced. The method for the 15 mm sphere was the same, 
except that the initial VOI limit was set at the nearest 0.5 Gy to the maximum brainstem 
dose initially recorded, and then subsequently lowered in steps of 0.5 Gy for each new 
optimisation. This was because the dose fall-off outside the smaller target is steeper in 
terms of absolute distance, therefore the maximum brainstem doses would be lower than 
for the larger target. Preliminary analysis showed that using steps of 0.5 and 1 Gy for 
the smaller and larger targets respectively would allow approximately 5 – 10 VOI limit 
steps in each case, which should be sufficient to obtain a reasonable picture of the 
relationship between VOI limit and maximum brainstem dose. 
 
The following data were recorded for each accepted plan: target (PTV) coverage, new 
conformity index (nCI), GI, QDI, brainstem point maximum dose, dose to 0.1 cm3 and 1 
cm3 of brainstem, and mean brainstem dose. Some of these values are automatically 
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generated by the planning system; the others were calculated using the DVH data and 
Microsoft Excel. 
 
The above method was performed three times on each of the eight plan baselines, using 
one of three different prescription isodose values: 55, 65 and 75 %. Previous work in 
this thesis had explored the prescription isodose range 50 – 80 %. However for some 
lesions it was not possible to use a prescription isodose as low as 50 %. It was also 
observed that using an 80 % prescription isodose gave the worst dose fall-off for each 
lesion planned. For these reasons it was decided to explore the 55 – 75 % prescription 
isodose range, using these three different prescription isodose values. 
 
As with the previous two studies, only treatment plans considered to be clinically 
acceptable were selected for further analysis. Once again, only plans with an estimated 
total treatment time of less than sixty minutes (delivering 18 Gy) were considered 
acceptable. In Chapter 4, using spherical targets, the nCI value had to be within 0.03 of 
the best achievable nCI for that lesion, to ensure that steep dose fall-off was not 
produced at the expense of conformality. For this study the acceptable nCI range was 
relaxed to within 0.05 of the best achievable value for each lesion. This is because in 
situations where brainstem sparing is an important requirement, a slightly greater 
compromise on conformality may be accepted. 
 
Previously, clinically acceptable plans were required to have > 95 % PTV coverage by 
the prescription isodose. This is common practice in many radiosurgery centres. 
However, for this study the PTV coverage requirement was increased to > 97 %. 
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Experience with CyberKnife planning at this centre has shown that for most intracranial 
cases, > 97 % PTV coverage is an achievable objective. It is only really when there is 
significant overlap of the PTV with a radiosensitive OAR, or when the lesion is very 
close to more than one OAR, that PTV coverage drops below this level. Indeed, in a 
retrospective analysis of the all the clinically acceptable plans produced in Chapters 4 
and 5 (where > 95 % PTV coverage was the requirement), 75 % plans actually had > 97 
% PTV coverage. Increasing the coverage requirement to 97 % will bring all plans up to 
this level, and thus help to reduce the volume of PTV receiving doses less than the 
prescribed dose. 
 
By introducing an OAR to be spared, this study provides a more difficult planning 
challenge than the previous two studies. Brainstem sparing will inevitably cause some 
deterioration in overall plan quality, such as the dose delivered to tissue a long way 
from the target. It was therefore necessary to try to quantify the peripheral dose 
distribution – something which is usually assessed in a more qualitative manner. For an 
18 Gy treatment, the QDI provides a measure of the volume of tissue receiving >/= 4.5 
Gy, and will therefore give some idea as to the effects of brainstem sparing on lower 
dose volumes. However, it was felt that there should be an additional measure of dose 
away from the target which would identify unacceptable “fingers” of moderately high 
dose. For this reason, volume of tissue outside the outer optimisation shell receiving >/= 
6 Gy was calculated for each plan produced. In a clinically acceptable plan, this volume 
was required to be < 1 cm3.
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Results 
 
Clinically acceptable treatment plans were produced for both spherical targets (15 and 
30 mm), at each of four different distances from the brainstem, using the method 
described above. The maximum brainstem dose for each plan produced was plotted 
against the brainstem VOI limit value used, and the results for all eight sphere/distance 
combinations are shown in Figure 6.1.  In each case, as the VOI limit was reduced, the 
maximum brainstem dose fell accordingly, and this continued until a clinically 
acceptable plan could no longer be produced. For the 15 mm target, a loss in 
conformality was always the first unacceptable feature to appear (ie nCI value outside 
the accepted 0.05 range). For the 30 mm target, in most cases conformality was 
maintained as the VOI limit was lowered, but ultimately at the expense of an 
unacceptable 6 Gy volume (ie > 1 cm3) outside the outer shell. In seven of the eight 
graphs, the plots lie close to, but just above, the y = x line, showing that the plans 
produced come very close to achieving the specified VOI limit in each case. In the case 
of the 15 mm sphere overlapping the brainstem, the plots drift away from the y = x line, 
although the overall trend is still one of reducing brainstem maximum doses as the VOI 
limit is lowered. 
 
Each graph in Figure 6.1 shows three separate plots for plans produced using the three 
different prescription isodose values (55, 65 and 75 %). The choice of prescription 
isodose value appears to have very little effect on the maximum brainstem dose for a 
given VOI limit. However, in some cases it does affect how far the VOI limit can be 
“lowered” whilst still producing a clinically acceptable plan. This is shown more clearly 
in Table 6.1. In the case of the 30 mm target, the range of VOI limit values is almost 
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Figure 6.1: Graphs of maximum brainstem dose against brainstem VOI limit from treatment plans for 
each sphere, at each of four different distances from the brainstem. Plans produced with prescription 
isodose values of 55, 65 and 75 % are plotted separately on each graph. The dotted line shows y = x in 
each case.
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  Range of brainstem VOI limit values (Gy) over which clinically acceptable plans could be produced 
Sphere size Prescription isodose 
12 pixel 
distance 
6 pixel 
distance 
3 pixel 
distance 
0 pixel 
distance 
15 mm 
55 % 4.0 – 0.5 6.5 – 2.0 9.0 – 5.0 18.5 – 16.0 
65 % 4.0 – 0.5 6.5 – 2.5 9.0 – 5.5 18.5 – 16.0 
75 % 4.0 – 1.0 6.5 – 3.0 9.0 – 6.5 18.5 – 16.0 
30 mm 
55 % 6.0 – 1.0 8.0 – 2.0 12.0 – 4.0 19.0 – 12.0 
65 % 6.0 – 1.0 8.0 – 2.0 12.0 – 4.0 19.0 – 12.0 
75 % 6.0 – 1.0 8.0 – 2.0 12.0 – 4.0 19.0 – 13.0 
"
Table 6.1: Showing the range of brainstem VOI limit values over which clinically acceptable plans could 
be produced, for each target size/brainstem distance combination. 
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identical for the three different isodose values. However, with the 15 mm target, using 
the 55 % prescription isodose value allowed the VOI limit to be lowered furthest, 
followed by the 65 % value, and then finally the 75 % value. This means that in many 
cases the lowest brainstem maximum doses (within clinically acceptable plans) were 
obtained using the 55 % prescription isodose value. 
 
Tables 6.2a-c show Spearman’s Rank correlation coefficients for the relationship 
between point maximum brainstem dose and the dose to 0.1 cm3 (Table 6.2a), 1 cm3 
(Table 6.2b) and the mean brainstem dose (Table 6.2c). Once again, the results are 
shown separately for each target, at each of the four “target-brainstem” distances. The 
tables show a very strong (> 90 %), statistically significant positive correlation between 
maximum dose and all three brainstem dose-volume measurements. This applies to both 
targets when not actually overlapping the brainstem (ie at 3, 6 and 12 pixel distances). It 
also applies to the 30 mm target when overlapping the brainstem (0 pixel distance). In 
the case of the 15 mm target overlapping the brainstem, there is a significant moderately 
strong positive correlation (0.72) between maximum dose and the dose to 0.1 cm3, but a 
very weak (and non-significant) correlation with both the dose to 1 cm3 (0.07) and the 
mean brainstem dose (-0.03).  
 
The relationship between brainstem maximum dose and overall external dose gradient 
in the plans produced is summarised in Figures 6.2 (Gradient Index) and 6.3 (Quarter 
Dose Index). The general trend in Figure 6.2 is that as the maximum brainstem dose is 
lowered (through progressively lower VOI limits), the Gradient Index (GI) increases. 
However, in the case of the 30 mm target, and to a lesser extent with the 15 mm target, 
the brainstem dose can be lowered some way before there is any significant 
!&*"
"
Table 6.2a 15 mm diameter sphere 30 mm diameter sphere 
Distance from 
brainstem 
Correlation 
Coefficient p value 
Correlation 
Coefficient p value 
12 pixels 0.985 < 0.0001 0.988 < 0.0001 
6 pixels 0.990 < 0.0001 0.987 < 0.0001 
3 pixels 0.982 < 0.0001 0.990 < 0.0001 
0 pixels 0.721 0.0028 0.989 < 0.0001 
 
Table 6.2b 15 mm diameter sphere 30 mm diameter sphere 
Distance from 
brainstem 
Correlation 
Coefficient p value 
Correlation 
Coefficient p value 
12 pixels 0.983 < 0.0001 0.983 < 0.0001 
6 pixels 0.985 < 0.0001 0.986 < 0.0001 
3 pixels 0.917 < 0.0001 0.967 < 0.0001 
0 pixels 0.069 0.7718 0.968 < 0.0001 
 
Table 6.2c 15 mm diameter sphere 30 mm diameter sphere 
Distance from 
brainstem 
Correlation 
Coefficient p value 
Correlation 
Coefficient p value 
12 pixels 0.969 < 0.0001 0.971 < 0.0001 
6 pixels 0.985 < 0.0001 0.973 < 0.0001 
3 pixels 0.969 < 0.0001 0.949 < 0.0001 
0 pixels -0.03 0.8966 0.923 < 0.0001 
 
Table 6.2a-c: Spearman’s Rank correlation coefficients for the association between point 
maximum brainstem dose and the dose to 0.1cm3 brainstem (Table 6.2a), 1cm3 brainstem (Table 
6.2b) and mean brainstem dose (Table 6.2c). Results are shown separately for treatment plans of 
the two different spherical targets, at each of the four different distances from the brainstem. All 
coefficients are statistically significant at p = 0.05 except for the values shown in red. 
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Figure 6.2: Graphs of Gradient Index against brainstem maximum dose, from treatment plans for the 15 
mm (left) and 30 mm (right) spheres, at each of the four different distances from the brainstem.  Plans 
were created using different brainstem VOI limit values. Results for the three different prescription 
isodose values (55, 65 and 75 %) are plotted on each graph. 
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Figure 6.3: Graphs of Quarter Dose Index against brainstem maximum dose, from treatment plans for the 
15 mm (left) and 30 mm (right) spheres, at each of the four different distances from the brainstem.  Plans 
were created using different brainstem VOI limit values.  Results for the three different prescription 
isodose values (55, 65 and 75 %) are plotted on each graph. 
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deterioration in GI. In fact with the larger target, at 3, 6 and 12 pixel distance, the GI 
initially falls as the brainstem dose falls, before levelling out and then increasing. There 
is a clear effect of prescription isodose on GI in the case of the smaller target, with GI 
values increasing as the prescription isodose increases from 55 % - 75 %. For the larger 
target this effect is less marked although using the 55 and 65 % isodoses consistently 
produced lower GI values than the 75 % isodose. All these results are in keeping with 
those from the previous two chapters. 
 
In Figure 6.3, the relationship between maximum brainstem dose and QDI is 
demonstrated. As the brainstem dose is lowered the general trend is, once again, one of 
worsening external dose gradient. However, as seen with GI, in most cases there is a 
large fall in brainstem dose before any significant increase in QDI values. Indeed this is 
even more the case with QDI compared to GI. As before, this is seen especially with the 
larger target. For example, with the 30 mm target at 3 pixel distance from the brainstem, 
the brainstem maximum dose can be lowered from 12 – 6 Gy before the QDI rises 
above 7.5. Unlike in Figure 6.2 (with GI), there is a less clear relationship between 
prescription isodose and QDI in these graphs. Certainly with the 30 mm target, the 3 
plots largely overlie each other. In the case of the 15 mm target, there is no clear pattern 
across the four different graphs. 
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Discussion 
 
This study concerns the specific clinical situation of an intracranial target lying close to 
(or even overlapping) the brainstem on one side, and bounded on all other sides by 
cerebral cortex. This is a common clinical problem, and one that demands very steep 
dose fall-off towards the brainstem, without a significant detriment to the external dose 
gradient in all other directions, as well as other important plan features such as 
conformality and target coverage. The main purpose of the study was to improve 
CyberKnife radiosurgical planning of targets close to the brainstem, by exploring 
various relevant features of Sequential optimisation in MultiPlan. 
 
The results confirm that the VOI limit is given a very high priority within Sequential 
optimisation, and the algorithm will generally try to meet the value chosen, even as this 
value is lowered further and further, eventually at the expense of some other aspect of 
plan quality. In the case of the 15 mm target, conformality was eventually lost as the 
VOI limit is lowered. However, with the 30 mm target, it was usually possible to 
maintain excellent conformality. This may be because, as there is more volume in inside 
the larger target, there is greater flexibility in terms of the number of possible plan 
solutions which can be generated. The algorithm therefore produces a solution which 
tries to the meet the VOI limit and maintains conformality, but ultimately at the expense 
of an increase in moderate dose areas away from the target (as measured by the 6 Gy 
volume outside the outer optimisation shell). 
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For targets close to (approximately 2.5 – 10 mm), but not overlapping, the brainstem 
there was a very strong, statistically significant positive correlation between the 
maximum brainstem dose and the three other brainstem dose endpoints (doses to 0.1 
cm3 and 1 cm3, and mean dose). This applied to plans for both targets. Lowering the 
brainstem VOI limit in this situation serves to lower all of the measured brainstem 
endpoints, and not just the maximum dose. It has also been shown that lowering the 
brainstem dose eventually comes at the cost of a less steep overall external dose 
gradient, as measured by both Gradient Index and Quarter Dose Index. This is perhaps 
unsurprising given the inevitable limitations of any planning system. However, 
encouragingly, it appears that the use of a VOI limit can often lower the brainstem dose 
substantially before there is any significant change in GI and QDI. Whilst this applies to 
the planning of both targets, it is especially true in the case of the larger one. 
 
The brainstem VOI limit is thus an extremely useful planning tool for targets located 
close to the brainstem. The decision regarding how hard to “push” the limit will vary 
from case to case, depending on the relative importance of brainstem dose, overall 
external dose fall-off, and other aspects of plan quality. Whilst the results have come 
only from the planning of spherical targets, on the basis of previous work in this thesis it 
is reasonably likely that planning of irregularly-shaped lesions will give similar results. 
However, there should be some caution when translating these results to the planning of 
targets close to other intracranial OARs (eg optic nerves or chiasm), as variations in 
shape and/or volume of an OAR may affect the relationship between maximum  dose 
and other dose endpoints. It should also be noted that the brainstem maximum doses 
seen in Figure 6.1 for targets at 6 and 12 pixel distances from the brainstem are well 
within the perceived safe dose limit to this structure, and therefore one might question 
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the importance of studying the effects of lowering the brainstem dose yet further. 
However there will be some situations, such as patients who have received previous 
radiotherapy, where limiting the brainstem dose to even lower levels would be 
desirable.  
 
Whilst the results discussed so far have been largely similar for the two different 
spheres, in the case of a target actually overlapping the brainstem (ie 0 pixel distance) 
different results were observed across the two targets. For the 30 mm sphere, maximum 
brainstem dose (and the other brainstem dose endpoints) continued to fall as the 
brainstem VOI limit was lowered over the range 19 – 12 Gy, in spite of the fact that the 
target and brainstem were overlapping, This was achieved at the expense of the 
minimum dose to the target, which also continued to fall accordingly from 17 Gy down 
to 10 Gy, although overall PTV coverage by the prescription isodose was maintained at 
> 97 %. In contrast, with the 15 mm sphere it was possible to achieve only a relatively 
modest reduction in maximum brainstem dose (approximately 1.5 Gy), and there was no 
correlation between maximum dose and either the dose to 1 cm3 brainstem, or the mean 
brainstem dose. The difference in behaviour between the targets may once again be a 
consequence of the greater flexibility available for planning the larger volume, whereby 
the system can maintain conformality and coverage whilst substantially lowering 
brainstem maximum dose (albeit at the expense of PTV minimum dose). This is 
especially the case given the constraints of > 97 % coverage and nCI within 0.05 of the 
best achievable value. For the smaller target, these constraints leave very little room for 
manoeuvrability using the techniques described above. 
 
!''"
"
Although reducing the minimum PTV dose is not ideal, if it allows brainstem dose 
sparing, and there is still > 97 % PTV coverage by the prescription isodose, then it may 
be the best compromise for a target overlapping the brainstem. As discussed, this was 
achievable for the 30 mm target, but not the 15 mm target using the above method. 
However, an additional technique which does allow further brainstem dose sparing for 
the 15 mm overlapping target is to create an “eroded PTV”. The brainstem volume is 
grown by a small margin (eg 2 mm) which can then be eroded out of the original PTV, 
so that the new, eroded PTV is at least 2 mm away from the brainstem throughout the 
volume. This new PTV is used in the optimisation steps, but the plan measures (such as 
coverage, conformality and minimum dose) are still recorded for the original PTV. 
Creating this narrow “corridor” appears to allow the optimisation algorithm to cope 
better with the conflicting demands of PTV coverage and brainstem dose limits. This is 
illustrated in Figure 6.4, showing the results of plans prescribed to the 55 % prescription 
isodose. The original brainstem maximum doses were previously shown in Figure 6.1, 
and are now compared with the results obtained by optimising to the eroded PTV. When 
compared to the original results, the new technique leads to further brainstem dose 
reductions of approximately 1.5 Gy, without any significant further lowering of PTV 
minimum dose. However, the lowest point maximum brainstem dose is still 16 Gy using 
this technique, and for further reduction it is likely that there would have to be a 
compromise on the strict PTV coverage and conformality constraints used in this study. 
 
The study also looked at the effect of prescription isodose value on the various 
dosimetric measures recorded, and the results are broadly similar to those seen in the 
previous two chapters. For the smaller target, there was once again an advantage in 
prescribing to the lowest isodose value (55 % in this case) as this yielded clinically 
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Figure 6.4: Graphs of brainstem maximum dose (upper graph) and PTV minimum dose (lower graph) 
against brainstem VOI limit, for plans produced for the 15 mm sphere overlapping the brainstem, using a 
55 % prescription isodose. The two plots show the original results (blue) and the results obtained if the 
plan is optimised to an eroded PTV, with a 2 mm gap between brainstem and the new optimisation target 
(red). Each plot stops at the lowest brainstem VOI limit where a clinically acceptable plan could be 
produced. Abbreviations: max. = maximum; min. = minimum. 
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acceptable plans with the lowest GI scores and the lowest brainstem maximum doses. In 
the case of the larger target, the effect of prescription isodose value was once again less 
marked than with the smaller one. Brainstem maximum doses and QDI values were 
largely unchanged across the isodose range 55 – 75%, although the GI scores were 
consistently worse using the 75 % isodose, compared to the lower two values. Thus the 
best choice of prescription isodose appears to be the same whether the aim is to produce 
steep even dose fall-off outside the target or, as in this study, very steep fall-off on one 
side. 
 
One limitation of this study was the use of the first clinically acceptable plan produced 
for each VOI limit value rather than selecting the best plan(s) from a selection (as with 
the previous two chapters), or even taking mean values across a set of plans. This meant 
that there was a reasonable amount of “noise” in the data collected, which reflects the 
inherent variability in dosimetric results seen in successive plans produced using the 
same plan settings. Unfortunately, due to the complicated design of the study, there was 
insufficient time to produce more than one clinically acceptable plan for each different 
combination of VOI limit/prescription isodose/target size/distance from brainstem. 
Whilst it was still possible to observe a number of important trends in the data collected, 
the results should be interpreted with this limitation in mind. 
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Summary 
 
For intracranial targets located very close to the brainstem, the brainstem VOI limit is a 
very powerful tool for lowering dose to this organ. Moderate dose reductions can be 
achieved with no compromise on other measures of overall plan quality. Further 
brainstem dose reductions can be achieved, but at the expense of overall external dose 
gradient, and either conformality (15 mm sphere) or areas of moderate dose distant to 
the target (30 mm sphere).  
When using a brainstem VOI limit with targets close to, but not overlapping, the 
brainstem, the maximum brainstem dose correlates very strongly (and significantly) 
with all other measured brainstem dose-volume endpoints, including mean dose. 
 
In the case of targets overlapping the brainstem, creating a narrow “corridor” of tissue 
between PTV and brainstem by using an eroded PTV allows the brainstem dose to be 
lowered further whilst maintaining PTV coverage. However, reducing PTV coverage 
and PTV minimum dose may be necessary if the brainstem dose needs to be lowered 
even further. 
  
!(+"
"
Chapter 7 – A dosimetric comparison of CyberKnife and Gamma 
Knife systems in the treatment of solitary intracranial brain lesions 
 
Introduction 
 
The safe delivery of a radiosurgical treatment requires sub-millimetre overall system 
accuracy. This allows little or no PTV margin to be added, and thus reduces the volume 
of normal tissue within the PTV. There are a number of different modern radiosurgery 
systems, although they can be broadly divided into frame-based and non-frame-based 
technologies. Gamma Knife is the oldest radiosurgery system, and whilst it has 
undergone several important changes over the last 40 years, it still relies on absolute 
immobilisation achieved with a pinned stereotactic frame, and contains very few 
movable components in order to preserve this accuracy. Overall system accuracy has 
been shown to be 0.48 – 0.7 mm (43, 44). 
 
CyberKnife is an example of a non-frame-based system which instead uses intra-
fraction image guidance to achieve the required accuracy. Published results using the 
“End2End Test” (Accuray Inc.) have demonstrated a total system accuracy of 0.44 – 
0.48 mm (37, 42) when tracking intracranial targets. However, it should be noted that 
this test does not include CT-MRI image registration, and therefore if the target is 
contoured using MRI then any error in registration will be additional to the quoted total 
system accuracy. This will be discussed in more detail later. 
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Radiosurgical systems must also be able to meet certain dosimetric requirements in the 
treatment plans produced. The prescription isodose line needs to conform very closely 
to the target contour so that target coverage is optimised whilst minimising the volume 
of normal tissue inside the line.  There also needs to be a steep external dose gradient 
outside the target, and the ability to shape isodose distributions to avoid especially 
radiosensitive OARs. The previous three chapters in this thesis have explored ways to 
optimise these dosimetric parameters when using CyberKnife to treat solitary 
intracranial targets. 
 
The importance of dosimetry in radiosurgery is illustrated by the large number of 
published dosimetric comparisons of the different radiosurgical techniques over the last 
twenty years. During this time a number of new systems have emerged. Additionally, 
most existing systems have undergone regular upgrades, improving their dosimetric 
capabilities or system accuracy (or both). Dosimetric comparisons continue, therefore, 
to be useful as the radiosurgical community attempts to reduce further the dose to 
normal tissue.  
 
In one of the earliest comparisons of CyberKnife and Gamma Knife planning 
capabilities, Yu et al (80) used a solitary 25 x 35 mm ellipsoid target centrally 
positioned in a head phantom, constructed such that the target was visible on both CT 
and MRI imaging. CyberKnife and Gamma Knife treatment plans for the target were 
compared, together with plans produced using the following gantry-based radiosurgical 
techniques:  multiple arcs, conformal static shaped fields and IMRT. All of the 
techniques were capable of achieving 100 % target coverage with comparable 
conformality as measured by Shaw et al’s (55) conformity index. The CyberKnife plan 
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had the worst dose fall-off as measured by the ratio of the volume irradiated to half of 
the prescribed dose, to the target volume. However an 80 % prescription isodose line 
was used in the CyberKnife plan, and previous work in this thesis has shown that 
substantial improvements in dose fall-off can be achieved by using a lower prescription 
isodose. Also, the method was restricted to comparing results for the one ellipsoid target 
contained in the phantom. 
 
Wowra et al (61) reported the Munich experience of radiosurgery using both Gamma 
Knife (between 1994 and 2005) and CyberKnife (2005 – 2007). They conducted a 
matched pairs comparison of dosimetric parameters and clinical outcomes from treating 
solitary cerebral metastases on both systems. Pairs were matched according to age, 
gender, performance status and primary tumour, but additionally target volumes had to 
be within 10 % or 0.25 cm3. They observed statistically significant results in favour of 
CyberKnife with regard to conformality (as measured by the Shaw index) and the 10 Gy 
volume (after the target volume had been deducted).  However, the mean conformality 
index in the matched Gamma Knife patients was 3.4. This is substantially worse than 
would be expected for most lesions treated at this centre, and may be in part due to the 
fact that these lesions were planned and treated on a model B Gamma Knife between 
1996 and 2005. 
 
Ma et al (81) performed a comparison of Gamma Knife, CyberKnife and Novalis 
radiosurgery systems. They developed an analytic model of dose fall-off characteristics 
near the target in radiosurgical treatment plans of solitary intracranial lesions. They then 
looked at ten different clinical cases previously treated using each of the three 
technologies (thirty cases in total), and assessed how well the plan characteristics fit 
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with their model. The model fitted very well in plans from all three systems, with 
correlation coefficients > 0.99 for each case. They also found no significant difference 
in dose fall-off between the systems, with mean Gradient Index (GI) values in the range 
2.89 – 2.94. However, the target volumes ranged from 0.3 – 30.3 cm3, and previous 
work in this thesis has shown that GI scores substantially lower than 2.9 can certainly 
be achieved for most lesions with volume > 1.5 cm3 using CyberKnife. The scores are 
also higher than those achieved for most clinical Gamma Knife cases treated at this 
centre. 
 
A fairer comparison would arguably use a number of identical targets planned on each 
system, rather than different cases as described in the above study.  Perks et al (82) 
performed a comparison of Gamma Knife and gantry-based linac radiosurgery 
dosimetry using the same eight acoustic neuroma patients for each system. The target 
volume (the enhancing mass seen on MRI) was outlined on the same MRI images for 
each system in order to have targets as close to identical as was possible. However, even 
with the same person contouring the volume on each system, it is likely that there would 
still be some variation in the contour for each target across the two systems. This is 
important in a dosimetric comparison study as small changes in dimensions and volume 
can affect the radiosurgical parameters produced, especially in the case of very small 
targets. 
 
A target contour can be saved as a “Radiotherapy Structure Set” (RTSS), which is a 
DICOM (Digital Imaging and Communications in Medicine) file associated with the CT 
or MRI DICOM files for the images on which the target was contoured. This RTSS file 
can be exported from and imported into radiosurgery planning systems together with the 
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associated CT or MRI image files. This allows a single identical target contour to be 
planned in different radiosurgical systems. Unfortunately, this method has traditionally 
not been possible for comparisons involving the Gamma Knife system, as GammaPlan 
software editions up to version 8 do not have the capability to import or export RTSS 
files. However, GammaPlan versions from 9.0 (2008) onwards do support DICOM 
RTSS import/export, albeit as an optional extra package.  
 
Ma et al (83) used this new capability in their next dosimetric comparison of Gamma 
Knife with CyberKnife and Novalis (with micro-MLC), this time looking at treatment 
plans for multiple intracranial targets. They selected the single case of a patient with 12 
brain metastases and created treatment plans for various subsets of target combinations 
(3, 6, 9 or 12 targets). The new Conformity Index (nCI)(57) scores were consistently 
lowest in plans produced using Gamma Knife, as was the volume of tissue outside the 
target irradiated to various different doses. They therefore concluded that the normal 
brain tissue dose in this clinical situation is apparatus dependent. At the time of writing 
there has been no published comparison of Gamma Knife and CyberKnife using 
identical contours for solitary intracranial targets. The aim of this study is to carry out 
such a comparison. 
 
There are some additional problems when attempting to conduct a planning study of 
Gamma Knife and CyberKnife using identical lesions which may have been previously 
planned and treated on either system. The first problem relates to CT scanning. CT is 
essential for CyberKnife treatment planning (and indeed treatment planning for most 
modern radiotherapy systems) as the electron density information is used by the dose 
calculation algorithms. Furthermore the CT must cover the whole head including the 
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vertex and skin at the sides since the system will not allow any beams to enter through 
any part of the head where the skin contour is not known. In contrast, CT is not a 
requirement for Gamma Knife planning as long as a full head MRI has been performed, 
as the system assumes uniform electron density for all tissue inside the skin contour. If 
CT is required to assist contouring it is usually only acquired through the area of interest 
in the brain in order to reduce unnecessary radiation exposure. Consequently very few 
patients treated with Gamma Knife have had the full head CT which is required to plan 
the lesion with CyberKnife. A review of patients treated at two London Gamma Knife 
centres (St. Bartholomew’s Hospital and The Cromwell Hospital) between 1999 and 
2010 found only five patients (with seven intracranial lesions) who had had full head 
planning CT scans compatible with CyberKnife. Even in these cases, the CT had been 
acquired with a stereotactic frame fixed to the skull. This can produce considerable 
artefact which may affect the intracranial electron density values required for 
CyberKnife dose calculation. 
 
An alternative approach would be to use CT and MRI imaging from patients previously 
treated on CyberKnife, and import the images for use in GammaPlan. However, these 
“frameless” images cannot be used for full planning and treatment in GammaPlan. This 
is because the stereotactic frame forms the fixed reference for the 3-dimensional 
coordinates used in planning and treatment. A “pre-planning” mode was introduced in 
GammaPlan version 7 (2006) which allows frameless images to be imported, contoured 
and planned, although 3-dimensional coordinates are not assigned and therefore certain 
functions such as collision checks cannot be performed. Additionally, planning cannot 
proceed without generating the full head contour which is usually done using a plastic 
helmet affixed to the frame. Fortunately the most recent software upgrade (version 10.0) 
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enables the skin contour to be produced from frameless CT images. Thus neither of the 
above approaches is perfect and this is reflected in the experimental method used in this 
study. 
 
A major potential confounding factor in any dosimetric comparison of two different 
radiosurgery systems is the experience of the treatment planner(s) with each system. 
There is a considerable learning curve when a dosimetrist (or planning physicist) starts 
planning on a new radiosurgery system, especially since the planning techniques differ 
so much across the main systems in use. Also software upgrades often introduce new 
features, and it may take an experienced planner some time before the new features are 
used most efficiently. It would be unusual for a single planner to have the same 
experience using two different systems, which explains why most comparison studies 
are collaborative projects involving planners from two or more centres. Previous work 
in this thesis has given the author extensive experience of planning solitary intracranial 
lesions on CyberKnife. As with previous studies, the intention is for the author to 
collect as much of the experimental data as possible, creating treatment plans for all 
lesions in both MultiPlan and GammaPlan, and in so doing improve proficiency in 
Gamma Knife treatment planning. However it is acknowledged that this may not 
represent a fair comparison across both systems in view of the greater experience with 
CyberKnife. The decision was therefore made to collaborate with a Gamma Knife 
treatment planner (IP) with the greatest UK experience, who would also plan the lesions 
in GammaPlan. 
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Methods 
 
Target lesions for the planning comparison were selected from intracranial cases 
previously treated at either the CyberKnife centre, London, or one of two London 
Gamma Knife centres (Barts and The London and The Cromwell Hospital). Cases of 
both solitary and multiple brain primary or metastatic tumours were reviewed to find 
appropriate targets, although in the case of multiple tumours only a single lesion would 
be planned at a time. 
 
Ten target lesions were used, and were individually chosen such that they were 
representative of the range of solid tumours treated on both systems. The range of 
tumour histologies was as follows: metastases (five lesions), meningioma (two lesions), 
acoustic neuroma (two lesions), and chordoma (one lesion). Target volume was required 
to be less than 13 cm3. This is the approximate volume of a sphere of 30 mm diameter, 
and it is generally accepted that Gamma Knife can comfortably treat targets up to 
approximately this size. Volume was also required to be greater than 0.5 cm3. This is 
because with targets of very small volume, very small changes in the treatment plan 
arrangement can have an enormous impact on parameters such as conformality. This 
can make dosimetric comparison on the basis of such parameters difficult. 
 
Five lesions (in four patients) had been previously treated using Gamma Knife, and 
therefore had CT and MRI scans performed with a stereotactic frame in-situ. These had 
been selected from the five Gamma Knife patients who had whole-brain CT scans 
which would be compatible with CyberKnife planning, as discussed previously. Five 
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lesions (in five patients) had been previously treated using CyberKnife, and therefore 
had CT and MRI images without a frame. Five of the lesions were “peripheral”, being 
located > 2 cm away from brainstem, cochlea or optic apparatus. In these cases, an even 
dose fall-off on all sides was required. The other five lesions were “central”, being < 2 
cm away from one or more of these especially radiosensitive structures. Here, it was 
likely that a steeper dose fall-off towards these structures would be desirable. 
 
Anonymised CT and MRI images for all ten targets were imported into MultiPlan 
v.3.5.1, and new patient files were created (patients 01 – 10). CT/MRI image fusion was 
performed, and then the CTV for each target was contoured with reference to both 
image sets. No margin was applied in producing the PTV from the CTV. This is 
common Gamma Knife practice. A small CTV – PTV margin of up to 2 mm is 
sometimes applied in CyberKnife planning, in order to account for any inaccuracies of 
CT/MRI registration. However it was not used in this study as the main goal was to 
compare the dosimetric capabilities of the two systems, and the fairest way to do this is 
with identical contours. Intracranial OARs were also contoured, including whole brain 
and (where appropriate) brainstem, optic apparatus and cochlea. All contours for each 
patient were then saved as an RTSS.DICOM file associated with the planning CT.  
 
The CT images, together with the associated RTSS file, for each patient were then 
imported into GammaPlan v10.1, and new patient files were created. In the case of the 
five lesions originally treated on Gamma Knife, the original head frame/helmet 
measurements were used to generate the external skin contour. For the five lesions 
scanned without a frame, the skin contour was produced by applying the new auto-
contour function to the CT images, followed by manual adjustment. 
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The ten targets were all individually planned on each system, with the goal of creating a 
plan which optimised external dose gradient and conformality. As with previous studies, 
plans were required to have an estimated treatment time of less than sixty minutes. This 
assumed a single fraction of 18 Gy for all targets except the two acoustic neuromas, for 
which a single fraction of 13 Gy would be delivered. Estimation of treatment time on 
CyberKnife has been previously discussed in Chapter 4. For Gamma Knife, treatment 
time is affected by the dose rate, which in turn is dependent on the activity of the cobalt 
sources which decay over time. GammaPlan gives an estimated treatment time for all 
plans produced, using an estimated dose rate for the system on that particular day. In 
this study, the treatment time shown was then adjusted in each case to give an estimated 
treatment time assuming an even dose rate of 3 Gy/minute for all plans. This was 
chosen as a reasonable average dose rate for most Gamma Knife systems. 
 
It was decided that % PTV coverage for all plans should be controlled relatively strictly. 
This is because % coverage for a given plan has a direct effect on both the 12 Gy 
volume (V12) and the minimum dose to the PTV, both of which are parameters to be 
used for comparison. This is illustrated by the graph in Figure 7.1 which shows how the 
V12 can be lowered for a treatment plan simply by lowering the % PTV coverage (ie 
prescribing up to a slightly higher isodose value). The graph also shows that the 
consequence of prescribing up to reduce the V12 is a reduction in the minimum PTV 
dose. In Chapter 6, clinically acceptable CyberKnife plans were required to have > 97 
% PTV coverage, which can be easily ensured as coverage for each plan produced on 
MultiPlan is given to the nearest 0.01 %. Unfortunately, GammaPlan only gives
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Figure 7.1: Graph showing the effect of changing the PTV coverage (by adjusting the prescription 
isodose) on the minimum dose to the PTV and the 12 Gy volume (V12). The data are taken from a single 
treatment plan produced for a 30 mm spherical target. 
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coverage to the nearest 1 % for plans produced. For this study, therefore, it was required 
that all plans for comparison should have a PTV coverage of 97 % to the nearest 1 %.  
 
In the case of CyberKnife planning, multiple inverse-planned iterations were performed 
for each case, following the strategy developed in previous chapters of this thesis, until 
a plan was produced which appeared to give the best results in terms of the parameters 
under comparison. For Gamma Knife planning, the standard forward-planning approach 
was followed, whereby “shots” of variable diameter (and shape) are placed one by one, 
with real-time update of the plan isodosimetry. The position and weighting of each shot 
is then adjusted in order to optimise the plan parameters (see Chapter 2 for further 
details on Gamma Knife treatment planning). Each case was planned three times by the 
author (AM), and the best plan selected for comparison. Each case was also planned 
once by the leading UK Gamma Knife planning physicist (IP). 
 
The following information was recorded for each plan, and formed the basis of the plan 
comparison: prescription isodose value, estimated treatment time, Conformity Index 
(CI) (Shaw et al ), new Conformity Index (nCI) (see Chapter 4), Gradient Index (GI) 
(Paddick et al (60)), Quarter Dose Index (QDI), V12, and PTV point minimum and 
mean doses. These latter two values were then expressed as a percentage of the 
prescribed dose as there were two prescription doses being used in the study (18 Gy and 
13 Gy). For the five “central” targets, the maximum and mean doses to any OARs 
within 2 cm of the target were also recorded. Comparisons were made between the 
CyberKnife plans, and the Gamma Knife plans produced by IP. As stated previously, 
this was to ensure that the person creating the plans on each system had extensive 
planning experience using that system. The Wilcoxon Signed-Ranks test was used to 
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compare each of the above plan parameters between the two groups. This is a non-
parametric equivalent of the paired t-test, and is preferred to the t-test when the sample 
number (n) is less than 50.  Similar comparisons were also made between Gamma Knife 
plans produced by AM with those produced by IP, in order to assess the effect of 
experience on Gamma Knife plan quality. 
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Results 
 
Table 7.1 shows the characteristics of the ten target lesions used in this study. The 
lesions have been numbered 1 – 10 in increasing order of volume, as measured in 
MultiPlan. As previously stated, the targets were selected such that they were a 
reasonable representation of solid tumours treatable with both systems. The volume 
(measured in MultiPlan) ranged from 0.87 – 11.71 cm3 (mean volume 3.18 cm3). 
Surprisingly, whilst the target contours were identical, the target volumes were different 
when measured by the two different systems. The volume measured in GammaPlan was 
consistently smaller than that in MultiPlan, the median difference being 9.5 % (range 6 
– 16 %). 
 
The treatment parameters for all ten targets planned on both systems are summarised in 
Table 7.2. The table also shows the results of statistical comparison between the plans 
produced on each system, for each parameter, using the Wilcoxon Signed-Ranks test. 
With respect to the comparison between CyberKnife plans and Gamma Knife plans 
produced by IP, prescription isodoses were generally lower in the Gamma Knife plans, 
although this did not quite reach statistical significance at the 5 % level (p = 0.0547). 
Estimated treatment time was required to be </= 60 minutes, and within this restriction 
the range of treatment times was similar on both systems across the ten targets (p = 
0.9219). Conformality was also similar across both systems, with the median 
Conformity Index (CI) slightly lower in the GK plans, and the median new Conformity 
Index (nCI) slightly lower in the CK plans; neither comparison reached statistical 
significance. The median value for both of the measures of external dose gradient (GI 
and QDI) was lower (ie steeper dose fall-off) in the CyberKnife plans, however again a
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Table 7.1: Characteristics of the ten target lesions selected for the dosimetric comparison. Organs-at-risk 
(OARs) excludes whole brain. !"##$%$&'$!!"!!"#$%& ! !"" !"#$%&#'(!!"#$%&!!"##"$%"&!!"#$%&!"#$%&#'(!!"#$%& . 
Target Tumour type Location 
OARs 
within 
2 cm 
System 
treated 
on 
Volume in 
MultiPlan 
(cm3) 
Volume in 
GammaPlan 
(cm3) 
Difference 
in volume 
Lesion 
1 
Acoustic 
Neuroma Central 
Brainstem 
Cochlea Gamma 0.87 0.73 16 % 
Lesion 
2 Meningioma Central Brainstem Gamma 1.22 1.12 9 % 
Lesion 
3 
Acoustic 
Neuroma Central 
Brainstem 
Cochlea Cyber 3.04 2.7 11 % 
Lesion 
4 Metastasis Peripheral  Cyber 3.08 2.59 16 % 
Lesion 
5 Chordoma Central 
Brainstem 
Chiasm Gamma 3.09 2.91 6 % 
Lesion 
6 Meningioma Peripheral  Gamma 3.27 3.03 7 % 
Lesion 
7 Metastasis Peripheral  Gamma 4.12 3.89 6 % 
Lesion 
8 Metastasis Central Brainstem Cyber 5.77 5.07 12 % 
Lesion 
9 Metastasis Peripheral  Cyber 9.01 8.09 10 % 
Lesion 
10 Metastasis Peripheral  Cyber 11.71 10.67 9 % 
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Table7.2: Summary of the parameters for the treatment plans produced using CyberKnife and Gamma 
Knife systems. The median and range over the ten targets is shown for each system. Separate values are 
given for Gamma Knife plans produced by IP, and those by AM. PTV minimum and mean doses have 
been expressed as a percentage of the prescription dose. The results of the Wilcoxon Signed-Ranks Test 
comparison is shown for each parameter. CK  = CyberKnife; GK = Gamma Knife. 
 
Plan Parameter 
(Median and Range) 
 
 
CyberKnife 
 
Gamma Knife 
(IP) 
 
Gamma Knife 
(AM) 
 
p value 
CK 
vs 
GK (IP) 
p value 
GK (IP) 
vs 
GK (AM) 
Prescription isodose 
(%) 
49.5 
(48 – 61) 
45 
(40 – 54) 
49.5 
(46 – 50) 0.0547 0.0977 
Treatment time 
(mins) 
45.8 
(21.5 – 58.9) 
36.3 
(28.8 – 60.0) 
55.5 
(37.6 – 59.2) 0.9219 0.0273 
Conformity Index 
(CI) 
1.07 
(1.03 – 1.18) 
1.06 
(1.01 – 1.15) 
1.08 
(1.04 – 1.19) 0.1641 0.0039 
new Conformity Index 
(nCI) 
1.10 
(1.06 – 1.21) 
1.13 
(1.07 – 1.24) 
1.16 
(1.11 – 1.27) 0.2500 0.0039 
Gradient Index 
(GI) 
2.53 
(2.39 – 3.02) 
2.54 
(2.53 – 2.71) 
2.60 
(2.54 – 2.68) 0.6953 0.1289 
Quarter Dose Index 
(QDI) 
6.72 
(6.35 – 9.31) 
7.15 
(6.94 – 7.6) 
7.29 
(7.09 – 7.46) 0.4922 0.0644 
12 Gy volume 
(V12) (cm3) 
6.15 
(1.18 – 19.84) 
5.62 
(0.94 – 19.61) 
6.02 
(0.95 – 19.83) 0.0020 0.0059 
PTV minimum dose 
percentage (%) 
85.3 
(75.7 – 93.1) 
65.8 
(53.3 – 76.7) 
71.4 
(59.2 – 77.8) 0.0020 0.1055 
PTV mean dose 
percentage (%) 
140.9 
(128.2 – 143.3) 
143.1 
(130.0 – 153.1) 
144.4 
(140.0 – 153.1) 0.1934 0.8203 
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statistically significant difference was not demonstrated. In contrast, the V12 values 
were significantly smaller in the Gamma Knife plans (p = 0.002), although PTV 
minimum doses were also significantly lower (p = 0.02). There was no significant 
difference in mean PTV doses (p = 0.1934).  
 
The different external dose gradient and conformality scores for each of the ten target 
lesions planned on CyberKnife, and on Gamma Knife by IP were examined in more 
detail. The results are displayed in Figures 7.2 and 7.3 respectively. Whilst there was no 
significant difference in the overall Gradient Index and Quarter Dose Index scores, 
Figure 7.2 shows that for both of these measures, Gamma Knife tended to perform 
better for the smallest lesions and CyberKnife better for the largest ones. Gamma Knife 
plans showed better GI scores for the smallest two lesions, and better QDI scores for the 
smallest three lesions. Of note, for the smallest lesion, the Gamma Knife performance 
was substantially superior in terms of external dose gradient. However, CyberKnife 
plans showed better GI scores for the largest three lesions, and better QDI scores for the 
largest five lesions. A similar pattern (although slightly less clear) was seen in the 
conformality performance as shown in Figure 7.3. Gamma Knife plans had superior CI 
scores for the smallest three lesions, and better nCI scores for two of the smallest three 
lesions. Conversely, CyberKnife plans had superior CI scores for the largest three 
lesions, and better nCI scores for the largest four lesions. 
 
Figure 7.4a shows the V12 scores for each lesion in CyberKnife and IP Gamma Knife 
plans. The V12 was smaller for each of the ten plans. However, as seen in Table 7.1, in 
spite of the identical contours, the target volumes were measured consistently larger in 
MultiPlan compared to GammaPlan. Figure 7.4b shows the V12 scores divided by the 
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Figure 7.2: Graphs showing the different Gradient Index (left graph) and Quarter Dose Index (right 
graph) scores for each of the ten plans selected from the CyberKnife system (blue), and Gamma Knife 
system planned by IP (red). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Graphs showing the different Conformity Index (left graph) and new Conformity Index (right 
graph) scores for each of the ten plans selected from the CyberKnife system (blue), and Gamma Knife 
system planned by IP (red). 
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Figure 7.4: The left hand graph shows the different 12 Gy volumes (V12) for each of the ten plans 
selected from the CyberKnife system (blue), and Gamma Knife system planned by IP (red). The right 
hand graph shows the V12 values divided by the Target Volume (PTV) in each case. 
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Table 7.3: Showing the point minimum and mean doses to especially critical organs-at-risk within 2 cm 
of the “central” targets planned in this study. Results are once again shown for the chosen plans produced 
using CyberKnife, and Gamma Knife with two different planners (IP and AM).  
Organ at 
Risk 
CyberKnife 
 
Gamma Knife (IP) 
 
Gamma Knife (AM) 
 
Minimum 
Dose (Gy) 
Mean Dose 
(Gy) 
Minimum 
Dose (Gy) 
Mean Dose 
(Gy) 
Minimum 
Dose (Gy) 
Mean Dose 
(Gy) 
Lesion 1 
Brainstem 7.4 0.7 6.5 0.7 6.8 0.7 
Lesion 1 
Cochlea 5.4 3.1 3.9 2.2 4.0 2.4 
Lesion 2 
Brainstem 2.8 0.8 2.8 0.6 2.8 0.6 
Lesion 3 
Brainstem 10.3 1.2 9.1 1.2 9.2 2.3 
Lesion 3 
Cochlea 10.3 7.0 10.5 5.5 9.1 5.3 
Lesion 5 
Brainstem 16.8 2.1 15.5 2.2 14.8 3.0 
Lesion 5 
Chiasm 4.7 3.7 6.0 4.5 3.8 2.2 
Lesion 8 
Brainstem 11.6 2.1 12.2 0.8 10.4 0.9 
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PTV (as measured by the software creating the plan) for each target. In this graph, the 
results are similar to those described for external dose gradient and conformality. The 
V12:PTV ratio was lower in the Gamma Knife plans for the smallest three lesions, and 
lower in the CyberKnife plans for the largest three.  
 
Returning to Table 7.2, and with respect to the comparison between Gamma Knife plans 
produced by IP with those created by AM, there was a significantly shorter treatment 
time in the IP plans (p = 0.0273). Conformality was also better in the IP plans, as 
measured by both CI (p = 0.0039) and nCI (p = 0.0039). External dose gradient was not 
significantly different as measured by GI (p = 0.1289) and QDI (0.0644). However, for 
both measures there was a non-significant trend towards steeper dose gradient in the IP 
plans, and the V12 was significantly smaller (p = 0.0059). On the other hand, there was 
a non-significant trend (p = 0.1055) towards lower minimum PTV doses in the IP plans.   
 
The doses to OARs within 2 cm of the five central lesions are shown in Table 7.3. 
Firstly, comparing the CyberKnife plans with those produced by IP on Gamma Knife, 
the minimum OAR dose was lower in the Gamma Knife plans for four of the eight 
OARs, and lower in the CyberKnife plans for three, with one OAR receiving an equal 
dose on both systems. Overall there was no significant difference between the systems 
(p = 0.375). Results were similar for the mean OAR dose, with four doses lower on 
Gamma Knife, two on CyberKnife, and two equal (p = 0.2188). There was also no 
significant difference in minimum (p = 0.2188) or mean (p = 0.8438) OAR doses when 
comparing Gamma Knife plans produced by IP and AM. 
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Discussion 
 
Developments in the field of radiosurgery seek to reduce further the doses delivered to 
normal tissue, and to improve efficiency of delivery. Dosimetric comparisons continue 
to be an important area of radiosurgical research as new systems are introduced and 
existing systems undergo regular upgrades. The aim of this study was to carry out a fair 
comparison of CyberKnife (CK) and Gamma Knife (GK), two specialist radiosurgical 
systems, across the range of intracranial targets treatable on both technologies. Recent 
GK software changes allowed the use of identical target contours in both systems in this 
comparison. However, the calculated volume of each contour set differed by up to 16 % 
across the systems. Thus in spite of the methods used, the targets under comparison 
were not truly identical. The same will have been true for previous comparisons 
between CK and GK in which “identical” targets were used (80, 83), although it has not 
been acknowledged in these publications. 
 
The above observation illustrates the fact that the generation of a 3-dimensional volume 
from a series of 2-dimensional contour lines is open to interpretation, and different 
radiosurgical systems have different algorithms for deciding whether or not each 
individual voxel is included within the target volume. This makes it hard to carry out a 
truly “fair” dosimetric comparison with identical volumes. The latest MultiPlan 
software upgrade (version 4.5) will change the way that the CyberKnife system 
interprets volume from contour lines. However, it remains to be seen whether this will 
result in volumes closer to those seen in GammaPlan for these lesions. 
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However, in spite of this observation some interesting results were obtained in this 
study. In general, there were fewer statistically significant differences between the plan 
parameters from CyberKnife plans and “IP” Gamma Knife plans than in the comparison 
between Gamma Knife plans produced by two planners with different levels of 
experience (IP and AM). This means that the experience of the treatment planner has 
the potential to be a more important variable than which of these two systems is being 
used. However there were a few areas where larger differences between CK and GK 
plans were observed.  
 
As discussed previously, external dose gradient and conformality are two of the most 
important features of a radiosurgical plan. In this study there was no significant 
difference between CK and GK with respect to the two different measures of dose 
gradient (GI and QDI) and two conformality measures (CI and nCI). However, a 
common pattern across all four measures was that GK values were superior when 
planning the smallest lesions, and CK values were better with the largest ones. Both 
systems tended to perform equally well for targets in the middle of the size range 
studied. By far the biggest difference in external dose gradient observed was for the 
smallest lesion (volume approximately 0.8cm3), where GK dose fall-off was 
considerably steeper. Targets of even smaller volume were not studied here, due to the 
problems of comparing parameters such as conformality across plans of very small 
volume. However, it is quite possible that GK would continue to outperform CK for all 
targets smaller than 0.8 cm3 volume (approximately 11 – 12 mm diameter), although 
this would need to be verified. 
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Conversely, all four of the above measures were superior on CK plans for each of the 
largest three targets (and both dose gradient measures were also better for the 4th largest 
target). It would appear, therefore, that CK starts to consistently out-perform GK for 
target volumes greater than about 5 cm3 (approximately 21 – 22 mm diameter). Targets 
larger than 13 cm3 volume (approximately 30 mm diameter) were not considered for 
comparison in this study as these volumes may not be suitable for single fraction 
radiosurgery. An additional advantage of CyberKnife is the ability to treat these larger 
volumes safely by fractionating. 
 
The V12 was significantly smaller in the GK plans compared to the CK plans, and 
indeed was smaller for each of the ten targets. This result does not really fit with those 
obtained for both of the external dose gradient parameters. However, as previously 
noted, the target volume was measured as smaller in GammaPlan than MultiPlan for all 
ten targets. The V12 was divided by the measured PTV for each plan in order to account 
for this, and the resultant parameter showed results which fit more consistently with the 
other dose gradient results – ie Gamma Knife was superior for the smallest lesions, and 
CyberKnife better for the largest ones. The GI and QDI parameters were not affected by 
the different measured target volumes in the two systems as these two measures are 
already ratios of one volume to another. 
 
The PTV minimum point dose was also significantly lower in the GK plans (median 
value 66 % vs 85 % of the prescription dose), and was individually lower for each of the 
ten targets. There have been concerns raised about the way in which GammaPlan 
calculates the minimum target dose value, and indeed a warning has been released by 
Elekta in the past, stating that this value may be inaccurate by as much as 10 %. 
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However, this is unlikely to account for such a large difference. Indeed, a comparison of 
the dose to 99 % of the PTV (D99) showed that this value was also lower in the Gamma 
Knife plans for 8 out of the 10 targets. In radiosurgery plan appraisal, whilst the % PTV 
coverage is recognised as an important parameter, far less attention has traditionally 
been paid to the minimum PTV dose. Gamma Knife local control rates have historically 
been very good, and it is not known whether changing the planning technique to ensure 
a higher minimum target dose may improve these rates even further. 
 
This last point highlights one limitation of dosimetric comparison studies: it is not clear 
how small differences in plan quality as defined by the various radiosurgical parameters 
discussed here translate directly to differences in clinical outcome. However, it makes 
good biological sense to aim to deliver an ablative radiation dose to as much of the 
target as possible and to minimise the dose to normal tissue. Most of the parameters 
used here provide a measure of one aspect of this overall goal, and indeed some have 
been shown to correlate with clinical outcomes on retrospective analysis, such as V12 
and the risk of post-radiosurgical complications. Together, the parameters represent a 
reasonable basis for treatment plan selection. 
 
There were some other limitations of the experimental method used. The problem of 
differences in target volume calculation between MultiPlan and GammaPlan has already 
been discussed. Another difference between the two systems is the precision with which 
certain plan measures are displayed. For example, minimum, mean and maximum doses 
to target and OARs are provided to the nearest 0.01 centigray in MultiPlan, but only to 
the nearest 0.1 gray in GammaPlan. Also, volumes such as target volume or V12 are 
provided to the nearest 0.01 mm3 in MultiPlan but only to the nearest 0.01 cm3 in 
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GammaPlan (for volumes larger than 1 cm3). This can cause problems when comparing 
similar values across the two systems. For example if the maximum dose to the 
brainstem is measured as 9.4 Gy in a Gamma Knife plan and 9.4412 Gy in a 
CyberKnife plan, for the purposes of this comparison the values had to be regarded as 
equal. This reduces the power to detect a statistically significant difference since equal 
values are discarded in the Wilcoxon Signed-Ranks test. 
 
Finally, a potential problem with applying these results directly to the clinical situation 
is that no CTV – PTV margin was used. This was to ensure a fairer dosimetric 
comparison between the systems. Both systems have demonstrated sub-millimetre 
overall system accuracy, and common Gamma Knife practice is to use no PTV margin. 
However in the case of CyberKnife, for targets contoured on MRI images, there is 
potential for further inaccuracy in the MRI – CT image registration, which is not 
included in the standard tests of overall accuracy. For this reason many CyberKnife 
centres would add a PTV margin of 1 – 2 mm for brain lesions contoured on MRI. Thus 
the use of CT electron density information to calculate dose is both a strength and a 
weakness of the CyberKnife system. On the one hand it allows much more accurate 
dose calculation, but on the other hand a small PTV margin is required for intracranial 
targets contoured using MRI images. The latest MultiPlan version (v.4.5) has greatly 
improved automatic image registration algorithms, which should allow the use of 
smaller PTV margins, and may actually obviate the need for a PTV margin altogether. 
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Summary 
 
Dosimetric comparison studies continue to be an important part of radiosurgical 
research as new delivery systems are developed and existing ones undergo regular 
upgrades. The difference between the dosimetric performance of CyberKnife and 
Gamma Knife over the ten targets used in this study is generally quite small, and for the 
majority of lesions treatable on both systems the choice of system may be less important 
than the experience of the treatment planner creating the plans. Nevertheless there does 
appear to be superior dosimetric performance with Gamma Knife for smaller targets and 
CyberKnife for larger ones, with this superiority being most apparent at both extremes 
of the treatable size range. 
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Chapter 8 – Discussion 
 
Safe delivery of radiosurgery requires a steep external dose gradient outside the target, 
but this must be considered in conjunction with other important plan parameters such as 
target coverage and conformality. There will be a limit for any radiosurgical system as 
to how steep a dose fall-off can be produced, and this is dictated by the constraints of 
the hardware of the system. This limit also applies to the other plan parameters. In the 
CyberKnife system, the available selection of circular field sizes and the range of non-
coplanar beam angles provide enormous flexibility, but ultimately also define the limits 
of what can be achieved. Other hardware factors such as the linac output (MU delivered 
per minute) may apply a further limit, for example if the overall treatment time is also a 
consideration. The role of MultiPlan treatment planning software is to create plans as 
close to these limits as possible. However, the software will only produce solutions 
based on the priorities and settings applied by the treatment planner. Due to the number 
of variables which can be adjusted, and the complexity of the optimisation algorithms, it 
takes considerable experience in order to interact with the software appropriately to 
produce the best results. The experimental work in this thesis has led to a more 
comprehensive understanding of these variables, so that the external dose gradient in 
clinically acceptable plans can be optimised in different intracranial clinical situations. 
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Summary of findings of the experimental chapters 
 
It is important to verify that the dose distribution of treatment plans produced and 
displayed in MultiPlan accurately reflects that which is actually delivered. In-house QA 
checks at this centre include monthly reference dose verification, and spatial accuracy 
via the “End2End test”.  However, the opportunity was taken to perform a more detailed 
verification using ionisation chamber reference dose and radiochromic film spatial dose 
distribution analysis simultaneously on ten consecutive CyberKnife treatment plans. 
This study was described in Chapter 3. The ionisation chamber reference dose measured 
was comfortably within 3 % of the planned dose for all ten plans – in fact only one 
reading (2.01 %) showed > 2 % error. With regard to spatial dose distribution analysis, 
using the film as a measure of reference dose, all ten plans exceeded the 95 % pass rate 
with 5 %/1 mm Gamma Index tolerance. Unfortunately 5 % dose difference tolerance is 
not really strict enough for a radiosurgical plan, and therefore there is a real need to 
improve the reference dose accuracy of Gafchromic EBT2 film. Whilst software is now 
available which can apply the manufacturer’s proposed correction for the intrafilm 
variation in active layer thickness, one centre has reported that this actually increases 
noise in the resulting dose images (84). On a more optimistic note, the film 
manufacturer acknowledges the inconsistencies of early batches of EBT2, and is 
working on reducing this. It may therefore be possible to perform 2-dimensional dose 
film analysis with a more appropriate, tighter dose difference tolerance in the near 
future. For the purpose of this thesis, the results from Chapter 3 demonstrated that the 
dose distributions shown in MultiPlan are sufficiently reliable for the subsequent 
analyses. 
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Chapters 4 and 5 explored the effect of the prescription (marginal) isodose value on the 
external dose gradient in the planning of solitary intracranial lesions in MultiPlan, for 
situations where an even dose fall-off on all sides of the target is desired. Chapter 4 used 
spherical “virtual” targets, and Chapter 5 used irregularly-shaped lesions from patients 
treated at this centre. The results were generally consistent across both chapters and 
were different for smaller and larger targets. For smaller targets (approximately < 20 
mm diameter or < 5 cm3 volume), there was a significant negative relationship between 
Gradient Index (GI) and prescription isodose value over the whole range explored. 
External dose gradient is therefore optimised by prescribing down to as close to the 50 
% isodose as can be achieved comfortably. GI can be safely used as a sole measure of 
dose fall-off here. In the case of larger targets (approximately > 25 mm diameter or > 8 
cm3 volume), whilst the effect of changing the prescription isodose is not as great, 
nevertheless the best dose fall-off is likely to be achieved using a prescription isodose in 
the range 55 – 65 %. The correlation between different measures of dose fall-off was 
less strong here, so it may be advisable to use V12 or even Quarter Dose Index, together 
with GI, during plan appraisal. 
 
A stepwise method for planning solitary intracranial lesions using MultiPlan has also 
been proposed, for the purpose of optimising external dose gradient without 
compromising on other important plan parameters. With practice, an optimised 
treatment plan can be produced in 1 – 3 hours (depending on target size) using this 
method. This has proved useful in the subsequent planning of cases at this centre, and 
has been shared with other CyberKnife centres. Validation of the method by different 
planners with a larger number of lesions would be useful to confirm the results observed 
here. 
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Chapter 6 concerned the specific clinical situation of a radiosurgical target lying close to 
(or abutting) the brainstem on one aspect, with cerebral cortex on all other sides. It was 
observed that adding a tight brainstem VOI limit produced moderate reductions in 
brainstem maximum dose without the need for any compromise on overall dose fall-off, 
coverage, conformality, and moderate dose distant to the target. Furthermore in most 
situations the brainstem maximum dose correlated strongly (and significantly) with the 
other measured brainstem dose-volume endpoints. Even further brainstem dose 
reductions could be achieved using this technique, but at the expense of at least one of 
the above plan parameters. With regard to prescription isodose, a similar picture to the 
previous two studies appeared to emerge: using the lowest prescription isodose value 
(55 %) was advantageous when planning the smaller (15 mm) target. For the larger (30 
mm) target, results with the 55 and 65 % isodoses were generally better than with the 75 
% isodose. Whilst the VOI limit is clearly a very useful planning tool in this situation, 
the latest MultiPlan software upgrade will offer the additional flexibility of DVH-based 
optimisation, for example the ability to constrain an OAR to a specific dose-volume 
value (eg kidney V12 < 25 %). Further work could look at how best to use VOI limits 
and DVH-based constraints together. 
 
A dosimetric comparison of the CyberKnife and Gamma Knife systems was performed 
in Chapter 7, looking once again at solitary intracranial lesions. Together, the ten targets 
comprised a reasonable cross-section of the range of solid tumours treatable on both 
systems with a single fraction approach. Treatment plans were compared using a wide 
range of radiosurgical parameters commonly used for plan appraisal. The results 
showed that whilst overall performance of the two systems across the ten targets was 
quite similar (and largely non-significant), Gamma Knife was capable of creating 
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superior plans for the smallest lesions, and CyberKnife for the largest ones, with very 
little difference for lesions of “intermediate size”. Gamma Knife plans had been 
produced by the author and also by a treatment planner with more than ten years’ 
experience with Gamma Knife. Comparing these plans showed that, especially for 
intermediate size lesions, the effect of planning experience has the potential to be a 
more important factor than which of the two systems is used. Caution was raised in 
view of the difference in both the calculated target volume (given that identical contour 
sets were used) and the precision of certain calculated plan parameters across the two 
systems. 
 
A possible general criticism of the experimental work in this thesis has been that 
numbers have been relatively small and non-parametric testing has been used 
throughout (the statistical reasons for which have been explained at each point). This 
may have resulted in the studies being underpowered to detect certain differences within 
the data. However, statistically significant results were obtained in each study in spite of 
these limitations, and it has therefore been possible to draw some important conclusions 
from the experimental work performed. 
 
Radiosurgical plan parameters revisited 
 
The 12 Gy volume (V12) is widely used in radiosurgery centres when assessing 
candidate treatment plans. It is not a pure measure of dose fall-off, as it is also 
dependent on the size of the PTV and dose prescribed. It is, however, a pure measure of 
the volume irradiated, and therefore it is unsurprising that it has been shown to correlate 
#+!"
"
with post-radiosurgical complications (12, 58). When comparing different plans for the 
same PTV, and using the same prescribed dose, then V12 can act as a relative measure 
of dose fall-off. This was the intention with the Gamma-Cyber comparison in Chapter 7, 
although unfortunately target volume was not identical on the two different systems, 
therefore V12 could not be used in this way. 
 
The V12 is also intimately related to the % PTV coverage as shown in Figure 7.1 
(Chapter 7), the volume decreasing as % coverage decreases for a given plan. 
Unsurprisingly, as % coverage decreases for a given plan, then so also does the 
minimum dose to the PTV. In Chapter 7 the required PTV coverage was required to be 
97 % (to the nearest 1 %) for all plans in order to minimise this effect, although from a 
V12 perspective it was still beneficial to give eg 96.5 % coverage rather than 97.4 %. 
When assessing candidate plans, V12 values therefore need to be compared together 
with % coverage, PTV minimum dose, and other measures of dose fall-off. 
 
Gradient Index (GI) has been used as the main measure of external dose gradient in this 
thesis. It has the advantage of being independent of prescribed dose and prescription 
isodose % value, as it is a ratio involving the prescription isodose and half-prescription 
isodose volumes. Also, because it is a ratio, the dose fall-off across targets of different 
sizes can be compared. However, the GI can be criticised for the fact that two plans for 
the same PTV can have the same half-prescription isodose volume, but different GI 
scores depending on the volume inside the prescription isodose line. This is illustrated 
in Figure 8.1. In this example, one plan has a “baggy” prescription isodose which 
conforms less well to the PTV, but which results in a lower GI score. However, if GI on
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Figure 8.1 Drawing of the isodosimetry of two candidate treatment plans for the same PTV, delivering 18 
Gy to the 60 % marginal isodose. Both plans have 100 % PTV coverage and identical 9 Gy volumes. 
Using the Gradient Index, plan B would have a lower (better) score by virtue of a more “baggy” marginal 
isodose line. However, plan A is more conformal, with less normal tissue inside the PTV, and this is the 
plan which should be selected. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Drawing of the isodosimetry of two candidate treatment plans for the same PTV, delivering 18 
Gy to the 60 % marginal isodose. Both plans would have comparable conformality as measured by nCI. 
Plan B has a smaller prescription isodose volume and 9 Gy volume. Using the R50 %, plan B would have 
a lower (better) score. However both plans have identical Gradient Index scores, and plan A has better 
PTV coverage. Plan A should therefore be selected. 
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candidate treatment plans is interpreted together with PTV % coverage and nCI values, 
then there is little danger of accepting the worse plan. 
 
An alternative dose gradient measure is the R 50 %: 
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where x would be the prescription isodose. This is now used in a number of centres, 
having been used in the RTOG 0236 lung SBRT trial (85). Like the GI, it is 
independent of prescribed dose and prescription isodose % value. In the example in 
Figure 8.1, this dose gradient measure would be equal for both plans. However, this 
measure is still affected by PTV % coverage in the same way as the V12, as illustrated 
in Figure 8.2. The two plans in this figure have the same GI score, since the ratio of 
prescription isodose volume : half-prescription isodose volume is the same. However, 
by choosing a smaller prescription isodose line with less PTV coverage, the R 50 % is 
lower in the right-hand example. 
 
It would seem, therefore, that no single measure of external dose gradient is perfect for 
every situation. The GI is certainly appropriate in most situations, provided that % 
coverage and conformality are relatively consistent across candidate plans. It is also 
apparent, though, that three of the most important radiosurgical plan parameters 
(external dose gradient, PTV % coverage and conformality) are inextricably linked 
together, and plan evaluation needs to take all of them into account. It would be useful 
to have a universal measure of plan quality which incorporates all of these measures. 
This would certainly make it easier to compare candidate treatment plans on one 
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system, and also the performance of different radiosurgical systems. However, not only 
do the best individual measures need to be selected, they also need to combined in an 
appropriate way. Wagner et al (86) proposed a Conformity Gradient Index (CGI) which 
illustrates some of the potential problems: 
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where TV = target volume, and PIV = prescription isodose volume. 
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where Reff.50%Rx is the effective radius (in cm) of the isodose which is half the 
prescription, and Reff.Rx is the effective radius of the prescription isodose. The 
conformality measure is basically the reciprocal of Shaw’s conformity index (CI), 
expressed as a percentage. It has already been demonstrated in Chapter 4 that this index 
can give false perfect scores. The dose gradient measure uses effective radius (the radius 
of a sphere with the same volume) and allows an arbitrary 3 mm dose fall-off before the 
measure drops below the perfect score of 100. This is certainly not a regularly-used 
stand-alone measure of dose gradient.  
 
With regard to how to combine the measures, the best approach is not immediately 
obvious since they are measuring completely different things. For example, whilst 
conformality provides information about the volume of normal tissue receiving doses 
greater than the prescription dose, dose gradient is more concerned with the (larger) 
volume of normal tissue receiving doses in excess of a lower dose (eg half the 
prescription dose). In the above example, the authors combine the conformality and 
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dose gradient measures by simply adding together and dividing by 2, thus giving each 
equal importance in an overall score out of 100. This means that, for example, if the CI 
increases from 1.1 – 1.25, this can be offset if the effective radius difference between 
half-prescription and prescription isodoses decreases from 5 – 4 mm. It is difficult to 
say whether or not this is reasonable, and one can argue that reducing the plan 
parameters to a single measure is not useful if the resultant measure is hard to interpret. 
Since there is no intuitive way of combining these measures, the conclusion of this 
thesis would be that they should continue to be used separately in radiosurgical plan 
appraisal. 
 
Suggestions for future research 
 
This thesis has focused on the planning of intracranial lesions using the CyberKnife 
system. This is the traditional radiosurgical site, and most previous research into dose 
gradients and other plan parameters has used targets in the brain. However, a number of 
modern radiotherapy systems, such as CyberKnife, are able to use on-line image 
guidance to treat with the required accuracy to use large dose-per-fraction radiation for 
targets outside the skull. The use of so-called Stereotactic Body Radiotherapy (SBRT) is 
increasing, with the two commonest treatment sites worldwide being the lung and spine. 
 
An extension of the work in this thesis could look at the CyberKnife planning of 
extracranial lesions, to see to what extent the findings can also be applied to sites 
outside the brain. The optimisation algorithms and range of collimator sizes are the 
same when treating extracranial lesions, so it is quite possible that much of this 
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intracranial work will be useful in the planning of body sites. However the CyberKnife 
treatment paths (and therefore the range of beam angles) are different for body targets. 
This, together with the different body skin surface contours and tissue depth (and 
therefore different source-target separation), means that the results from this thesis 
would still need to be verified for extracranial lesions. 
 
The dose tolerance for lung tissue, as with most parallel organs, is usually expressed as 
a dose to a percentage of total organ volume, for example V20 < 30 % for 2 Gy/fraction 
radical radiotherapy, and V20 < 20 % for a three-fraction SBRT regimen (as specified 
in the lung cancer STARS trial). The most clinically important lung radiation toxicities 
are pneumonitis and fibrosis, both of which can have a significant impact on lung 
function. The main group of lung cancer patients treated with SBRT are those with 
stage I disease who are not medically fit for surgical lobectomy. Since this is often due 
to poor lung function, then it is critically important that in SBRT the amount of 
radiation-induced lung toxicity is minimised. Many lung tumours are surrounded on all 
sides by healthy lung parenchyma, therefore in order to minimise the V20 a steep dose 
fall-off on all sides of the target is usually required. Chapters 4 and 5 demonstrated that 
the steepest external dose gradient (as measured by Gradient Index) is achieved using a 
prescription isodose close to 50 % for smaller targets, and in the range 55 - 65 % for 
larger ones. It would be interesting to see whether the same strategy optimises dose fall-
off when treating lung tumours. 
 
In contrast, spinal tumours are located close to (or sometimes abutting) the spinal cord. 
As a serial organ, spinal cord tolerance in radiosurgery is described in terms of 
maximum point dose, or dose to a very small volume of cord, such as 0.035 or 0.1 cm3. 
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Optimising dose fall-off in the direction of the cord is usually a priority in spinal 
radiosurgical planning. However, there may be other important OARs to consider, such 
as exiting nerve roots, or the oesophagus, and therefore overall external dose gradient 
and other plan parameters may also be important. Chapter 6 explored the effects on 
overall plan quality of applying a firm restriction on dose to an OAR close to an 
intracranial target on one aspect. Once again, a verification of whether the same 
relationships exist when planning spinal lesions would be useful. 
 
Arguably the biggest difference when considering SBRT, as opposed to intracranial 
radiosurgery, is the presence of significant inter- and intra-fraction target and OAR 
movement. The ability to identify, and compensate for, target movement between 
fractions is critical to the safe and effective delivery of SBRT.  Additionally, with 
CyberKnife, where the fraction time is usually between 30 and 90 minutes, this must 
also be done during each fraction for all targets, regardless of whether or not they move 
with breathing. CyberKnife uses planar imaging, and therefore relies on implanted 
fiducial markers in order to track the position of many extracranial tumours. The 
fiducials therefore act as surrogate markers for tumour position. A minimum of three 
fiducials are required in order for the system to determine the target position according 
to all six dimensions (anterior-posterior, left-right, superior-infererior, roll, pitch and 
yaw). Furthermore, the fiducials must be > 20 mm apart, with no overlapping in either 
of the two 45-degree imaging planes. 
 
There are limitations inherent in CyberKnife fiducial tracking, and this is another 
possible area for future research. Firstly, there are some situations where it is not 
possible to insert safely at least three fiducials near/in the tumour. Examples include 
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patients with very poor lung function, in whom each needle pass carries the risk of life-
threatening pneumothorax, and some pancreatic or abdominal nodal tumours, where 
major blood vessels may abut the target on most aspects. Where only one or two 
markers are inserted, the system can track any intra-fraction translational movements, 
but not the rotational ones (rotational position can only be set up at the start of the 
fraction, using Xsight Spine tracking). Secondly, even if the route of fiducial insertion is 
straightforward and safe, it may not be possible to insert three markers directly into the 
target, and still meet the above criteria for effective tracking. In this situation, at least 
some of the fiducials must be inserted around the target rather than inside it. Fiducials 
outside the tumour may not move in exactly the same way as the tumour itself, even if 
they are within the Accuray recommended maximum distance of 6 cm from the tumour. 
 
A clearer, more quantitative understanding of these limitations would help clinicians 
with the appropriate use of fiducials with CyberKnife, including the size of CTV-PTV 
margins needed to account for any potential errors. It would also be very helpful for 
treatment radiographers and physicists, as decisions often have to be made during 
treatment regarding which (and how many) fiducials to use for tracking. 
 
A dosimetric comparison of CyberKnife and Gamma Knife for intracranial radiosurgery 
(Chapter 7) has formed part of this thesis. There are a number of modern gantry-based 
radiosurgery systems in use, and it would interesting to extend the work in Chapter 7 to 
look at the ability of a gantry-based radiosurgery system to plan the same targets. It is 
hoped that such a collaboration will be possible in the future. Additionally, further 
research into the CyberKnife system in the area of extracranial treatment could also 
include a similar comparison with other SBRT or IMRT delivery systems. For example, 
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CyberKnife is designed primarily as a radiosurgical tool for treating relatively small 
targets. However, gantry-based IMRT delivery systems commonly deal with 
substantially larger targets. The most recent advances in IMRT delivery involve the use 
of modulated arc therapy (eg RapidArc (Varian Medical Systems, Palo Alto, CA) and 
VMAT (Elekta)), which confers greater target conformality and treatment efficiency, 
both in terms of time and monitor units used. As the target size increases there will be a 
point at which IMRT planning systems are capable of producing better quality plans 
than CyberKnife. Observations from this centre suggest that the size at which this 
occurs may actually be smaller than one might think. Indeed, as the maximum target 
diameter increases beyond approximately 6 cm the external dose fall-off in plans 
produced using CyberKnife appears to become less steep. This may be in part due to the 
fact that the largest field size available is a 60 mm diameter circle. A formal dosimetric 
comparison of CyberKnife and, for example, RapidArc planning would provide useful 
information in this area, thus helping clinicians to be better informed when deciding on 
the most appropriate radiotherapy system to use for each patient. 
 
It has previously been noted that target dose inhomogeneity affects the “effective” dose 
delivered. This is particularly pertinent since this thesis has demonstrated that external 
dose gradients can be achieved in CyberKnife radiosurgery by using lower marginal 
idosose values than are currently favoured in centres around the world. More 
widespread use of generalised Equivalent Uniform Dose (gEUD) could make future 
comparisons of treatments across different systems (and centres) more meaningful, 
although unfortunately the accuracy of the gEUD calculation will tend to reduce as the 
degree of heterogeneity increases! 
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The importance of dose rate in radiotherapy has also previously been noted (32). In the 
experimental work in this thesis, treatment times for the clinically acceptable plans 
produced were not allowed to exceed 60 minutes. However, even with this restriction 
there could be a substantial dose rate effect when comparing, for example a 60 minute 
treatment with one which takes 20 minutes. There are now a number of different 
systems capable of delivering radiosurgery, and treatment times can vary considerably. 
Further work to improve understanding of the dose rate effect in radiosurgery will help 
to establish equivalent doses across the different systems.  
 
Additionally, there is some evidence that for a given treatment time, the way in which 
the target is irradiated may have further radiobiological significance. For example, 
CyberKnife radiosurgical treatment usually comprises 100 – 200 beams, each of which 
only irradiates part of the target volume. For a given voxel within the target, the single 
fraction will actually consist of multiple short periods of variable dose delivery, with 
variable pauses in between which may allow some repair of sublethal damage. This 
pattern will be different for every voxel within the target. Murphy and Lin (87) have 
shown that the variable voxel irradiation schedules occurring during a CyberKnife 
fraction can translate into a spatially-variable reduction in effective dose within the 
target. Hopewell (88) has similarly demonstrated that in a Gamma Knife treatment, the 
BED can vary significantly across the different voxels in the target for the same reasons. 
Further work could look at methods to reduce this variability and/or optimise tumour 
control probability for a given radiosurgery treatment by altering the beam/shot 
sequence or weighting, or even simply identifying the best beam or shot with which to 
start the fraction.  
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Conclusions 
 
Small field dosimetry is a controversial area of radiotherapy Quality Assurance, and 
some of the tools commonly used are in need of improvement. Ionisation chamber and 
radiochromic film analysis have confirmed that CyberKnife treatment plans in 
MultiPlan are a reasonably accurate reflection of the treatment which is actually 
delivered, although it would be desirable to be able to use stricter spatial dose 
distribution tolerances in the future. 
 
The choice of prescription isodose affects the steepness of the external dose gradient in 
CyberKnife planning of solitary intracranial targets, as demonstrated with both spherical 
“virtual” targets and irregular lesions. The optimum prescription isodose for smaller 
targets is as close to 50 % as can be achieved comfortably. For larger targets, the 
optimum value is likely to be in the range 55 – 65 %. A stepwise method has been 
proposed for optimising dose fall-off in the planning of solitary intracranial lesions, 
where even dose fall-off on all sides is desired. 
 
When an especially radiosensitive OAR lies near an intracranial target on one aspect, 
introducing a tight dose limit for this OAR during planning (using a VOI limit) can 
reduce the dose to this structure substantially without any real compromise on other 
important plan parameters. Using “eroded” target volumes may further help the 
optimisation process when the OAR abuts or overlaps the target. 
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Whilst the dosimetric performance of CyberKnife and Gamma Knife in the planning of 
solitary brain targets is generally similar, there is evidence to suggest that Gamma Knife 
dosimetry is superior for very small lesions, and CyberKnife is superior for lesions at 
the upper end of the single fraction target size range. The experience of the treatment 
planner has the potential to be a more important factor for lesions which both systems 
treat well.  
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Appendix – Outputs related to this thesis 
 
Presentations 
Martin A, Cowley I, Plowman P. Choosing a value for the prescription isodose: how 
this affects external dose gradient in CyberKnife planning of intracranial lesions. Oral 
presentation, CyberKnife Robotic Radiosurgery Summit, San Francisco, February 
2011. 
Martin A, Cowley I, Hiscoke K, Plowman P. Differences in reported target volumes: 
are different planning systems truly comparable ? Oral presentation, The Radiosurgery 
Society SRS/SBRT Scientific Meeting, San Diego, February 2012. 
 
Publications 
Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clinical Oncology 
2010;22(3)157-172. 
Martin A.G.R, Cowley I.R, Taylor B.A et al. (Stereotactic) radiosurgery XIX: spinal 
radiosurgery – two year experience in a UK centre. British Journal of Neurosurgery 
2012;26(1)53-58. 
 
Papers in preparation 
Martin A, Cowley I, Plowman P. Steep external dose gradient is at the expense of 
target dose inhomogeneity in CyberKnife planning of solitary intracranial lesions. 
2011 CyberKnife®Robotic Radiosurgery Summit Friday, February 11, 2011 
Choosing a Value for the Prescription Isodose: How this Affects the External Dose Gradient in  
CyberKnife Planning of Intracranial Lesions  
Alexander Martin, Ian Cowley, Nicholas Plowman 
Objectives: In the treatment of intracranial lesions, common CyberKnife practice is to use a 
prescription isodose of around 65-80%. This differs from, for example, Gamma Knife radiosurgery 
where a prescription isodose of around 50% is often used. Further, it has been shown with the 
Gamma Knife system that the dose gradient outside the PTY is often steepest when using an 
even lower prescription isodose of around 40%. The objective of this study was to explore 
whether the steepness of dose fall-off outside the PTY is affected by the choice of prescription 
isodose when using CyberKnife, and if so, to describe this relationship further. 
Methods: A spherical "virtual" target was created in a central location within the brain CT of a 
patient selected at random. Multiple treatment plans were generated using Multiplan v.3.5.1. 
Planning variables were manipulated to vary the prescription isodose of the treatment plan 
across the range 50-80%. For each plan the Gradient Index (Gil was calculated. For a plan 
prescribed to the X% isodose, GI = [volume contained within the X/2% isodose)/{volume 
contained within the X% isodose). All plans were setup to deliver a single fraction of 18 Gy to the 
target. Plans were required to be "clinically acceptable", meeting the following criteria: overall 
treatment time </= 60 minutes (where estimated treatment time = (Number of beams/6) + 
(Number of monitor units/800) l: PTY coverage by the prescription isodose >95%; new 
conformality index (nCl) required to be within 0.03 of the best achievable nCi for the target. 
Planning was performed using both Simplex optimization with 3 fixed collimators, and Sequential 
optimization with the Iris collimator. The process was carried out on spherical targets of 3 different 
diameters: 15 mm, 30 mm and 50 mm. It was then repeated with five real intracranial lesions 
previously treated at this centre. 
Results: For the 15 mm spherical target, a positive relationship was observed between 
prescription isodose and Glover the isodose range of 50-80%. Thus, as the prescription isodose 
was lowered, the dose gradient outside the PTY became steeper. For the two larger spheres, the 
dose fall-off was again shallowest with the 80% isodose, but there was little difference in GI scores 
across the 50-70% prescription isodose range. The median PTY of the five treated lesions was 5.79 
cm3 [2.25-23.16 cm3). For each of the lesions, a positive relationship was once again observed 
between prescription isodose and Glover the isodose range of 56-80%. 
Conclusions: In CyberKnife radiosurgery for intracranial targets, the steepness of dose fall-off 
outside the PTY is an important treatment parameter, and one which is affected by the choice of 
prescription isodose. Optimizing dose gradient requires the use of lower prescription isodoses than 
are commonly seen reported in the literature. An inevitable consequence of this strategy would 
be greater inhomogeneity of dose within the PTY. 
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Abstract
Stereotactic body radiotherapy (SBRT) combines the challenge of meeting the stringent dosimetric requirements of stereotactic radiosurgery with that of
accounting for the physiological movement of tumour and normal tissue. Here we present an overview of the history and development of SBRT and discuss the
radiobiological rationale upon which it is based. The published results of SBRT for lung, liver, pancreas, kidney, prostate and spinal lesions are reviewed and
summarised. The current evidence base is appraised and important ongoing trials are identified.
! 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Key words: Cyberknife; radiosurgery; stereotactic body radiation therapy; stereotactic body radiotherapy
Statement of Search Strategies Used and
Sources of Information
A search for the published results of stereotactic body
radiotherapy for lung, liver, pancreas, kidney, prostate and
spinal lesions was carried out using Ovid Online via the
Athens website. Medline and Embase databases were
selected, and the following terms were searched for, in all
fields: ‘radiosurgery’, ‘stereotactic radiosurgery’, ‘stereo-
tactic body radiotherapy’, ‘stereotactic body radiation
therapy’ and ‘cyberknife’. Appropriate publications were
selected from the lists generated, and additional papers
found through a manual search of the references contained
in these publications. Searches were carried out in April
2009. The review also includes certain additional papers
published after April 2009 that were considered to be
especially pertinent to this subject, and some information
obtained from oral presentations at the 2nd European
Workshop on Stereotactic Radiation Therapy and Whole
Body Radiosurgery, Berlin, 27–28 March 2009. Information
on the history and radiobiology of stereotactic body radio-
therapy was obtained from the above publications and
further internet searching. Information on the stereotactic
delivery systems was obtained from the manufacturers’
websites, and through direct communication with the
manufacturers.
Introduction
Stereotactic body radiotherapy (SBRT) refers to the
precise irradiation of an image-defined extracranial lesion
using a small number (one to five) of high-dose fractions. It
has developed from intracranial single-fraction stereotactic
radiotherapy (also known as radiosurgery), which is
conceptually different from conventionally fractionated
radiotherapy (CFR). In its fractionated form, SBRT shares
characteristics of both radiosurgery and CFR. The high doses
per fraction strive towards an ablative tumour effect,
whereas the use of modest fractionation implies the need to
allow some normal tissue recovery.
The safe delivery of very large doses per fraction requires
effective patient immobilisation, precise target localisation
(which may involve fusion of different imaging modalities),
sophisticated planning software, accurate treatment
delivery and the ability to produce a steep isodose gradient
outside the target volume. In addition, extracranial lesions
pose further challenges to treatment delivery due to inter-
and intrafraction tumour and critical organ motion. Until
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recently this has limited the ability to deliver stereotactic
radiotherapy to targets outside the brain. However,
advances in image guidance have allowed treatment
systems to account for such motion and, consequently, the
use of SBRT is increasing.
History
Stereotactic surgery was first described by Horsley and
Clarke in 1906. They developed a method of locating deep-
seated brain lesions by assigning coordinates in three
planes to neuroanatomical structures, based on cranial
landmarks [1]. In 1947, Spiegel et al. [2] introduced frame-
based stereotaxy using a plaster head cap known as a ster-
eoencephalatome, and a three-dimensional coordinate
system relative to this.
Lars Leksell, a Swedish neurosurgeon, was the first
person tomarry the two developing fields of stereotaxy and
radiation therapy, and introduced the term ‘radiosurgery’ in
1951 [3]. He used a rigid metal stereotactic head frame fixed
to the skull. Small intracranial targets were localised rela-
tive to the frame and radiation was delivered in a single
high-dose fraction. The technique initially used 250 kV
X-rays, but in 1967 the first Gamma Knife prototype was
developed, using 179 cobalt-60 sources focused on the
target. Since then, the Gamma Knife has become widely
used for stereotactic radiosurgery, with sub-millimetre total
system accuracy [4]. However, Gamma Knife stereotactic
treatment is largely limited to intracranial targets.
The 1980s saw the adaptation of linear accelerators
(linacs) for intracranial stereotactic delivery, again using
rigid stereotactic head frames, and specialist dosimetry
software, e.g. X-Knife (Radionics, Boston, MA, USA). In 1995,
Hamilton et al. [5] proposed a method of delivering linac-
based stereotactic radiotherapy to spinal lesions using
a prototype rigid ‘extracranial stereotactic frame’ and
associated three-dimensional coordinate system. Immobi-
lisation was achieved by transcutaneous frame fixation to
spinous processes superior and inferior to the target. They
reported an overall treatment accuracy of 2 mm, but the
technique was time-consuming, cumbersome and limited
to the delivery of single fractions. Also, as with intracranial
immobilisation methods, this approach relied upon a fixed
relationship between target and bony anatomy.
Around the same time, Lax et al. [6] developed a stereo-
tactic body frame, which, together with a vacuum bag,
immobilised the patient from head to mid-thigh. They
found the set-up reproducibility for liver and lung lesions to
bewithin 5–8 mm for 90% of the patients. Many stereotactic
radiotherapy systems today use a similar set-up with body
frame immobilisation. However, for most extracranial sites
the position of the tumour does not enjoy a fixed relation-
ship relative to the external body contour, and can move
both between and during each fraction of radiotherapy. An
external body frame alone is therefore not sufficient to
ensure accurate delivery of radiation to the target. Lax et al.
[6] showed that diaphragmatic movements could be
reduced to 5–10 mm by applying a pressure on the
abdomen, and some centres have developed corsets to limit
diaphragmatic movement. However, the safe delivery of
large fractions of radiotherapy also requires sophisticated
image guidance.
Image guidance in radiotherapy became a realistic
concept with the development of the electronic portal
imaging device and software to aid quantitative evaluation
of patient set-up, thus allowing correction of translational
errors. The next step was moving from ‘off-line’ to ‘on-line’
image guidance (i.e. adjusting the patient’s position before
each fraction on the basis of imaging). Accurate identifica-
tion of the tumour position has improved with the use of
inserted metal fiducial markers with planar images, or
alternatively with the development of volumetric image
guidance (e.g. cone beam computed tomography or in-
room computed tomography on rails). More recently,
improved software together with more sophisticated
treatment couches havemeant that correcting for rotational
set-up errors is now possible. Finally, intrafraction image
guidance is now available and is a key component of some
of the stereotactic treatment systems described below.
Stereotactic systems that use planar imaging have great
flexibility with respect to taking multiple intrafraction
images, but largely rely on implanted fiducials. Percuta-
neous fiducial insertion can be technically difficult, espe-
cially in the upper abdomen, where it may be necessary to
pass through other organs to reach the target lesion. In the
lung, there have been concerns about the complication
rates observed with percutaneous fiducial implantation. A
25–40% incidence of pneumothorax requiring drainage has
been reported [7,8]. However insertion techniques are
improving. In a recent series described below, Van der Voort
van Zyp et al. [9] used either a percutaneous or a vascular
approach, depending on the perceived risk of pneumo-
thorax. Only four of 70 patients developed pneumothorax,
and in only one of these cases was a chest drain necessary.
‘Xsight Lung’ is a feature of the CyberKnife SBRT system (see
below), which allows the tracking of certain peripheral lung
tumours without the need for implanted fiducials.
Fractionation and Radiobiology
In CFR, the tumour volume is irradiated together with
a margin to account for tumour and organ motion, and
inaccuracies of planning, set-up and delivery. The total dose
is limited by the tolerance of normal tissue within, or close
to, the planning target volume (PTV). The therapeutic
benefit achieved with dose fractionation has been recog-
nised for over 100 years. Conventional fractionation has
emerged as a result of these early clinical observations, and
subsequent changes have been driven largely by clinical
outcomes. The development of radiobiological concepts,
such as the linear quadraticmodel [10] andWithers’ ‘4 Rs’ of
radiotherapy [11], has led to further understanding of the
tissue effects of fractionation.
By contrast, radiosurgery exploits the potent radiobio-
logical effect of large single doses of radiation, which tran-
scends the considerationsproposedbyWithers. The aim is to
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ablate all tissue within the PTV, and the small margins used
ensure that minimal normal tissue is destroyed. Consider-
able dose inhomogeneity within the target volume is stan-
dard practice, due to the internal dose gradient achieved by
using a low prescription isodose (commonly 40–60% with
Gamma Knife radiosurgery). There is some evidence to
suggest that, rather than being a problem, carefully planned
target dose inhomogeneity may enhance the tumoricidal
effect [12].
Fractionated SBRT sits somewhere between the extremes
of CFR and radiosurgery. Large doses per fraction are used
and a moderate internal dose gradient achieved, with
a typical prescription isodose of 60–80%. Unlike intracranial
radiosurgery, inter- and intrafraction movement of tumour
and organs at risk is a big problem. This increases the risk of
irradiating normal tissue (and missing the tumour) during
treatment. Also, the overwhelming clinical experience of
treating extracranial tumours is with conventional frac-
tionation. For these reasons, moving away from fraction-
ation completely is a big step for many extracranial sites.
The linear quadratic model and its derivatives can help
clinicians to predict tissue response to altered fractionation
regimens. However, there has been concern that it does not
accurately predict tumour cell response at the higher doses
per fraction seen with stereotactic treatment [13]. It is not
clear to what extent modest fractionation (two to five
fractions) differs from a single fraction with respect to
tumour response and normal tissue effects.
Unsurprisingly, therefore, there has been a large varia-
tion in dose and fractionation across SBRT series published
to date. Although some SBRT centres adopt a ‘single large
fraction’ strategy for many patients, other centres would
prefer to fractionate in similar cases. Current regimens have
in many cases been derived empirically, often the result of
cautious dose escalation, as illustrated by phase I trials in
non-small cell lung cancer (NSCLC) [14], liver metastases
[15] and pancreatic carcinoma [16].
Overview of Stereotactic Body
Radiotherapy Systems
A number of modern linacs with on-board imaging
capabilities meet the basic image guidance requirements
for delivering SBRT, e.g. Varian Trilogy (Varian Medical
Systems, Palo Alto, CA, USA) and Elekta Synergy (Elekta,
Stockholm, Sweden). A micro multileaf collimator can be
added to produce the required degree of conformality for
stereotactic plans.
More recently there has been the introduction of linacs
fully adapted as integrated stereotactic delivery systems.
Novalis TX has a Varian Trilogy linac base with micro
(2.5 mm) multileaf collimator. Other features include the
BrainLAB Other features include the BrainLAB ‘‘ExacTrac
X-ray 6D’’ system providing near real-time image guidance
with six degrees of freedom, a corresponding robotic
treatment couch, and associated software (BrainLAB,
Munich, Germany). Elekta Axesse is a similar integrated
system.
The TomoTherapy Hi-Art System (TomoTherapy, Madison,
WI, USA) has a ring gantry as used in diagnostic computed
tomography scanners and delivers helical intensity-
modulated radiotherapy (IMRT) via thousands of small
beamlets. Couch movement is continuous during radiation
delivery. The system has on-board image guidance with
megavoltage computed tomography.
CyberKnife (Accuray, Sunnyvale, CA, USA) is an image-
guided robotic radiosurgery system.Acompact 6 MVX-band
linac is mounted on a six-joint robotic arm. This provides
flexibility in beam pattern generation, allowing the system
to produce very conformal, non-isocentric plans (Fig. 1). As
with Novalis TX, a robotic couchwith six degrees of freedom
and near real-time kV image guidance also feature.
Lung
Lung SBRT is additionally challenging because of the
problems of accounting for intrafraction target movement
with breathing. Most of the published data come from
centres using gantry-based linacs with vacuum and/or
frame body immobilisation, and diaphragmatic pressure to
reduce breathing movement.
Four-dimensional computed tomography planning
allows the construction of a volume that takes into account
the tumour position at all phases of the respiratory cycle. It
has been shown to increase accuracy and reduce the
volume irradiated in conformal radiotherapy, and is now
being used in some lung SBRT centres.
Respiratory gating methods, such as active breathing
control (used in some series), have sought to reduce the
volume of tissue irradiated by requiring a smaller clinical
target volume–PTV margin. The latest gantry-based
stereotactic systems (e.g. Novalis TX) allow respiratory
gating using infrared chest wall tracking and intrafraction
X-ray imaging. CyberKnife uses a similar respiratory
tracking system (Synchrony RTS). However, here, the
predictive model that anticipates tumour movement with
breathing allows the robotic arm to move the beam
accordingly during radiation delivery. This obviates the
need for respiratory gating.
Primary Non-small Cell Lung Cancer
Surgery remains the standard of care for early stage
NSCLC. A 5-year survival rate of 65% has been reported for
pathological stage I patients [17], and a recent analysis of
975 patients (85% stage I) revealed a 5-year local control of
78% [18].
However, the preferred procedure (lobectomy) results in
a significant loss of functional pulmonary reserve and is
associated with operative morbidity and mortality. Also,
a large number of surgically resectable patients are medi-
cally inoperable (mainly due to cardiovascular or respira-
tory co-morbidity). CFR has traditionally been the standard
alternative to surgery for these patients, but the total dose is
limited by lung tolerance for peripheral tumours, and
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mediastinal tolerance for central tumours. Published data
have shown 5-year survival after CFR for stage I NSCLC to be
in the region of 15–30% and, importantly, 5-year disease-
specific survival little better at 25–30%. There does,
however, seem to be a dose–response relationship [19,20].
Stereotactic radiotherapy allows safe treatment with
a higher biological equivalent dose (BED) than is possible
with CFR. This has led to improved local control rates.
Several important published series of lung SBRT are
summarised inTable1. The largest is a Japanese retrospective
reviewof 257 patients from14 institutions [21]. Patients had
resectable stage I disease, but were either medically inop-
erable or declined surgery. Therewas considerable variation
in immobilisation and respiratory motion management
protocols, and also heterogeneity of dose and fractionation
(30–84 Gy in 1–14 fractions). Five-year actuarial local
control rateswere 84% for patients receiving a BED of 100 Gy
or more (based on assumed tumour a/b of 10) and 37% for
those receiving less than 100 Gy. This dose–response rela-
tionship corroborates that seen with CFR discussed earlier.
Therewas no difference in the recurrence rates of squamous
cell carcinoma and adenocarcinoma. Five-year overall
survival formedically operable patients receiving the higher
dose range was 71%. This was achieved with relatively low
rates of radiation toxicity.
JCOG 0403 is an ongoing Japanese multi-institutional
phase II trial for medically operable or inoperable stage IA
disease. On the basis of results seen in Japanese series,
patients receive 4!12 Gy fractions (BED 106 Gy). The
results are awaited.
There have also been a number of published series of
gantry-based lung SBRT from European centres [22–26].
Two large retrospective series are summarised in Table 1,
both reporting 88% local control at around 3 years [23,24].
More recently, Baumann et al. have published the results
of a phase II trial of 57 non-central stage I tumours treated
to a dose of 45 Gy in three fractions [26]. The tumours
were small (70% T1, maximum tumour volume 51 cm3),
but the results are nevertheless very impressive. Three-
year local control and overall survival were 92 and 60%,
respectively. Twenty-eight per cent of patients experi-
enced grade 3 toxicity, and there was one case of grade 4
dyspnoea in a patient who received SBRT to both lungs for
metachronous primary tumours. However, there was no
evidence of a decrease in FEV1 or subjective worsening of
breathing capacity [26].
In the USA, McGarry et al. [14] carried out a phase I dose-
escalation study with 47 medically inoperable stage I
patients, with a starting dose of 3! 8 Gy. The maximum
tolerated dose was not reached for patients with T1
tumours, but for T2 tumours >5 cm it was reached at 66 Gy
in three fractions. Local control was 79% with a median
follow-up of 15 months, but nine of the 10 local failures
occurred at doses of "16 Gy per fraction [14].
A subsequent phase II study from the same institution
enrolled 70 inoperable stage I patients with peripheral or
central (within 2 cm of the proximal bronchial tree)
tumours, giving 60–66 Gy in three fractions. Two-year local
control and overall survival were estimated at 95 and 54%,
respectively. However, eight patients developed grade 3–4
pulmonary or skin toxicity, and there were six possible
cases of grade 5 pulmonary toxicity. The risk of severe lung
toxicity was 11 times higher for central tumours compared
with peripheral tumours [27].
On the basis of these results, centrally located tumours,
as defined above, were excluded from two subsequent
Fig. 1. Axial slice from the CyberKnife plan of a sacral metastasis. The planning target volume is shown in red overlay. The treatment is
prescribed to the 80% isodose (green line). The other isodose lines shown are 95% (red), 90% (orange), 70% (white), 60% (yellow), 50% (pink), 40%
(purple), 30% (light blue), 20% (blue) and 10% (dark blue).
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Table 1
Selected published series of stereotactic body radiotherapy for primary non-small cell lung cancer
Reference Type of
publication
Number of
patients
Accounting for tumour
movement
Location Dose Follow-up Local control Overall survival Grade !3
radiation
toxicity
[21] Multi-centre
retrospective
series
257 Varied (breath hold;
respiratory gating; slow
computed tomography
scan)
Peripheral
or central
30–84 Gy/1–14
fractions
Median
38 months
(2–128)
5 year 84% for
BED ! 100 Gy
5 year 47% (71%
for medically
operable, and
BED ! 100 Gy)
5.4% lung
1% oesophagitis
1.2% dermatitis
[23] Multi-centre
retrospective
series
138 Abdominal pressure if
needed
Peripheral
(mainly) or
central
30-48 Gy/2–4
fractions
Median
33 months
88% at median
33 months
3 year 55% 10%
[26] Multi-centre
phase II
57 Abdominal pressure if
needed
Peripheral 45 Gy/3
fractions
Median
35 months
3 year 92% 3 year 60% 26% grade 3
2% grade 4
[24] Single centre
retrospective
series
68 Planning target volume
margins guided by
computed tomography
assessment
Peripheral
or central
24–40 Gy/3–5
fractions
Mean
17 months
3 year 88% 3 year 53% 6% pneumonitis
3% rib fracture
[14] Single centre
phase I, dose
escalation
47 Abdominal pressure Peripheral
or central
24 Gy/3
fractions
escalating to
72 Gy/3
fractions
Median
15 months
79% at median
15 months
– 11% lung
2% pericardial
2% dermatitis
[27] Single centre
phase II
70 Abdominal pressure Peripheral
or central
60–66 Gy/3
fractions
Median
17.5 months
2 year 95% 2 year 54% 20% (includes 6
possible grade
5 cases)
[28] Single centre
retrospective
series
27 Four-dimensional
computed tomography
planning
Central or
superior
40–50 Gy/4
fractions
Median
17 months
100% at median
17 months
(50 Gy) or
57% (4 Gy)
– 11% grade 2–3
pneumonitis/
chest wall pain
[30] * Single centre
retrospective
series
59 Synchrony respiratory
tracking system
Peripheral
or central
15–67.5 Gy/1–5
fractions
1–33 months 90% free from
persistent or
recurrent
disease
86% 0% grade 4/5
toxicity
7% grade 1–3
pneumonitis
[9] * Single centre
retrospective
series
70 Synchrony respiratory
tracking system
Peripheral 45 or 60 Gy/3
fractions
Median
15 months
2 year 96%
(60 Gy) or
78% (45 Gy)
2 year 62% 10% late
toxicity
4% acute
toxicity
BED, biological equivalent dose.
* All studies used a gantry-based linear accelerator except (CyberKnife).
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phase II trials. The RTOG 0236 trial recruited medically
inoperable patients with T1-3 N0 disease (and <5 cm
diameter), treating with 60 Gy in three fractions. It closed in
October 2006 and full results are awaited. The RTOG 0618
trial is currently underway, treating operable T1-3 N0
patients with the same dose and fractionation.
For central tumours, the maximum tolerated dose is still
under investigation. Chang et al. [28] treated a series of 27
centrally or superiorly located lesions with a slightly more
modest dose of 40–50 Gy in four fractions. At a median of
17 months, there was no local recurrence seen in the 20
patients receiving 50 Gy (BED 112.5 Gy). There were three
cases of grade 2–3 skin/chest wall toxicity and one brachial
plexopathy, related to a large volume of plexus receiving
40 Gy. However, there was no observed grade !3 pulmo-
nary or oesophageal toxicity. RTOG 0813 is a phase I/II
dose-escalation trial underway for central stage I tumours
in medically inoperable patients.
There have been a number of published series of primary
lung SBRT using CyberKnife [8,9,29,30]. Brown et al. [30]
treated 59 stage I patients with peripheral tumours. Doses
ranged from15to67.5 Gy inonetofive fractions.With follow-
up ranging from 1 to 33 months, only 10% of patients had
persistent or recurrent disease, and overall survival was 86%.
More recently, van der Voort van Zyp et al. [9] have
published the results of 70 peripheral stage I tumours
treated with either 45 or 60 Gy in three fractions. The
estimated 2-year local control rate was 96% for the 59
patients treated with 60 Gy, and 78% for those receiving
45 Gy. Two-year overall survival was 62% for the whole
group. The incidence of grade 3 late toxicity was 10%.
A specialised ‘body Gamma Knife’ system has been
developed in China, consisting of 30 cobalt-60 sources
arranged around the patient. The published results look
promising [31], but the technology is not yet available
outside China.
SBRT seems to be a safe and effective treatment for early
stage NSCLC. With respect to local control, achieving
a BED> 100 seems to be very important. Unfortunately,
there are still no published randomised data comparing
SBRT and surgery for operable patients with early stage
disease (and no published randomised comparisons of
SBRT and CFR for medically inoperable patients). However,
phase III trials are now underway. ROSEL is a Dutch multi-
centre randomised study of gantry-based SBRT vs surgery
for peripheral stage IA NSCLC. Respiratory motion is
accounted for by either four-dimensional computed
tomography or slow computed tomography scanning, and
the radiotherapy dose is 60 Gy in three fractions (or five
fractions if adjacent to the chest wall or mediastinum). The
Lung Cancer STARS Trial is an international randomised
trial of SBRT with CyberKnife vs surgery for stage IA or IB
patients (maximum diameter <4 cm). Peripheral tumours
receive 60 Gy in three fractions, and central tumours 60 Gy
in four fractions. It will be some time before these trials
produce mature data, and in the meantime surgery
remains the standard of care. For the large number of
medically inoperable patients, SBRT is emerging as the best
treatment option.
Lung Metastases
The term ‘oligometastases’ refers to a finite small number
of metastases confined to a single or limited number of
organs [32]. Long-term follow-up of patients after surgical
resection of lung and liver metastases has shown that some
of these patients are effectively cured after surgery [33,34].
For example, in an analysis of over 5000 patients with lung
metastases, survival after complete surgical resection was
36% at 5 years and 22% at 15 years [33]. Thus, in some
cancers there seems to be a stable tumour state somewhere
between purely localised and widely metastatic. This,
together with the results of administering ablative doses of
radiation to primary lung tumours (see above), has led to
increasing interest in the use of SBRT for oligometastases.
The early data on SBRT for pulmonary metastases
emerged as heterogeneous published series including both
primary and metastatic lung lesions. Wulf et al. [22] pub-
lished their results of gantry-based SBRT using an Elekta
stereotactic body frame. Of the 61 patients, 20 had stage I/II
primary NSCLC and 41 had one or two pulmonary metas-
tases. They received 3"10–12.5 Gy or a single fraction of
26 Gy for small peripheral lesions. With a median follow-up
of 9 months, local recurrence/progression was seen in
five of the 51 metastatic lesions. Once again there was
evidence of a dose–response relationship, as four of these
five lesions had received the lowest dose (3"10 Gy). In
a subsequent publication from the same centre, at a median
follow-up of 18 months they reported recurrence in six of
48 metastatic lesions, giving a crude local control rate of
88%. Symptomatic pneumonitis was seen in 10% of patients,
with one case of grade 3 pneumonitis [35]. Similar results
have been seen in other such series [36,37].
More recently, several series of purely metastatic lung
cases have been reported. Norihisa et al. [38] treated 35
patients with one or two lung metastases. The primary site
was controlled and there were no other organs involved.
The original dose of 48 Gy in four fractions was escalated to
60 Gy in five fractions for 16 patients. Two-year results for
overall survival, local control and progression-free survival
were 84, 90 and 35%, respectively. Local control was 100% in
patients receiving 60 Gy. One case of grade 3 pulmonary
toxicity was reported.
Rusthoven et al. [39] extended their inclusion criteria to
patients with one to three lung metastases, in a multi-
institutional phase I/II study. Low burden extrathoracic
disease was also permitted. Again, the dose was safely
escalated, from 48 to 60 Gy in three fractions. The 2-year
actuarial local control rate for their 38 patients was 96%.
However, 2-year overall survival was 39%, reflecting the fact
that 63% had disease progression outside the treated area(s)
at a median of 4 months after treatment.
Brown et al. [40] have published their series of 35
patients treated with SBRT using CyberKnife. All 69
metastases were technically resectable, but the patients
were medically inoperable. There were no other sites of
spread, although up to eight pulmonary lesions were
treated for each patient. The prescribed dose varied widely
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from 5 to 60 Gy in one to four fractions, depending on the
proximity to organs at risk and the number of sites treated.
With a median follow-up of 18 months, 77% of patients
were still alive, and 71% had local control in all treated areas.
Only one patient developed!grade 3 acute toxicity (grade 4
pneumonitis, which settled with treatment). This occurred
after retreatment of three lesions within 12 months of
previous stereotactic radiotherapy to the same PTVs.
As with primary NSCLC, there are as yet no published
randomised data comparing surgery and SBRT for oligo-
metastatic lung disease, but the results seen are encour-
aging, and the non-invasive approach with low risk of
toxicity makes it an attractive option for these patients.
Liver Metastases
As with lung metastases, surgical series of metastectomy
for liver metastases have shown a proportion of long-term
survivors. In a series of 1000 patients from Memorial Sloan-
Kettering Cancer Center with resectable liver-only metas-
tases from colorectal cancer, survival was 37% at 5 years and
22% at 10 years [34]. Surgery remains the gold standard for
resectabledisease, butmanypatients areunresectable, either
due to theextent ofmetastatic disease, insufficient functional
liver reserve or general medical condition. There has, there-
fore, been interest in potentially curative, non-surgical
options for unresectable patients with oligometastatic
disease. Radiofrequency ablation is widely practiced, with
local control rates comparable with surgery for lesions less
than 3 cm [41], but lesions close to large vessels or the dia-
phragm are contraindicated for this technique. Transarterial
embolisation, chemoembolisationandradioembolisationare
further options.
Although whole liver radiation has been used in the past
for palliation [42], the radiosensitivity of normal liver tissue
has limited the ability to deliver a radical dose to oligome-
tastases in the liver using conventional radiotherapy tech-
niques. Radiation-induced liver disease (RILD) is now well
documented as a potentially life-threatening condition.
SBRT offers the opportunity to deliver ablative doses, while
staying within acceptable liver dose–volume histogram
constraints. Table 2 summarises the main published series
of SBRT for metastatic liver tumours. Longer term survival
data are still awaited in the context of oligometastases.
Patients with liver metastases formed part of Blomgren
et al.’s [43] early series of SBRT using the Elekta stereotactic
body frame. Since then there have been a number of pub-
lished series and early phase trials in this area. Herfarth et al.
[44] from the University of Heidelberg published the results
of a phase I/II trial of single-fraction SBRT for unresectable
liver lesions. Four of the 37 patients had primary liver
tumours and the remaining 33 had metastases (maximum
fourmetastases per patient; 56metastases in total). The dose
was escalated from 14 to 26 Gy, without any incidence of
grade !3 toxicity. Actuarial 18-month local control was 68%
forall patients, but82% for thosepatients receiving20–26 Gy.
In North America there have been a number of different
approaches to dose and fractionation. Stanford University
has published single-fraction SBRT experience in lung [29]
and pancreatic [16,45,46] cancers. From the same institu-
tion, a phase I single-fraction dose-escalation trial for
unresectable liver tumours has been published in abstract
form. Twenty patients were treated (of whom 16 had liver
metastases), with the dose starting at 18 Gy and increasing
to 30 Gy. There were two cases of grade 2 duodenal ulcer-
ation and seven cases of grade 1 toxicity, but no other side-
effects. A complete or partial response was seen in 17 of the
25 sites treated, but the median follow-up was only 7
months [47].
Other centres have adopted a three-fraction approach to
treating liver metastases. In a phase I study by Schefter et al.
[15] for 18 patients with one to three metastases, the dose
was escalated from 36 to 60 Gy without causing any dose-
limiting toxicity. In fact, no toxicity greater than grade 1 was
recorded. Patients were treated with gantry-based SBRT,
using a body frame and either abdominal compression or
active breathing control to account for respiratory motion.
The final results of a subsequent multi-institutional phase II
study from the same group have recently been published. In
the phase II part, all patients received 60 Gy in three frac-
tions. Thirty-six of the 47 patients were assessable for local
control, which was estimated to be 92% at 2 years (100% for
lesions <3 cm diameter). Overall survival was 30% at 2
years, although 45% patients had active extrahepatic disease
at the time of treatment [48].
The University of Rochester have published the results of
a more fractionated approach, treating 69 patients with 174
metastases (maximum six per patient). The dose varied
considerably (Table 2), although the preferred dose was
50 Gy in 10 fractions. There was no toxicity !grade 3. Local
control was slightly lower (57% at 20months), but the series
included lesions up to 12 cm in diameter [49]. The authors
are also involved in the RTOG 0438 phase I dose-escalation
trial (recently closed), in which patients with up to five
lesions, <8 cm diameter, have been treated with 40–50 Gy
in 10 fractions.
In a recently published phase I study from Princess
Margaret Hospital, Toronto, Canada, patients were treated
with a six-fraction regimen. The dose was individualised,
varying between 27.7 and 60 Gy depending on the calcu-
lated risk of RILD, and a cautious dose-escalation protocol
was followed. These patients had up to eight metastases,
and in some cases very large treatment volumes (gross
tumour volume over 3000 cm3 in one case). Furthermore,
over half of the 68 patients had extrahepatic disease. There
were no cases of RILD or dose-limiting toxicity. Side-effects
were more prevalent than in the other trials described
above, which may well reflect the larger treatment
volumes. One-year local control was 71%, with a median
overall survival of 18months [50]. A phase II trial from these
investigators is currently underway.
Primary Liver Tumours
Wherever possible, surgery is the treatment of choice for
primary hepatocellular carcinoma (HCC), but a significant
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Table 2
Selected published series of stereotactic body radiotherapy for liver tumours
Reference Type of
publication
Number of
patients
Primary or
metastases
Maximum tumour
diameter
Dose Follow-up Local control Overall
survival
Toxicity !grade 3
[44] Phase I/II 37 (60 lesions) 4 primary, 56
metastases
6 cm 14–26 Gy/1
fraction
Mean
9.5 months
18 month 67%
(81% for lesions
receiving 20–26 Gy)
1 year 72% 0%
[51] Phase I/II 25 (45 lesions) 11 primary, 34
metastases
7.2 cm 25–37.5
Gy/3–5 fractions
Median
12.9 months
2 year 82% 2 year 54% 16% acute
4% late
[47] Phase I
(abstract)
20 (26 lesions) 4 primary, 22
metastases
– 18–30 Gy/1
fraction
Median
7 months
79% crude local
control
– 0%
[48] Phase I/II 47 (63 lesions) Metastases (1–3
lesions per patient)
5.8 cm 36–60 Gy/3
fractions
Median
16 months
2 year 92% 2 year 30% 2%
[49] Retrospective
series
69 (174 lesions) Metastases (1–6
lesions per patient)
12.2 cm 30–55 Gy/7–20
fractions
Median
14.5 months
20 month 58% Median
14.5 months
0%
[50] Phase I 68 Metastases (1–8
lesions per patient)
Median tumour
volume 75 cm3
27.7–60 Gy/6
fractions
Median
10.8 months
1 year 71% Median
17.6 months
10% acute
1% late grade 4
duodenal bleed
[53] Phase I 41 Primary (31 HCC,
10 IHC)
Median tumour
volume 173 cm3
24–54 Gy/6
fractions
Median
17.6 months
1 year 65% 1 year 51% 44% acute
2% late
gastrointestinal
bleed
[54] Retrospective
series
20 Primary HCC 6.5 cm 50 Gy/5–10
fractions
Median
23 months
2 year progression-
free survival 32.5%
2 year 43.1% 0%
HCC, hepatocellular carcinoma; IHC, intrahepatic cholangiocarcinoma.
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number of patients are not suitable for either resection or
liver transplantation [52]. Studies have shown radio-
frequency ablation and transarterial chemoembolisation to
be effective treatments, but again not all patients are suit-
able. In primary liver disease, SBRT has been used
predominantly in patients in whom other local treatments
are not suitable, or who have recurred after previous local
treatment. Primary liver tumours have comprised
a proportion of some of the SBRT publications described
above (Table 2). However, there have also been exclusive
published series of primary liver tumours [53,54].
Following the same individualised approach used in
their treatment of liver metastases [50], Princess Margaret
Hospital published a parallel phase I study of 41 patients
with unresectable HCC or intrahepatic cholangiocarcinoma.
Patients were required to have Child-Pugh A liver function,
and >800 cm3 of uninvolved liver, but tumour sizes were
large (Table 2). One-year local control was 65%, with 51%
1-year overall survival. There was no RILD or dose-limiting
toxicity, but a high incidence of grade 3 liver dysfunction
[53]. Once again, a phase II trial is underway.
Choi et al. [54] reported the results of SBRT for 20
patients with HCC. The tumours were generally smaller,
with a mean diameter of 3.7 cm and 90% of patients were
of Eastern Cooperative Oncology Group performance status
0–1. The patients were treated on a linac with ISOLOC
image guidance and a breath-hold technique. Eighty per
cent of patients had at least a partial response and 2-year
overall survival was 43%, with no toxicity !grade 3.
In a recent oral presentation, Mirabel reported the Lille
experience of treating HCC and liver metastases. Twenty-
one patients with HCC received 45 Gy in three fractions.
One-year progression-free survival was 94% and themedian
survival was estimated to be 18 months. There was one case
of grade 3 late duodenal stenosis.
There have also been published series of SBRT used in
combinationwith transarterial chemoembolisation for HCC,
showing that these two modalities can be used together
safely, where appropriate [55,56].
Pancreas
Surgery is the standard of care for pancreatic cancer, but
unfortunately only 20% of patients are diagnosed with
resectable disease [57]. Patients with metastatic disease at
diagnosis proceed directly to systemic therapy. For locally
advancednon-metastatic (ormedically inoperable) patients,
the optimum treatment is less clear. Trials have shown
chemoradiotherapy to improve survival compared with
radiotherapy alone [58,59], but there is conflicting evidence
as to whether chemoradiotherapy is superior to chemo-
therapyalone, both in comparisonwith 5-fluorouracil-based
chemotherapy [60,61] and with newer gemcitabine-based
regimens [62,63].
Local failure is still a problem in patients treated with
CFR. In one study, 58% of patients treated to 60 Gy with
concurrent chemotherapy had local failure as the first site of
progression [64]. The radiotherapy dose prescribed is
limited by the small bowel and, especially, duodenal
toxicity, although the latter becomes less important after
palliative gastrojejunal bypass surgery, which is carried out
in some centres. The development of conformal radio-
therapy has led to interest in the possibility of safe dose
escalation to achieve better local control. A Dutch phase II
study treated patients with a dose of 70–72 Gy in 2 Gy
fractions, but local control with a median follow-up of 9
months was only 56%. There were also unacceptable normal
tissue effects, with 9% grade 3 acute toxicity and 18% grade
3–5 late toxicity, including three deaths due to gastroin-
testinal bleeding [65].
There has been hope that SBRT may succeed where
CFR has failed in safe and effective dose escalation. In
a phase II study of SBRT using a conventional linac,
Hoyer et al. [66] treated 22 patients with locally
advanced pancreatic cancer, with a dose of 45 Gy in three
fractions. Local control at 6 months was again disap-
pointing at 57%, and median survival only 5.4 months,
with 95% developing metastatic disease at the time of
recurrence. Furthermore, 64% patients experienced
!grade 2 toxicity, including one case of non-fatal gastric
ulcer perforation.
Other published results have, however, been more
promising. Koong et al. [16] carried out a phase I dose-
escalation trial of single-fraction SBRT using CyberKnife,
for patients with locally advanced disease. Two of the 15
patients had received previous chemoradiotherapy to
50 Gy. The dose started at 15 Gy and was increased to
25 Gy in 5 Gy increments. No toxicity !grade 3 was
reported, although the median follow-up was only 5
months. In the group receiving 25 Gy, local control was
achieved until death or the end of follow-up. However, the
median survival was only 11 months for the whole study
group.
In a phase II trial from the same authors, 19 unresectable
patients received 45 Gy IMRT to the pancreas and regional
lymph nodes, with concurrent 5-fluorouracil chemo-
therapy, followed by a 25 Gy SBRT boost to the pancreas.
Sixteen of the patients completed all therapy as planned. In
all patients the first site of progression was distant, with
a median time to progression of 4 months, and 15 of these
patients continued to have local control until death. The
median survival was still only 7.5 months. Also, two
patients (11%) developed grade 3 gastrointestinal acute
toxicity, and there were cases of medically managed late
duodenal ulceration, although the precise number is not
clear [45].
More recently, an updated series of 77 patients treated
with a 25 Gy single fraction has been published by the
same institution, with a median follow-up of 6 months
[46]. Although this is the largest series of SBRT for
pancreatic cancer to date, it is heterogeneous. Nineteen per
cent of patients had metastatic disease and 10% had
recurrent local disease. Also, 27% were resectable, with
surgery not possible due to either medical reasons or
metastatic disease. Nevertheless, the results confirm that
this regimen provides good local control, with an esti-
mated 84% freedom from local progression at 12 months.
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Unfortunately, the median survival was still only 6.7
months from the time of radiosurgery treatment, although
only 9% of patients had received chemotherapy. Ten per
cent of patients developed !grade 3 acute or late gastro-
intestinal toxicity.
Although SBRT can significantly reduce local recur-
rence, and may improve quality of life as a result, there
is no evidence yet that it improves overall survival. It
should be stressed that systemic therapy is central to the
management of locally advanced patients, as most will
still die of metastatic disease. With this in mind, a short
course of stereotactic radiotherapy is much less likely to
interfere with a patient’s systemic therapy regimen, than
5–7 weeks of CFR. Patients of good performance status
with at least stable disease after initial chemotherapy,
and a positron emission tomography scan negative for
distant disease at that time, may be the ones most likely
to benefit from stereotactic radiotherapy to the primary
tumour.
Kidney
Renal cell carcinoma (RCC) has traditionally been viewed
as a radioresistant tumour, as the results of CFR on primary
[67] and metastatic [68] lesions have been disappointing.
However, published series of radiosurgery for metastatic
RCC in the brain have shown that the tumour is sensitive to
extreme hypofractionated treatment [69,70]. This has led to
interest in the use of SBRT for primary RCC, and for extra-
cranial oligometastatic RCC.
Beitler et al. [71] were the first to report an exclusive
series of SBRT for non-metastatic RCC, treating nine patients
who had refused surgery. The dose was 40 Gy in five frac-
tions using a standard linac with a stereotactic body frame.
The treatment volume varied from 2 to 743 cm3 (median
97 cm3). With a median follow-up of 27 months, overall
survival was 44% and no in-field tumour recurrence was
seen. All of the four surviving patients had initial tumours
<3.4 cm and had follow-up of at least 4 years.
Svedman et al. [72] have reported on seven patients who
had nephrectomy for their primary tumour, and then
subsequent SBRT for metastasis to the contralateral kidney.
They were able to achieve control locally in six of the
patients (median 49 months of follow-up), while main-
taining stable renal function in five of them. Serum creati-
nine rose by about 20–30% in the other two patients.
Wersall et al. [73] published the Karolinska Institute
5-year experience of gantry-based SBRT in ‘extracranial’
RCC (primary and metastatic tumours). They treated 162
lesions in 58 patients, including eight inoperable primary
tumours and 117 lung metastases. The dose was heteroge-
neous, varying between 25 and 45 Gy in two to five frac-
tions according to the size and location of the lesions.
Overall local control was impressive at 90% with a median
follow-up of 37months. However, 40% patients experienced
side-effects, and half of these registered side-effects were
grade 3 in severity [73]. The authors published prospective
phase II results the following year, which confirmed the
impressive local control seen with their technique (98% in
the 82 treated RCC lesions) [74].
Similar local control has also been reported using the
Novalis stereotactic system [75]. Fourteen patients with 23
extracranial renal cell metastases were treated with a dose
of 24–40 Gy in three to six fractions. Local control was 87%,
albeit at 9 months of follow-up, and symptomatic relief was
achieved in 93% of patients.
Although the local control seen in these series is
encouraging, further prospective studies are needed in this
area. In 2008, Duke University Medical Center started
a phase I/II study of SBRT for patients with either locally
recurrent/progressive RCC or metastatic RCC progressing on
sorafenib. Unfortunately this trial has closed due to slow
accrual.
In the Karolinska Institute 5-year series, 74% of patients
with metastatic disease at the time of treatment developed
new metastases during follow-up [73]. Given the unpre-
dictable natural history of renal cell metastases, rando-
mised data are needed to determine whether an aggressive
management strategy, involving SBRT, significantly
improves survival in oligometastatic RCC.
Prostate
There is randomised evidence showing that dose esca-
lation in CFR for localised prostate cancer results in
improved biochemical progression-free survival, at the
expense of an increased risk of late rectal toxicity [76,77].
There is also increasing evidence to suggest that the a/b of
prostate cancer is considerably lower than many other
cancers, and indeed lower than that of the surrounding
organs at risk [78]. The precise value is still uncertain,
although it has been estimated to be as lowas 1.2 [79]. If this
is true, and if the linear quadratic model is assumed to be
sufficiently accurate at very high doses per fraction, then
hypofractionation should improve the therapeutic ratio of
prostate radiotherapy. A number of randomised trials of
hypofractionation are underway, the results of which
should provide more information.
There has been a Canadian series of 30 low-risk localised
prostate cancer patients treated with extreme hypo-
fractionation (35 Gy in five daily fractions) using IMRT. At 6
months there was no grade 3 toxicity, but longer follow-up
is needed to assess efficacy [80].
SBRT has been shown to produce favourable rectal dose–
volume histograms when compared with IMRT and
conformal three-dimensional CFR [81]. This, together with
the extreme hypofractionation of stereotactic treatment,
would suggest that a stereotactic approach could
significantly improve the therapeutic ratio of prostate
radiotherapy, in addition to the obvious convenience to
patients and radiotherapy departments of shorter courses
of treatment. Published series have looked at predomi-
nantly low-risk localised prostate carcinoma, as the risk of
microscopic disease outside the gland is very low. There is
also early interest in using SBRT as a boost after CFR for
intermediate and high-risk patients.
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Madsen et al. [82] have published a series of 40 low-risk
patients treated with SBRT using a conventional linac with
stereotactic cones. The patientswere treated in a ‘flex-prone’
position with inserted fiducial markers for on-line image
guidance, and six stationary non-coplanar fields. A dose of
33.5 Gy in five fractions was used, as this is equivalent to
78 Gy in 2 Gy fractions to the tumour, assuming an a/b of 1.5.
With a median follow-up of 41 months, the actuarial 4-year
biochemical progression-free survival was 90% using the
Phoenixdefinition (prostate-specific antigennadirþ 2 ng/ml
rise). One case of acute grade 3 urinary toxicitywas reported,
and there was no late toxicity "grade 3.
King et al. [83] have reported the preliminary results of
a phase II clinical trial of prostate SBRT using CyberKnife.
Forty-one low-risk patients were given 36.25 Gy in five
fractions either daily or on alternate days. Seventy-eight per
cent of the 32 patients with a minimum follow-up of 12
months achieved a prostate-specific antigen nadir#0.4, and
the results show that the nadir continued to fall up to and
beyond 3 years. There were no cases of prostate-specific
antigen failure with a median follow-up of 33 months.
There were two cases of grade 3 late urinary toxicity, but no
"grade 3 rectal toxicity.
The planning method described by King et al. [83] aims
for a relatively homogenous dose distribution within the
PTV. This differs from high dose rate (HDR) brachytherapy,
a technique with proven efficacy [84,85], where there is
substantial heterogeneity of dose within the target, often
with a high dose in the peripheral zone of the gland.
Fuller et al. [86] set out to mimic the dosimetry achieved
with HDR brachytherapy in their patients receiving pros-
tate SBRT. They have published the early results of 10 low-
and intermediate-risk patients, using a dose of 38 Gy in
four fractions – a standard HDR brachytherapy dose. For
each plan, a corresponding simulated HDR brachytherapy
plan was produced. Qualitatively, the external beam
radiation plan achieved a similar PTV coverage, but
a lower urethral dose and a sharper rectal dose falloff.
Follow-up is currently too short to assess efficacy. Both
homogenous and heterogeneous dosimetric approaches
are under further evaluation in the USA, in multicentre
phase II trials.
With the long natural history associated with low- and
intermediate-risk prostate cancer, longer follow-up is
necessary to confirm the efficacy (and resultant late
toxicity) of SBRT. Furthermore, there are already effective
treatments supported by long-term data, including surgery,
permanent seed brachytherapy, HDR brachytherapy, cryo-
therapy and CFR. However, if longer follow-up shows at
least comparable efficacy, with a continued favourable
toxicity profile, then the non-invasive nature of SBRT,
together with the short treatment duration, will make it
a very attractive option for these patients.
Spine Metastases
Conventional radiotherapy is widely used in the
management of spine metastases, for local control,
palliation of pain and treatment of spinal cord compression
[87–89]. However, the prescribed dose is limited by spinal
cord and cauda equina radiation tolerance [87,90,91]. The
steep dose falloff seen with SBRT allows the delivery of
a higher dose to the tumour, while staying within cord
tolerance. This will increase the probability of long-term
tumour control and effective analgesia. Spinal SBRT has
developed directly from intracranial radiosurgery, with
heavy neurosurgical involvement. It is unsurprising, there-
fore, that many of the published series of spine SBRT have
used single-fraction regimens (Table 3).
Chang et al. [92] have reported on a phase I/II trial of
gantry-based, intensity-modulated SBRT for spinal metas-
tases, using a body frame and ‘near simultaneous’
computed tomography image-guided treatment. Forty-six
per cent of patients had had previous spinal surgery. Using
a dose of 30 Gy in five fractions or 27 Gy in three fractions,
1-year local control was 84% for the 74 treated lesions, and
mean pain scores were significantly reduced. There were
three cases of acute grade 3 toxicity, but no significant late
toxicity. There have been other reports of intensity-modu-
lated SBRT for spinal metastases [93–98], including series
using Novalis [95–97] and tomotherapy [98].
There have been a number of publications of SBRT using
CyberKnife in this setting [99–105]. From Pittsburg
University, Gerszten et al. [99] published a series of 500
metastatic spinal lesions in 393 patients. Sixty-nine per cent
of lesions had received previous radiotherapy, such that any
further meaningful conventional irradiation was not
possible. Cervical lesions were tracked relative to skull bony
landmarks; lesions at other levels required intra-osseus
gold fiducial insertion for system tracking. Patients received
a single fraction of 12.5–25 Gy, depending on the previous
radiation dose and the proximity to cord/cauda; the median
follow-up was 21 months. Local control was 90% in patients
with no previous radiotherapy, and 88% overall. Long-term
pain improvement was seen in 86% of patients in whom the
indication for treatment was pain. There were no cases of
radiationmyelopathy observed in the follow-up period [99].
Smaller, more specific, series of patients with spinal
metastases from primary melanoma [100], breast [101],
lung [102] and RCC [103] have also been published by the
same authors.
Wowra et al. [104] reported the Munich experience of
single-fraction SBRT, using ‘XSight Spine’ software (Accu-
ray), which verifies the tumour position relative to spine
bony landmarks, thus allowing fiducial-free tracking of
spinal lesions. They treated 102 patients with one or two
malignant spinal tumours, many of which were spine
metastases. One-third of patients had received previous CFR
to the treatment site. With a prescribed dose of 15–24 Gy,
local control for 134 treated lesions was 98% at 15months of
follow-up; median pain scores (using a 10-point visual
analogue scale) were significantly lower. In a recent oral
presentation, theMunich series has increased to 348 lesions
in 287 patients. Forty-nine of these patients had benign
spinal tumours treated. With a median follow-up of 9.6
months, local control was 94% for malignant lesions and
100% for benign lesions. There have been seven cases of late
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Table 3
Selected published series of stereotactic body radiotherapy (SBRT) for spinal tumours
Reference Type of
publication
Number of
patients
Previous
treatment
Primary or
metastases
Prescribed dose Follow-up Local
control
Overall survival
after SBRT
Symptom improvement
[92] * Phase I/II 63 (74 lesions) 56% radiotherapy
46% surgery
Metastases 30 Gy/5 fractions or
27 Gy/3 fractions
Median
21 months
1 year
84%
1 year 69% Mean BPI pain score and
narcotic use lower at
6 months
[96] y Prospective
series
49 (61 lesions) 0%
radiotherapy
Metastases 12–16 Gy/1 fraction 6–24
months
95% 1 year 74% Verbal/VAS pain scores lower
in 85%
6% pain relapse within
follow-up
[99] Prospective
series
393 (500
lesions)
69%
radiotherapy
Metastases 12.5–25 Gy/1 fraction Median
21 months
88% – VAS pain score improved in
86% patients where indication
for radiotherapy was pain.
Clinical improvement in 85%
patients with progressive
neurological deficit
[104] Prospective
series
102 (134
lesions)
32% radiotherapy Metastasesþ
sarcoma
15–24 Gy/1 fraction 15 months 98% Median 1.4 years Median VAS pain score
significantly lower
[105] Prospective
series
200 (274
lesions)
46% radiotherapy Primary and
metastases
21–37.5 Gy/3–5
fractions
Median
12 months
– Median 14.5 months
for metastatic
patients
Mean VAS pain score
significantly lower and
continued to improve
throughout follow-up.
Non-significant trend towards
increased SF-12 quality of life
score
[107] Prospective
series
51 (55 lesions) 8% radiotherapy
51% surgery
Primary
intradural
16–30 Gy/1–5 fractions Median
23 months
98% 96% Significant pain reduction 70%
meningioma and 50%
schwannoma patients
[108] Prospective
series
73 (73 lesions) 8% radiotherapy
26% surgery
Primary
intradural
12–20 Gy/1 fraction Median
37 months
100% – Long-term pain improvement
73% patients (VAS pain score)
BPI, Brief Pain Inventory; VAS, visual analogue scale.
* Authors used CyberKnife except (conventional linear accelerator).
y Authors used CyberKnife except (Novalis).
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toxicity: one patient with myelopathy, three with spinal
instability and three with tumour haemorrhage.
There has been a recent publication from Georgetown
looking specifically at pain and quality of life after SBRT for
metastatic and primary spinal tumours [105]. Two hundred
patients with 274 spinal lesions received 21–37.5 Gy in
three to five fractions. Seventy-six per cent of patients
reported pain at baseline. The mean visual analogue scale
pain scores improved significantly, and continued to
improve throughout the follow-up period (median 12
months). There was a non-significant trend towards
improved quality of life, as measured by the SF-12 survey.
Primary Spine Tumours
Microsurgical resection is a safe and effective treatment
for benign spinal tumours [106]. However, surgery may not
always be possible, for example with post-surgical recur-
rence or medical co-morbidity. SBRT is a useful treatment in
these situations.
Several series of CyberKnife SBRT for benign intradural
tumours have been published [107–110]. From Stanford
University, Dodd et al. [107] treated 55 tumours in 51 patients
inwhom surgery was contraindicated. Doses ranged from 16
to30 Gy inone tofive fractions, although80%of patientswere
treated with one or two fractions. The median follow-up was
23 months. There was evidence of tumour growth after
treatment in one patient, but local control was 100% in
patients followed up for more than 2 years.
Similarly, Gerszten et al. [108] have reported on 73
intradural lesions treated with a single fraction of 12–20 Gy.
With a median follow-up of 37 months, local control was
once again 100%, and there was long-term improvement in
pain scores in 73% of patients.
There have been smaller, more specific, published series
of SBRT for nerve sheath tumours [111], chordomas [112]
and sarcomas [113]. Stanford University have also published
a series of SBRT for spinal arteriovenous malformations
[114], although further work is needed here to establish
efficacy and the optimum radiation dose.
Late spinal cord toxicity is oneof themajor concernswhen
planning radiotherapy to spinal lesions. In the largest pub-
lished retrospective review, 1075 patients with primary or
metastatic tumours were treated with SBRT at Stanford or
Pittsburgh University between 1996 and 2005. Six patients
developed radiation-induced late myelopathy at 2–9
months after treatment. In threeof thesepatients, symptoms
improved with intervention, and one patient progressed to
paraplegia. Specific dosimetric factors associated with the
development of myelopathy could not be identified [115].
The data presented for both primary and metastatic
lesions show that SBRT can safely administer higher doses
to spinal tumours than is possible with conventional
radiotherapy. It is also a non-invasive alternative to surgery
for spine metastases, both as primary treatment in unirra-
diated patients, and as a salvage technique for progressive
disease in previously irradiated patients. It has been shown
to improve disease-related pain and neurological
symptoms. However, once again there are no randomised
data comparing SBRT and surgery. Surgery remains the
optimum strategy for intradural primary tumours and,
where possible, would be the favoured option in metastatic
cases where spinal stabilisation or significant neural
decompression is required [116,117].
Conclusion
Advances in image guidance and radiotherapy planning
software, together with improved accuracy of treatment
delivery, have led to the successful use of stereotactic
radiotherapy for extracranial targets. Careful patient selec-
tion is especially important. As the volume of normal tissue
within the target periphery is related to the cube of the
target’s radius, smaller lesions are preferable. The steep
dose falloff outside the target volume means that lesions
with unclear, infiltrative margins should be avoided. In
patients with active disease distant to the treatment site(s),
SBRT is unlikely to improve survival, although may achieve
good palliation through local control. Similarly, in radical
treatments, the risk of distant micrometastatic disease must
be carefully considered before proceeding. These qualifica-
tions aside, phase I/II data seem to be very promising, with
excellent local control rates at a number of treatment sites.
The results of phase III comparisons with surgery and other
treatment modalities are eagerly awaited.
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system (Elekta, Sweden) uses frame-based immobilisation. 
Unfortunately, most extracranial targets do not have a ! xed 
relationship relative to any external frame, and tradition-
ally this has limited the ability to deliver radiosurgery to 
targets outside the skull. However, modern image guidance 
techniques allow near  ‘ real-time ’ imaging linked directly to 
therapy delivery. Consequently, newer treatment systems 
can assess, and compensate for, extracranial target motion 
with the required accuracy for delivering radiosurgery. " us, 
stereotactic coordinates are replaced by intrafraction image-
guided tracking of the actual location of the target (or a sur-
rogate, such as implanted radiopaque  ‘ ! ducial ’ markers or 
adjacent bony landmarks). A consequence of this  ‘ frameless ’ 
approach is the easy ability to fractionate treatment  – some-
times desirable when the radiation tolerance of abutting or 
encompassed normal tissues is a particular concern. 
 CyberKnife (Accuray, Sunnyvale, CA) is one such image-
guided radiosurgery system, capable of treating both intra- 
and extracranial targets. 4 For spinal lesions, Xsight Spine 
(Accuray Inc.) skeletal tracking software allows  ‘ ! ducial-free ’ 
target localisation by direct reference to the adjacent bony 
vertebral elements, using non-rigid image registration. " e 
mean total system targeting error when using Xsight Spine 
has been measured at 0.52 – 0.61  mm. 5,6 " is paper reports 
the early UK experience using this technology to treat spinal 
lesions. 
 Materials and methods 
 All treated patients were previously discussed at a specialist 
radiosurgical multidisciplinary team meeting (MDT). Most 
patients had a single lesion for consideration, although up 
to three lesions in any patient were considered. " e main 
indications for treatment were as follows: 
 1.  Primary spinal lesions where surgery was not considered 
feasible or appropriate. 
 ORIGINAL ARTICLE
 Abstract 
 Introduction . Modern radiotherapy image guidance enables the 
treatment of extracranial targets with the required accuracy for 
safe delivery of radiosurgical treatments. The ! rst two years ’ 
experience of spinal radiosurgery in a UK radiotherapy centre 
is reported.  Materials and methods . Patients with primary or 
metastatic spinal lesions were treated using the CyberKnife 
stereotactic radiotherapy system. Xsight Spine (! ducial-free) 
tumour tracking software was used in all cases. Treatment was 
delivered using either a single or a three-fraction schedule, 
between February 2009 and March 2011.  Results . Fifty-three 
spinal lesions were treated, comprising 14 primary lesions in 
12 patients, and 39 metastases in 29 patients. The prescription 
dose ranged from 8 to 30 Gy in 1 – 3 fractions. Fifty-nine percent 
of patients experienced no acute side e" ects from treatment. 
There were three cases of acute grade 3 back or nerve root pain, 
all of which responded to a short course of oral corticosteroids. 
At a median follow-up of 11.1 months, local control and overall 
survival were 91 and 65%, respectively. Pain improvement 
was seen in 75% of symptomatic metastases at 6 months post 
treatment.  Conclusions . Early UK experience con! rms that 
radiosurgery is well tolerated with excellent local control rates. 
Longer-term prospective data are needed to clarify the role of 
spinal radiosurgery for patients in this country. 
 Keywords:  CyberKnife ;  radiosurgery ;  spinal tumour ;  spine , 
 stereotactic body radiotherapy.
 Introduction 
 Radiosurgery is a well-established treatment for intracranial 
targets, and has changed best standard practice for many 
conditions that were previously solely treated by conven-
tional surgery. 1 – 3 Precise patient immobilisation for intrac-
ranial radiosurgery is achieved most frequently by using a 
pinned stereotactic frame. For example, the Gamma Knife 
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2.  Spine metastases in the context of oligometastatic 
disease.
 3.  Symptomatic spine metastases in patients with more 
widespread metastatic disease, but overall prognosis 
estimated to be greater than 6 months. 
 Patients underwent CT simulation using a GE LightSpeed 
16 slice scanner (GE Healthcare, Buckinghamshire, UK). ! ey 
were positioned supine on a memory foam mattress with a head 
rest and knee supports, and arms by their sides. For lesions in 
the cervical spine, head and neck immobilisation was achieved 
using a thermoplastic shell. Axial CT slices of 1.25  mm thick-
ness were fused with recent MR images (2.5 – 3  mm axial thick-
ness) to assist target and normal tissue delineation. 
 Image fusion, target delineation, and treatment planning 
were performed using MultiPlan version 3.1.0 or 3.5.1 soft-
ware (Accuray Inc.). Target and  ‘ organ-at-risk ’ volumes were 
contoured by a clinical oncologist, often with the assistance 
of either a neuroradiologist or a surgeon. ! e prescrip-
tion dose and the number of fractions (one or three) was 
decided on an individual patient basis, taking into account 
any previous radiotherapy to the treatment site, the tumour 
volume, and the proximity of the spinal cord/cauda equina. 
Where possible, the doses used were in accordance with this 
centre ’ s evidence-based treatment protocol. All doses were 
prescribed to the marginal isodose, aiming for   ! 95% target 
coverage by the prescription isodose. Treatment was deliv-
ered using a G4 CyberKnife, and Xsight Spine tracking was 
used in all cases. Fractionated treatments were administered 
on consecutive days wherever possible. 
 Acute toxicity was reported by the treating consultant at 1 
month post treatment, and graded according to National Can-
cer Institute (NCI) Common Terminology Criteria for Adverse 
Events v3.0 (2003). Outcomes data were obtained from the 
referring consultant at 3, 6, 9, and 12 months after treatment 
and 6 monthly thereafter. Length of follow-up was de" ned as 
the time from the start of CyberKnife treatment to the date that 
the referring consultant last had contact with the patient, or 
a recorded date of death. Local treatment failure was docu-
mented on the basis of either clinical or radiological evidence 
of disease progression inside, or immediately adjacent to, the 
treatment " eld. For painful metastatic lesions, the referring 
clinician was asked to state, at each follow-up point, whether 
the pain was  ‘ better ’,  ‘ stable ’, or  ‘ worse ’ than baseline levels. 
 Results 
 Treatment details 
 Fifty-three spinal lesions were treated. ! ese comprised of 
39 metastases in 29 patients and 14 primary spinal lesions 
in 12 patients. Patient and treatment details are summarised 
in Table I, and further information on the lesion histology/
primary tumour site is shown in Table II. ! e prescribed dose 
ranged from 8 to 30 Gy in 1 – 3 fractions. For patients with no 
previous radiotherapy to the treatment area, the most com-
mon prescribed doses were 18 Gy in one fraction for smaller 
lesions and 30 Gy in three fractions for larger ones. ! e pre-
scription isodose ranged from 52 to 80% (median 65%). Plan-
ning target volume (PTV) coverage was   ! 95% in 44 of the 53 
lesions (83%). ! e other nine lesions were very close to the 
spinal cord, and PTV coverage was compromised in order to 
meet spinal cord dose constraints. 
 Sample cases 
 Case 1. A 33-year-old female with neuro" bromatosis type 
2 presented with a neuro" broma at the L4 left exit foramen, 
causing radicular pain in her left leg. Surgery was felt to be 
inappropriate due to the multiplicity of lesions. ! e patient 
had not undergone previous spinal radiotherapy. She received 
15 Gy in one fraction, prescribed to the 69% isodose. Improved 
pain was seen at 1 month post treatment, and the patient was 
pain-free with stable imaging appearances at 12 months. 
 Case 2 . A 34-year-old female had a cavernous angioma 
at the T9 vertebral level. Since 2007, the patient had two 
episodes of bleeding with proprioceptive loss in the lower 
 Table I. Summary of patient and treatment characteristics. 
Patient and treatment 
characteristics No.
Age Median 59 years (27 – 89 years)
Previous radiotherapy to 
treatment site
19/41 (46%)
Previous spinal surgery 14/41 (34%)
Location of lesions:
  Vertebral 39/53 (74%)
  Paravertebral 4/53 (8%)
  Intradural extramedullary 4/53 (8%)
  Intramedullary 6/53 (11%)
Vertebral level of lesions
  Cervical 10/53 (19%)
  ! oracic 16/53 (30%)
  Lumbar 19/53 (36%)
  Sacral 8/53 (15%)
Planning target volume (PTV) Median 23.9 cm 3 (0.1– 308.7 cm 3 )
PTV coverage by prescription 
isodose
Median 96.8% (87.6 – 99.6%)
New conformity index (nCI) a Median 1.29 (1.08 – 1.66)
Prescribed dose range 8 – 30 Gy in 1 – 3 fractions
Prescription isodose Median 65% (52 – 80%)
 a nCI   "   (PIV   #   TV)/TIV 2 , where PIV   "   prescription isodose volume, 
TV   "   tumour volume, and TIV   "   tumour isodose volume (volume of tumour 
contained within the prescription isodose). 
 Table II. Details of the treated lesions by histology (primary lesions) 
and primary site (metastases). 
Target details No.
Metastases by primary site
  Breast 10
  Kidney 8
  ! yroid 6
  Sarcoma 5
  Prostate 3
  Lung 2
  Unknown primary 2
  Colorectal 1
  Skin (melanoma) 1
  Oesophagus 1
Primary lesions by histology
  Haemangioblastoma 4
  Chordoma 2
  Haemangiopericytoma 2
  Meningioma 2
  Cavernous angioma 1
  Fibrosarcoma 1
  Haemangioendothelioma 1
  Neuro" broma 1
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limbs. ! e patient was considered at high risk of cord 
damage with surgical resection. She had not undergone 
previous spinal radiotherapy. ! e patient received 12 Gy in 
one fraction, prescribed to the 75% isodose. Within the tar-
get, hot spots of more than 15 Gy were achieved due to the 
internal dose gradient (Fig. 1). At 6 months post treatment, 
there was stable neurology with no further bleeds. 
 Case 3 .  A 62-year-old female had a metastatic neuroen-
docrine tumour in the L5 vertebral body, with an unknown 
primary site. ! e tumour extended into the spinal canal, 
close to the cauda equina. ! e patient had not undergone 
previous spinal radiotherapy. She received 16 Gy in one 
fraction, prescribed to the 70% isodose, with an excellent 
response (Fig. 2). 
 Acute toxicity 
 Of the 41 treated patients, 24 (59%) experienced no acute side 
e" ects. ! e acute toxicity seen in the remaining 17 patients is 
summarised in Table III. ! ere were six cases of nerve root 
pain, which was an exacerbation of existing symptoms in 
four of the six patients. In all cases, the pain responded to a 
short course of oral corticosteroids. ! ere was no grade  ! 3 
toxicity and all acute toxicity had resolved by 1 month post 
treatment. 
 Local control and overall survival 
 Of the 41 patients treated, 5 patients were less than 3 months 
post treatment at the time of analysis, and 2 patients were 
lost to follow-up within 3 months of completing treatment 
(both patients moved abroad). Outcomes data are presented 
for the remaining 34 patients (47 lesions) with a median 
follow-up of 11.1 months (2.1 – 22.6 months). Local disease 
progression was documented in 4 of the 47 treated lesions, 
giving a crude local control # gure of 91%. In three of these 
cases, local progression occurred inside the treated # eld, 
after treatment doses of 15 Gy in three fractions, 21 Gy in 
three fractions, and 16 Gy in one fraction. In the fourth case 
(paravertebral chordoma), progression occurred adjacent to 
the treated area, and the patient underwent further spinal 
radiosurgery to the recurrence. Of the 34 patients, 12 died 
(65% crude overall survival # gure). Ten of these patients had 
been treated for metastases, and all died of their systemic 
 Fig 1. Cavernous angioma of the thoracic cord. Left panel shows a sagittal slice from a T2-weighted MRI; right panel shows a reconstructed sagittal 
CT slice with an isodose plan, and the PTV (dark blue overlay) and spinal cord (light blue overlay) contoured. Note the internal dose gradient within 
the PTV. ! e isodose key is in the top right corner; doses are shown in centigray (cGy), where 1 Gy   "   100 cGy. 
 Fig 2. Axial T2-weighted MRI demonstrating the metastatic neuroendocrine tumour in the vertebral body of L5. Left panel shows the tumour 
appearance at baseline; right panel shows the appearance 9 months after radiosurgery. Note the tumour regression from the spinal canal, and the 
associated signal change. 
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Several series of spinal radiosurgery have been published 
worldwide. 8 – 15 Table IV summarises the wider international 
experience. 
 In this series, 59% of patients tolerated treatment with no 
acute side e! ects. Exacerbation of pre-existing nerve root 
pain was the most common side e! ect, and this responded 
well to oral corticosteroids. A prophylactic short course of 
dexamethasone is now recommended for all symptomatic 
patients at the time of treatment. Myelopathy is a serious 
potential late e! ect of radiotherapy. In the largest published 
analysis of patients treated with spinal radiosurgery, 6 out 
of 1075 patients (0.6%) developed radiation-induced myel-
opathy at 2 – 9 months after treatment. 16 To date, there have 
been no cases of myelopathy in this series, but continued 
follow-up is necessary as this complication can develop up 
to a few years after treatment. 
 " ere was one case of vertebral  ‘ collapse ’ following 
radiosurgery in a patient with a large vertebral body metas-
tasis, who had previously received a signi# cant dose of 
radiotherapy. In a published series of 71 spinal metastases, 
each receiving a single fraction of 18 – 24 Gy, a new vertebral 
fracture (or progression of an existing fracture) was seen in 
27 vertebral bodies (38%) with a median time to event of 25 
months. 17 Multivariate analysis revealed lytic radiological 
appearance, vertebral level below T10, and an increasing 
extent of vertebral body involvement as independent risk 
factors. " is raises the issue of whether prophylactic sur-
gery or vertebroplasty should be considered in radiosurgery 
patients  ‘ at risk ’ of subsequent vertebral fracture. However, 
while there has been some progress in predicting pathologi-
cal fractures based on radiological appearance,  the selection 
of patients most likely to bene# t from prophylactic interven-
tion remains challenging. Current practice at this centre is 
to fractionate radiosurgery for larger vertebral metastases in 
an attempt to reduce the risk of fracture or collapse. Fig. 3 
is a proposed $ ow chart for the complementary use of con-
ventional surgery, vertebroplasty, and radiosurgery in the 
management of spinal tumours. 
 " ere are limitations to the data presented here. " e 
numbers treated are modest, and follow-up is relatively 
short. " e pain assessment is crude, but a more formal 
assessment was limited by poor patient compliance with 
disease. Two patients had primary spinal tumours: one died 
of a progressive cerebellar haemangioblastoma; the other 
died as a consequence of local progression of her treated 
spinal meningioma. 
 Pain relief and late toxicity 
 Pain information was received on 20 symptomatic metasta-
ses treated. At 3 months post treatment, pain was recorded 
by the referring consultant as  ‘ better ’ in 13 metastases (65%) 
and unchanged in the remaining 7 lesions. At 6 months, 
pain was recorded as  ‘ better ’ in an additional 3 metastases, 
although in 1 of the previous 13 cases, pain had returned to 
baseline levels. " us, in 15 of the metastases (75%), pain was 
improved at 6 months post treatment. One patient developed 
a wedge fracture of the L3 vertebral body requiring stabilisa-
tion surgery. " is occurred 2 months after receiving a single 
fraction of 16 Gy. " ere has been no myelopathy or other late 
treatment-related toxicity to date. 
 Discussion 
 Radiosurgery has altered practice with regard to the de# ni-
tive treatment of many intracranial lesions. 1 – 3 Intracranial 
and spinal tumours comprise a similar selection of histolo-
gies, and invasive surgery to both these sites carries the risk of 
neurological morbidity. 3,7 It is therefore likely that the devel-
opment of highly sophisticated spinal radiosurgery will have 
a signi# cant impact on the management of spinal lesions. 
 Table III. Details of acute toxicity experienced in the ! rst month 
following spinal radiosurgery. 
Symptom
Grade 1 
toxicity
Grade 2 
toxicity
Grade 3 
toxicity
Grade  ! 3 
toxicity
Abdominal pain 0 1 0 0
Back pain 2 1 1 0
Diarrhoea 0 1 0 0
Dyspepsia 1 0 0 0
Fatigue 2 5 0 0
Limb weakness 0 1 0 0
Nausea 4 2 0 0
Nerve root pain 2 2 2 0
 All toxicity is graded according to NCI Common Terminology Criteria for Adverse 
Events v3.0 (2003). 
 Table IV. Selected published series of radiosurgery for spinal tumours. 
References No. of patients
Primary or 
metastases Previous treatment Prescribed dose Local control Overall survival
Yamada  et al . 8,b 93 (103 lesions) Metastases 0% RT; 0% surgery 18 – 24 Gy/1 F 90% at median 15 months Median 15 months
Ryu  et al . 9,a 177 (230 lesions) Metastases 0% RT 8 – 18 Gy/1 F  – 3 year 35%
Chang  et al . 10,b 63 (74 lesions) Metastases 56% RT; 46% surgery 27 Gy/3 F or 30 
Gy/5 F
1 year 84% 1 year 69%
Gerszten  et al . 11 393 (500 lesions) Metastases 69% RT Maximum dose: 
12.5 – 25 Gy/1 F
88% at median 21 months  – 
Wowra  et al . 12 102 (134 lesions) Metastases and 
sarcoma
32% RT 15 – 24 Gy/1 F 98% at 15 months Median 1.4 years
Gagnon  et al . 13 200 (274 lesions) Both 46% RT 21 – 37.5 Gy/3 – 5 F  – Median 14.5 months 
(metastatic 
patients)
Gerszten  et al . 14 51 (55 lesions) Primary intradural 8% RT; 51% surgery 16 – 30 Gy/1 – 5 F 98% at median 23 months 96% at 23 months
Dodd  et al . 15 73 (73 lesions) Primary intradural 8% RT; 26% surgery 12 – 20 Gy/1 F 100% at median 37 months  – 
Authors used CyberKnife except: aNovalis system (BrainLAB, Germany); bconventional gantry-based linear accelerator with external body frame/cradle and in-room 
CT image guidance.
Abbreviations: RT " radiotherapy; Gy " gray; F " fraction(s).
Br
 J 
Ne
uro
su
rg 
Do
wn
loa
de
d f
rom
 in
for
ma
he
alt
hc
are
.co
m 
by
 M
ika
il G
ez
gin
ci 
on
 11
/08
/11
Fo
r p
ers
on
al 
us
e o
nly
.
  Spinal radiosurgery  – two year experience 
Y
Y
Y
N
N
N
Clinical neurological
deficit?
Known histology?
Biopsy
Surgical decompression,
stabilisation & biopsy
Mechanical pain, radionecrosis,
fracture or neurological deficit?
Continue follow up
Spinal canal
compromise (MRI)?
vertebroplasty
Surgical decompression
& stabilisation
Vertebral fracture
or collapse?
Assessment
Follow up
Spinal
Radiosurgery
Y Y
N N
 
Fig 3. Proposed ! ow chart showing the complementary indications for conventional surgery, vertebroplasty, and radiosurgery in the management 
of spinal tumours. Y ! Yes; N ! No. 
postal questionnaires. Finally, the heterogeneity of the 
lesions treated and doses used means that it is hard to make 
! rm conclusions based on the local control and overall 
survival ! gures observed. Nevertheless, the data show that 
spinal radiosurgery is feasible and well tolerated, and the 
local control rate is in line with previous published series. 
While this treatment is now established in many countries, 
it is only recently available in the UK. High-quality prospec-
tive data are needed to con! rm e"  cacy and establish spi-
nal radiosurgery as a treatment option within the National 
Health Service. For unresectable primary spinal tumours, 
published series show excellent local control, but further 
data establishing long-term freedom from toxicity would 
still be welcome. For metastases in the context of oligometa-
static disease, prospective trials with longer follow-up are 
needed to clarify whether the excellent local control rates 
translate to improved overall survival. Finally, for symptom-
atic metastases, there are no randomised data con! rming 
superior rates and duration of pain relief over conventional 
palliative radiotherapy techniques. Systems capable of 
delivering spinal radiosurgery are now available in the NHS, 
and it is hoped that prospective trials in this area will follow 
shortly. 
 Conclusion 
 Modern radiotherapy technology allows treatment of 
extracranial lesions with  ‘ stereotactic ’ accuracy, and 
worldwide published results of spinal radiosurgery have 
shown excellent local tumour control with few side effects. 
Early UK experience has confirmed that spinal radiosur-
gery is well tolerated, with local control rates similar to 
previous published data. Longer-term prospective data 
are required to confirm efficacy and toxicity profiles, and 
to help identify those patients most likely to benefit from 
this technique. 
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